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ABSTRACT
ABSTRACT
The most common inherited sensory disorder that affects I in 1 000 children is severe hearing loss.
In developed countries, about a third of cases have a genetic origin, 80% of which are autosomal
recessive forms (DFNB). Before 1993 few genes causing hearing loss had been identified, but since
then a large number of genes related to this problem have been identified. Studies indicate that the
DFNBI locus, located at position 13q11-12, contributes to 20% of all childhood deafness and may
have a carrier rate as high as 2.8%. There are two genes linked to DFNB 1, GJB2 and GJB6, which
are the major genetic cause of non-syndromic autosomal recessive deafness. GJB2 and GJB6
encode the connexin proteins connexin 26 and 30 (Cx26 and Cx30), respectively.
The specific aim of this study was to determine the role of GJB2 and GJB6 in deafness within the
South African population, since there are no published results involving South African patients with
non-syndromic autosomal recessive deafness. This study therefore involved the identification of
mutations within the coding region of the GJB2 and GJB6 genes in the South African population
and the determination of their specific allele frequencies. Another aim of this study was to analyse
the effectiveness of three single-strand conformation polymorphic (SSCP) gel electrophoresis
systems in the detection of GJB2 mutations, for use in a standardised diagnostic program.
A total of 44 families were recruited and divided into either the familial or sporadic study group,
which consisted of 16 and 28 families, respectively. Control samples were also screened from 50
Caucasians and 50 Mixed Ancestry individuals collected from the general population. To achieve
the aims of this study, polymerase chain reaction (PCR) amplification followed by automated DNA
sequencing of the coding regions of GJB2 and GJB6 was performed. The three SSCP systems that
were tested for their effectiveness in detecting mutations within the coding region of GJB2 included
mini polyacrylamide, SSCP-urea and two buffer gel electrophoresis systems.
In total, six previously reported mutations (35delG, 312de1l4, W24X, M34T, V37I and W44X), a
novel mutation (N62I), and four benign polymorphisms (V27I, A40A, R127H and V153I) were
detected in GJB2. In the GJB6 gene only the S199T polymorphism was observed. It was
determined that the most common mutations found within the Caucasian and Mixed Ancestry
populations of South Africa were 35delG and 312de1l4 of GJB2. An overall detection rate of
35.227% was achieved in non-syndromic autosomal recessive deafness amongst this patient cohort.
It was also observed that none of the SSCP gel electrophoresis systems were effective at detecting
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all of the GJB2 mutations. This could change if the systems were specifically optimised for the
cornmon mutations that were identified.
This study therefore, provides information that can be used in the formulation of a screenmg
program for non-syndromic autosomal recessive deafness specific to the South African population.
Further research should be conducted involving other genes, in addition other population groups of
South Africa to provide a more comprehensive genetic diagnostic and counselling tool.
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Die mees algemene oorerflike sensoriese steuring wat 1 in 1 000 kinders affekteer is ernstige
gehoorverlies. In ontwikkelde lande het omtrent een-derde van die gevalle 'n genetiese oorsprong,
waarvan 80% outosomaal resessiewe vorms is (DFNB). Tot en met 1993 is min gene wat
gehoorverlies veroorsaak geïdentifiseer, maar sedertdien is 'n groot aantal gene gelokaliseer en
verskeie is ook al gekloneer. Studies toon dat die DFNB 1 loci, wat in posisie 13q 11-12 gevind
word, 20% van doofheid in kinders veroorsaak, en dit het 'n draer frekwensie van so hoog as 2.8%.
Twee gene wat koppeling met DFNBI toon, GJB2 en GJB6, is die vernaamste genetiese oorsaak
van nie-sindromise autosomaal resessiewe doofheid. GJB2 en GJB6 koder vir die connexin proteïne
26 en 30 (Cx26 en Cx30), onderskeidelik.
Die spesifieke doel van hierdie studie is om die rol van GJR2 en GJB6 in doofheid binne die Suid-
Afrikaanse populasie te bepaal, aangesien daar tans nog geen gepubliseerde resultate omtrent Suid-
Afrikaanse pasiënte met nie-sindromiese outosomaal resessiewe doofheid is nie. Hierdie studie
handel dus oor die identifikasie van mutasies wat binne die koderende areas van die GJR2 en GJB6
gene voorkom in die Suid-Afrikaanse populasie, asook oor die bepaling van hulle spesifieke alleel
frekwensies. Verder het hierdie studie ten doelom die effektiwiteit van drie enkel-string
konformasie polimorfisme (SSCP) gel-elektroforese metodes in die opsporing van GJB2 mutasies
te analiseer met die oog op toekomstige gebruik in 'n gestandardiseerde diagnostiese program.
Altesaam 44 families is ingesamel en gekategoriseer in familiële of sporadiese studie-groepe met 16
en 28 families onderskeidelik. Kontrole monsters van 50 Kaukasiese en 50 Gemengde Herkoms
individule uit die algemene populasie is ook getoets. Om die doeleindes van die studie te bereik is
PKR amplifikasie en outomatiese DNS volgordebepaling van die koderende area van GJB2 en
GJR6 gedoen. Die drie SSCP sisteme wat getoets is vir hulle effektiwiteit in die identifisering van
mutasies in die koderende area van GJB2 sluit in mini poli-akrielamied, urea en twee-buffer gel
elektroforese sisteme.
In totaal is ses gerapporteerde mutasies (35delG, 312de114, W24X, M34T, V37I en W44X), 'n
nuwe mutasie (N62I), en vier onskadelike polimorfismes (V27I, A40A, R127H en V153I)
opgespoor in GJB2, maar in GJB6 is net die S199T polimorfisme waargeneem. Uit die resultate kon
afgelei word dat 35deiG en 312de114 van GJB2 die mees algemene mutasies binne die Kaukasiese
en Gemengde Herkoms bevolkings van Suid Afrika is. Die total ontdekking standaard van 35.227%·
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vir nie-sindromise autosomaal resessiewe doofheid tussen herdie patient kohort was bereik. Verder
is waargeneem dat geen van die SSCP gel elektroforese metodes effektief was om al die mutasies
van GJB2 op te spoor nie. Die situasie kan egter verander as die sisteme spesifiek geoptimiseer
word vir die algemene mutasies wat gevind is.
Hierdie studie verskaf dus inligting wat gebruik kan word in die verskaffing van 'n diagnostise
program vir nie-sindromise outosomaal resessiewe doofheid wat spesifiek is vir die Suid-
Afrikaanse populasie. Verdere navorsing wat ander gene en ander populasie groepe van Suid-Afrika
insluit, behoort egter uitgevoer te word om uiteindelik 'n meer uitgebreide genetiese diagnostiese en
raadgewing diens daar te stel.
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Severe hearing loss is the most common inherited sensory disorder that affects approximately 0.1%
of children worldwide (Kelley et al., 1998). The majority of cases of hearing impairment in
developed countries is thought to be due to genetic factors. Approximately 80% of all congenital
deafness cases are the result of autosomal recessive inheritance or sporadic mutational events
(Estivill et al., 1998).
Studies have indicated that mutations within the gene, GJB2, located at position 13q11-12, are
major contributors to prelingual, non-syndrornic recessive deafness within Caucasian populations
(Antoniadi et al., 2000). This gene encodes the gap-junction protein connexin 26 (Cx26), which is
expressed in the inner ear and plays an important role in cell signalling by recycling potassium ions
(Kelley et al., 1998). More than 70 variants have been identified within the Cx26 gene but some
represent benign polymorphisms (Smith and" Van Camp, 1999; Kelley et al., 2000). The most
common deletion is 35de1G, which accounts for approximately 75-80% of all non-syndromic
autosomal recessive cases of deafness involving the GJB2 gene. Other mutations are found in
particular populations, such as the 167delT mutation that is found specifically in the Ashkenazi
Jewish population at a rate of 4% (Tekin et al., 2001).
It has been reported that the phenotypes due to GJB2 mutations are variable and mostly independent
of the mutation. A possible explanation for this is that there are either environmental factors or
modifying genes that can affect the phenotype of a particular GJB2 genotype (Rabionet et al.,
2000). Another interesting phenomenon that has been noticed is that between 10 and 42% of cases
of GJB2 mutations harbour only one mutant GJB2 allele and even some familial cases that are
linked to the DFNBI locus have no evidence of any mutations in GJB2. In both instances it was
therefore considered that another connexin gene positioned closely to GJB2 might be responsible
for the non-syndromic autosomal recessive hearing loss phenotype (Del"Castillo et al., 2002). The
candidate gene was GJB6, which encodes the gap junction protein connexin 30 (Cx30). This gene
lies within 35 kb of GJB2 on chromosome 13q12 and is also expressed in the cochlea together with
Cx26. These two connexins share 76% similarity, with the major difference being the carboxy
terminus of GJB6 that is 35 amino acid residues longer than that of GJB2 (Rabionet et al., 2000).
To date few mutations related to non-syndromic recessive deafness have been reported in GJB6. A
large variant has been documented in the Askenazi Jewish population ..It was. identified at the 5' end
1
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of GJB6 and includes the first exon of the gene (Lerer et al., 2001). A second large deletion was
discovered in families from Spain and Cuba. This deletion, known as l1(GJB6-DI3S1830), crops
GJB6 and extends distally towards GJB2, but does not include this gene. This mutation is the
second most common mutation in the Spanish population after the 35deiG mutation of GJB2 (Del
Castillo et al, 2002). A recent report has indicated that the deletions observed in the two previously
mentioned studies are identical and involve the removal of approximately 309 kb of genomic DNA
(Del Castillo et al., 2003).
The high frequency of the 35deiG mutation makes molecular diagnosis and genetic counselling for
recessive and sporadic congenital deafness feasible. It has been estimated that screening specifically
for 35delG and 167delT mutations of GJB2 is expected to diagnose up to 50% of familial and 10 -
40% of sporadic cases in the USA and Europe. The identification of the cause of the deafness soon
after birth (before six months) allows families to adjust the educational process of the child to
improve communication skills that lead to better academic success in the child's future (Estivill et
al., 1998; Tekin et al., 2001). In a recent study of cochlea transplantation, the result suggests that
screening for GJB2 mutations may be used as a useful predictor of post-implantation speech
acquisition, thereby providing families with better pre-implantation counselling (Fukushima et al.,
2002).
A detailed look at the history of the identification of the genes implicated in hearing impairment and
the role Cx26 and Cx30 playas gap junctions within the ear is provided in Chapter 2. In this
chapter, the role of genetic counselling for non-syndromic recessive hearing loss is also discussed
together with the methods that are used for mutation detection. In Chapter 3 the materials and
methods employed in this study are presented. Chapter 4 follows with the reporting of the results as
well as a discussion of these results. Finally, chapter 5 provides a conclusion of the study together
with recommendations for (i) future research and (ii) future provision of a screening program for
non-syndromic autosomal recessive deafness in South Africa.
This is the first study to investigate the entire coding region of GJB2 and GJB6 for disease related
mutations in South Africans who suffer from autosomal recessive or sporadic deafness. This study
was conducted to identify known and novel mutations within the GJB2 and GJB6 genes and
determine their carrier rates in the South African population. The information generated in this
study will be used to improve the genetic counselling offered to families and individuals at risk of
developing non-syndromic hereditary deafness as well as those already afflicted by this disability.
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2.1 FUNCTIONING OF THE HUMAN EAR
The ear is divided into three sections, namely outer, middle and inner ear (Figure 2.1). The outer ear is
made up of the ear canal and pinna, which is involved in collecting and directing sound. The middle ear
includes the eardrum, auditory ossieles and the Eustachian tube, which connects the middle ear to the
nasopharynx. The function of the Eustachian tube is to equalize air pressure so that it is the same in the
middle ear as it is in the outer ear. If the air pressure is not maintained, the eardrum cannot function
properly as it detects small fluctuations in pressure caused by sound waves. Finally, the inner ear
comprises the cochlea as well as the mechanisms needed for balance, which includes three connected
semicircular canals filled with a fluid known as endolymph (Louwand Edwards, 1995; Mader, 1996).
During the hearing process, sound waves enter the pinna where they are directed down the ear canal,
for about 25 mm, until they reach the tympanic membrane, also known as the eardrum. The sound
waves are transferred via the tympanic membrane to the inner ear by the auditory ossicles, which
consist of three small bones, namely the malleus (hammer), incus (anvil) and stapes (stirrup). This
transfer occurs due to the sound waves causing the tympanic membrane to vibrate and these vibrations
are detected by the malleus that is attached to the inside of the tympanic membrane. The malleus
transfers the vibrations to the incus and finally the stapes, which fits into the vestibule of the inner ear.
At the stapes the vibrations are conveyed to the fluid found in the cochlea. Here the vibrations are
transformed into nerve impulses, by specialized cells, and are transported along the auditory nerve until
they reach the brain (Louwand Edwards, 1995; Mader, 1996).
3
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Figure 2.1: Cross-sectional view of the ear together with the genes responsible for the
expression of the major proteins in this area
semicircular canalS
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Adapted from Tekin et al., 2001.
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The majority of individuals at some stage will lose some degree of hearing as they age, due to disease,
exposure to loud noise or hereditary causes. There are basically three classes of hearing impairment and
they are briefly described as follows (Guilford et al., 1994):
.:. Conductive hearing loss involves a fault in the transferal of sound energy through the outer and
middle ear.
.:. Neurosensory hearing loss involves the incapability of the cochlear to convert the vibrations
caused by the sound waves into neural impulses and/or the inability of the auditory nerve to
detect or generate these impulses .
•:. Mixed hearing loss is a combination of both conductive and neurosensory hearing loss.
It is still not clear exactly which areas in the cochlea and the auditory pathway are affected in hearing
loss (Engel-Yeger et al., 2002). It is, however, assumed that in the case of deafness due to mutations in
connexin proteins, the functioning of gap junctions will be affected. This then leads to an impaired
recycling of potassium ions that occurs via the network of gap junctions from the epithelial supporting
cells to the cochlear endolymph (Pampanos et al., 2002). This will be discussed in further detail In
section 2.4.
2.2 HEARING IMPAIRMENT
2.2.1 CLASSIFICATION OF HEARING LOSS
One infant in 1 000 is affected by hearing impairment and the figure rises to 4% in people under age 45
(Estivill et al., 1998). Hearing loss comprises an entire range of clinical symptoms including congenital
versus late onset, conductive versus sensorineural and syndromic versus non-syndromic (Zelante et al.,
1997).
The known causes of sensorineural hearing loss can be broadly divided into genetic and environmental
causes. The genetic cases can be grouped according to syndromic and non-syndromic or congenital and
acquired causes, whereas the environmental cases are caused by viruses, bacteria, trauma, immunology,
or a drug-related source as well as other medical conditions (Kenna et al., 200 I).
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Until recently, genetic forms of deafness were thought to account for only 30% to 45% of cases, with
approximately two thirds of these cases being due to isolated, i.e. non-syndrornic, genetic forms. The
remaining cases were considered to be due to environmental (27% - 35%) or other unidentified causes
(Marlin et al., 2001). It has now been recognized that in developed countries, deafness due to an
environmental origin has become less frequent due to the improvement in public health conditions. It is
now estimated that hearing impairment due to genetic factors may be as high as 59% in some countries
(Kemperman et al., 2002; Pampanos et al., 2002).
Hearing impairment that is caused by genetic factors can be divided into syndromic forms, in which the
deafness is associated with a number of other abnormalities, and into non-syndrornic forms where
hearing loss is the only clinical feature (Morell et al., 1998). It has been observed that non-syndromic
forms of hearing impairment are usually the more severe as well as being almost exclusively
sensorineural in nature, due to cochlear defects. In the case of syndromic forms of deafness, the cause
is external and/or middle ear developmental defects that lead to conductive or mixed hearing loss
(Pampanos et al., 2002).
Approximately two thirds of inherited hearing loss is non-syndromic, with autosomal recessive
inheritance predominating (-80%). The remainder of the cases are characterized by autosomal
dominant (-20%), X-linked (-1%) and mitochondrial «1%) farms (Najmabadi et al., 2002; Pampanos
et al., 2002). Due to this high frequency of recessive non-syndromic deafness, it is suggested that a
large number of people in the general population are symptom-free carriers of mutations in genes that
are involved in hearing (Estivill et aI., 1998).
Hearing loss can also be divided according to the age of onset of the deafness. In the case of prelingual
hearing impairment it is diagnosed before the age of speech acquisition, therefore before two years of
age, whereas postlingual deafness develops at a later stage in life. Generally, it has been observed that
recessive deafness tends to be more severe due to the fact that in most cases the hearing loss is
profound, prelingual and penetrates fully. In the case of dominant deafness, on the other hand, the
hearing loss is often progressive and postlingual, and is frequently diagnosed clinically as unilateral or
mild bilateral deafness (Guilford et aI., 1994; Denoyelle et al., 1998). This observation may be
explained by the fact that in the case of autosomal recessive disorders there is usually a complete
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absence of the functional protein. Conversely, in the case of dominant disorders there is usually an
initial functioning of the protein followed by a cumulative, degenerative process due to the presence of
dominant mutations, which could lead to the subsequent hearing impairment development (Morton,
2002).
2.2.2 GENETIC LOCI INVOLVED IN HEARING IMPAIRMENT
Since 1997 many non-syndromic hereditary forms of deafness have been mapped in the human genome
using genetic linkage methodology. The loci are specified as DFNA (autosomal dominant), DFNB
(autosomal recessive), DFN (X-linked) or DFNM (modifying) depending on the mode of inheritance of
the hearing impairment. The loci are also then numbered consecutively to indicate the order of
discovery (Prasad et al., 2000; Kemperman et al., 2002; Morton, 2002).
Amongst the majority of the loci discovered, the underlying disease-causing gene has not been
identified (Kemperman et al., 2002). The abundant number of loci involved in non-syndromic deafness
attests to the large allelic genetic heterogeneity of this sensory defect (Ben Arab et al., 2000). Most of
these genetic types of hearing loss that have been identified are seen quite rarely except for DFNB I
(OMIM: 220290), which has been observed in approximately 40% of children with non-syndrornic
deafness (Greinwald and Hartnick, 2002; Kemperman et al., 2002).
2.3 DISCOVERY OF GENES IMPLICATED IN HEARING IMPAIRMENT
Even though the mechanism of hearing impairment has been studied for many years it is only recently
that the genetic background in the form of the genes and molecular system underlying this disorder has
begun to be unearthed (Morton, 2002). Whilst the genetic basis of non-syndrornic deafness is still at the
first stages of discovery, the identification of genes responsible for syndromic deafness is well
developed. This is primarily related to the problems faced in locating genes due to the fact that non-
syndromic deafness is an extremely heterogenic disorder (Guilford et al., 1994).
To date approximately 70 loci have been identified. 28 have been linked to recessive, 33 to dominant,
three to both dominant and recessive, five to X-linked, and two to mitochondrial hearing impairment
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(Kenna et al., 2000; Pampanos et al., 2002). Of the 70 loci, at least 58 genes involved in the hearing
process have been distinguished. Of these 58 genes, 34 have been linked to non-syndromic deafness of
which, 16 are autosomal dominant, 11 are autosomal recessive, one is X-linked and six are
mitochondrial genes (Table 2.1). A further 24 genes have been discovered that are responsible for
syndromic deafness (Morton, 2002). It has been suggested from population studies that as many as 100
genes may be involved in non-syndromic deafness (Guilford et al., 1995; Morell et al., 1998; Lalwani
2002 and Shahin et al., 2002).
Table 2.1: Documented genes that playa role in the auditory system
No. Gene Protein or RNA Map Position Syndromic Disorders
or non-
syndromic
hearing loss
ATP6BI 2cen-qI3 SHL Distal renal tubular acidosis
associated with sensorineural
deafness
2 BSND Barttin Ip32.3 SHL Bartter syndrome
3 CDN23 Cadherin 23 IOq21-q22 NSHL+ SHL Usher syndrome type ID
(USH ID); Usher syndrome type
ID (USHID) + DFNBI2
4 CLDNI4 Claudin 14 2Iq22 NSHL DFNB29
5 COCH Cochlin 14q12-qI3 NSHL DFNA9
6 COLlA2 Collagen type I a2 7q22.1 SHL Osteogenesis imperfecta
7 COL2AI Collagen type 2 a I 12q13.I-q 13.2 SHL Stickler syndrome (STL I)
8 COL4A3 Collagen type 4 a3 2q36-q37 SHL Alport syndrome
9 COL4A4 Collagen type 4 a4 2q36-q37 SHL Alport syndrome
10 COL4A5 Collagen type 4 a5 Xq22 SHL Alport syndrome
11 COLllAI Collagen type Il al Ip21 SHL Stickler syndrome (STL2)
12 COLlIA2 Collagen type Il a2 6p21.3 NSHL+SHL Stickler syndrome (STL3);
DFNAI3
13 DDP Xq22 SHL Mohr-Tranebjaerg syndrome
14 DFNA5 7p15 NSHL DFNA5
15 DIAPHI Diaphanous 5q31 NSHL DFNAI
16 DSPP Dentin 4q21.3 SHL Dentinogenesis imperfecta 1
sialophosphoprotein (DGlI); DFNA39
8
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17 EDN3 Endothelin 3 20qI3.2-qI3.3 Sill.., Waardenburg-Shah syndrome
(WS4)
18 EDNRB Endothelin receptor l3q22 Sill.., Waardenburg-Shah syndrome
B (WS4)
19 EYAI 8q13.3 Sill.., Branchio-oto-renal syndrome
20 EYA4 6q22-q23 NSHL DFNAIO
21 GJAI Connexin 43 6q21-q23.3 NSHL Autosomal recessive deafness
22 GJB2 Connexin 26 l3ql2 NSHL DFNBI
23 GJB3 Connexin 31 Ip34 NSHL DFNA2
24 GJB6 Connexin 30 13ql2 NSHL DFNA3 and DFNBI
25 KCNEI 21q22.I-q22.2 Sill.., Jervell and Lange-Nielsen
syndrome (JLNS2)
26 KCNQ4 Ip34 NSHL DFNA2
27 KVLQTl Ilp15.5 Sill.., Jervell and Lange-Nielsen
syndrome (JLNS I)
28 MITF 3pI2.3-pI4.1 Sill.., Waardenburg syndrome type II
(WS2); Tietz syndrome
29 MYH9 Myosin heavy chain 22q13 NSHL+ SHL May-Hegglin and Fechtner
9 syndromes; DFNAI7
30 MY06 Myosin 6 6ql3 NSHL DFNA22
31 MY07A Myosin 7A IlqI2.3-q21 NSHL + Sl-ïl. Usher syndrome type IB
(USHIB); DFNAII; DFNB2;
Atypical Usher syndrome
32 MY015A Myosin 15A 17ql1.2 NSHL DFNB3
33 NDP Norrin Xpl1.3 Sill.., Norrie disease
34 OTOF Otoferlin 2p22-p23 NSHL DFNB9
35 PAX3 2q35 Sill.., Waardenburg syndrome type I
(WS 1); Waardenburg syndrome
types I + III (WS 1 + WS3);
Craniofacial dysmorphism
(CDHS)
36 PCDH15 Protocadherin 15 10q21-q22 Sill.., Usher syndrome type IF
(USHlF)
37 POU3F4 Xq21.1 NSHL DFN3
38 POU4F3 5q31 NSHL DFNA15
39 PMP22 Peripheral myelin 17pl1.2 Sill.., Charcot-Marie- Tooth disease
40 12S rRNA Ribosomal RNA mitochondrial NSHL Sensorineural deafness
"9
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41 SLCI9A2 lq23.3 Slll__ Thiamine-responsive
megaloblastic anemia with
diabetes mellitus and deafuess
42 SLC26A4 Pendrin 7q31; 7q2I- NSHL+ SHL Pend red syndrome (PDS);
q34 DFNB4
43 SOX9 l7q24.3-q25.1 Slll__ Campomelic dysplasia
44 SOXlO 22ql3 Slll__ Waardenburg-Shah syndrome
(WS4)
45 STRC Stereocilin I5q21-q22 NSHL DFNBI6
46 TCOFI Treacle 5q32-q33.1 Slll__ Treacher Collins syndrome
47 TECTA Alpha tectorin 1Iq22-q24 NSHL DFNA8, DFNAI2, DFNB2I
48 TMCI 9q13-q2I NSHL DFNA36, DFNB7/BII
49 TMPRSS3 2Iq22.3 NSHL DFNB8, DFNB 10
50 tRNA-glu Transfer RNA mitochondrial SHL Diabetes and deafuess
51 tRNA-leu Transfer RNA mitochondrial SHL Mitochondrial
encephalomyopathy with lactic
acidosis and stroke-like episodes
(MELAS); Diabetes mellitis and
deafuess
52 tRNA-lys Transfer RNA mitochondrial SHL Myoclonic epilepsy and ragged-
red fiber disease (MERRF)
53 tRNA-ser Transfer RNA mitochondrial Slll__ Retinitis pigmentosum and
progressive sensorineural hearing
loss
54 tRNA-ser(UNC) Transfer RNA mitochondrial NSHL+SHL Sensorineural deafness;
Progressive myoclonic epilepsy,
ataxia and hearing loss;
Palmoplantar keratoderma and
deafuess
55 USHIC Harmonin IIpI5.I Slll__ Usher syndrome type 1C
(USHIC)
56 USH2A Usherin Iq4I SHL Usher syndrome type 2A
(USH2A)
57 USH3 3q21-q25 SHL Usher syndrome type 3 (USH3)
58 WFSI Wolframin 4p16 sin. +NSm, Wolfram syndrome; DFNA38;
DFNA6/AI4
Adapted from Morton, 2002.
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2.3.1 METHODS USED FOR GENE IDENTIFICATION
Due to hearing impairment being a very heterogeneous disorder it was thought that deafness was a
complex problem and therefore not much research was conducted. However, this complication,
especially when it comes to counseling and prevention, is no longer such a big problem in view of the
following factors (Zelante et al., 1997):
.:. Non-syndromic recessive deafness accounts for the majority (70 - 75%) of all cases of genetic
deafness .
•:. Up to 80% of all non-syndromic recessive hearing loss is linked to DFNB 1.
•:. A single frameshift mutation, 35de1G, found in DFNBI accounts for most of the hearing loss
associated with non-syndromic recessive deafness in the European Caucasian population.
Conventional methods, such as genetic linkage analysis, that were used for locating other disease genes
were not successful for the identification of genes related to deafness because of its complexity. For
non-syndromic recessive deafness, linkage analysis was hindered due to family size, as it is necessary
to use large consanguineous families or populations that have not been affected by immigration. For
non-syndrornic dominant deafness single, small families are sufficient. Another factor that complicated
analysis is the possibility of more than one deafness gene being present in a given family or that the
hearing loss was in fact due to a non-genetic cause (Guilford et al., 1994; Brown et al., 1996; Morton
2002).
Other methods for gene discovery had to be developed and it appears that positional cloning in humans
has been the most successful to date with a number of new genes relating to non-syndromic recessive
deafness being identified (Brown et al., 1996). Another method that was used, was the identification of
candidate genes from humans and mice as well as others animals (Morton 2002). This was used in
organ and tissue-specific techniques, which involved the construction of cochlear cDNA libraries from
humans and mice. These were subsequently used to identify possible genes by conducting mutation
screens, as a transcript map of the inner ear is a source of positional candidate genes. Candidate genes
were also used in the development of mouse models, as they are the ideal animal models for studying
hearing impairment. Mouse models were constructed for specific types of hearing loss so that research
Il
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could be done on the developmental time points involved in the disorder by studying the animals at
various stages of development from fetus to adult (Table 2.2). Even with all the progress that has
occurred in the identification of the genes involved in hearing loss, there are still relatively few mouse
models available (Brown et al., 1996; Morton, 2002).
Mouse mutant
Table 2.2: Mouse models of hearing impairment and their human orthologs
Ames waltzer (av)
Beethoven (Bth) and deafness (dn)
Chondrodysplasia (cho)
Col lal transgene disruption
Col Ila2 targeted null
Col 4a3 targeted null
Disproportionate micromelia (Dmm) and
Gene Human disorder(s)
Pcdhl5 Usher syndrome type IF (USHI F)
Tmel DFNA36, DFNB7/BII
Col Iial Stickler syndrome type 2 (STL2)
Collal Osteogenesis imperfecta (Ol)
Collla2 Stickler syndrome type 3 (STL3), DFNAI3
Col4a3 Alport syndrome
Col2al Stickler syndrome type I (STLl)
mutant transgenes
Dominant megacolon (Dom)
Dominant spotting (W)
Eyal bor and targeted null
Fgfr3 targeted null
Gata targeted null
SoxlO
Kit
Eyal
Fgfr3
Gata3
Kcne I targeted null and Kcne I pier Kcne I
Kcnel targeted null Kcnq l
Lethal spotting (Is) Edn3
Microphthalmia (mi) Mitf
Ndph targeted null Ndph
Pax2 targeted null Pax2
Piebald (s) Ednrb
Pou3f4 targeted null and sex-linked fidget (sif) Pou3f4
Pou4t3 targeted null and dreidel (ddl) Pou4t3
Quivering (qv) Spnb4
Shaker-I (shl) Myo7a
Shaker-2 (sh2)
Slc26a4 targeted null
Snell's waltzer (sv)
Myo15a
Slc26a4
Myo6
Waardenburg-Shah syndrome (WS4)
Piebald trait (PBT)
Branchio-oto-renal syndrome (BOR)
Craniosynostosi s
Hypoparathyroidism, sensorineural deafness and renal
dysplasia syndrome (HDR)
Jervell and Lange-Nielsen syndrome (JLNS2)
Jervell and Lange-Nielsen syndrome (JLNSI)
Waardenburg-Shah syndrome (WS4)
Waardenburg syndrome type 2 (WS2); Tietz syndrome
Norrie disease (ND)
Renal-coloboma syndrome
Waardenburg-Shah syndrome (WS4)
DFN3
DFNA15
Charcot-Marie-Tooth disease type 4F (CMT4F)
Usher syndrome type IB (USHIB); DFNB2; DFNAII;
atypical Usher syndrome
DFNB3
Pend red syndrome (PDS); DFNB4
DFNA22
12
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Splotch (Sp) Pax3 Waardenburg syndromes types I and 3 (WS I; WS3);
Craniofacial dysmophism, hand abnormalities, profound
sensorineural deafness (CDHS)
DFNA8/AI2; DFNB21
Thyroid hormone resistance
Charcot-Marie-Tooth disease type 1A (CMTlA)
Usher syndrome type ID (USHID); DFNB12
Tecta targeted null
Thrd targeted null
Tremble (Tr)
Waltzer (v)
Tecta
Thrb
Pmp22
Cdh23
Adapted from Morton, 2002.
Finally, a number of other techniques have also been tried, such as autozygosity mapping. The term
autozygosity in this context implies homozygosity for markers that are exactly alike by descent,
therefore inherited from a recent common ancestor. This method involves looking at consanguineous
families, with non-syndromic autosomal recessive deafness, that are probably autozygous for markers
that are linked to this disease locus. This approach is a very powerful tool for linkage analysis if
families containing a number of affected individuals in two or more sibships that are linked by
inbreeding can be found (Strachan and Read, 1999).
2.3.2 THE IDENTIFICATION AND LOCALIZATION OF DFNBI
The most important discovery connected with non-syndromic hearing loss was the identification of the
DFNB 1 locus by Guilford et al. (1994). This was the first locus to be described that was linked to
autosomal recessive deafness. Three years later the gene, GJB2, linked to the DFNB 1 locus was
mapped to position 13q12 and it was discovered that it encoded the gap junction 13-2protein, known as
connexin 26 (Cx26). To date, more than 60 mutations relating to non-syndrornic deafness have been
identified within GJB2 (Connexin Homepage, 2003). However, it is interesting to note that one
particular mutation, 35de1G, is particularly common, especially amongst Caucasian populations (Jun et
al., 2000; Kenna et al., 2001).
DFNB 1 was first identified by linkage analysis using two consanguineous families from Tunisia that
demonstrated autosomal recessive non-syndrornic deafness. This was further confirmed by the
observation of other consanguineous families, from different ethnic groups, with recessive non-
syndromic deafness. A number of non-consanguineous Caucasian families were also subsequently
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linked to several markers from chromosome 13q12-13 (Scott et al., 1998A; Ben Arab et al., 2000;
Pampanos et al., 2002).
Subtractive hybridization was used to identify Cx26. This was achieved by the selection for mRNAs
that were expressed in normal mammary epithelial cells, but were not present in mammary tumor cell
lines (Kelley et al., 2000). Kikuchi et al. (1995) conducted immunostaining research on the expression
of Cx26 in the rat cochlea. He discovered that staining occurred in non-sensory epithelial cells that
included the interdental cells of the spiral limbus, inner sulcus cells, supporting cells of the organ of
Corti, outer sulcus cells, and the cells found within the root processes of the spiral ligament. He also
found that staining occurred in the connective tissue cells of the cochlea that took into account the
mesenchymal cells that line the scala vestibuli, different types of fibrocytes of the spiral limbus and
spiral ligament, as well as the basal and intermediate cells of the stria vascularis. This information was
used together with data that was gathered from in vitro mutagenesis and physiological studies to link
Cx26 with the development of hearing impairment.
Shortly after identifying GJB2 as a possible candidate gene responsible for autosomal non-syndromic
recessive deafuess, a number of mutations were detected within GJB2 in three Pakistani families that
had been linked to 13qIl. This was followed by the detection of mutations in GJB2 among many other
families that originated from Italy, Spain and Israel. Thereby, the GJB2 gene was confirmed as a major
contributor to non-syndromic, autosomal recessive deafness in Caucasian populations (pampanos et al.,
2002).
Since then it has been demonstrated that the DFNB 1 locus is also responsible for a second type of non-
syndromic deafness, which is a dominant form known as DFNA3 (OMIM: 601544) (Guilford et al.,
1995; Denoyelle et al., 1998). It has been determined that GJB2 (Section 2.5) and GJB6 (Section 2.6)
are both responsible for DFNB 1 as well as autosomal dominant non-syndromic hearing loss (DFNA3)
even though they appear as two different forms of hearing impairment with totally contrasting
characteristics (Table 2.3).
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Table 2.3: Mutations in GJB2 that result in non-syndromic dominant hearing impairment
Dominant Mutations
Mutation name Description
delE42 deletion of AGG at 125
W44S G to C at 131
W44C GtoCat132
R75Q G to A at 224
R184Q G to A at 551
C202F G to T at 60S
Protein domainEffect
deletion of Glutamic acid at 142
Tryptophan at 44 into Serine
Tryptophan at 44 into Cysteine
Arginine at 75 into Glutamine
Arginine at 184 into Glutamine
Cysteine at 202 into Phenylalanine
EI
EI
El
El
EI
EI
Adapted from the Connexin Homepage, 2003.
2.4 GAP JUNCTIONS AND CONNEXINS
2.4.1 GAP JUNCTIONS AND THEIR ROLE IN HEARING
In animal tissue, when cells are adjoining each other, they are often connected by gap junction
structures that produce a widespread intercellular signaling mechanism, known as gap junctional
intercellular communication (GJIC). Therefore, GJIC allows for the passive flow of small molecules
between adjacent cells thereby connecting cells metabolically (Garrett and Grisham, 1999; Ahmad and
Evans, 2002). Gap junctions promote the fast exchange of intercellular ions and other molecules, which
results in almost immediate action potentials being produced. Due to this property, gap junctions are
found in neurons and other excitable cells, such as epithelial cells as well as smooth and cardiac muscle
cells (Zelante et al., 1997; Prasad et al., 2000). Gap junctions are also found in cells that are not
directly connected with the circulatory system, such as the lens cells of the eye, where GJIC provides a
means of nutrient transportation (Garrett and Grisham, 1999).
Gap junctions are formed from hexameric arrangements of specific proteins, known as connexins. Each
sub-unit of the arrangement, known as a connexon or hemichannel, is made up of six connexins that
form a cylinder, with an average length of 7.5 nm and diameter of 2.5 nm. In this conformation the
connexons are usually tilted, with regards to the sixfold axis running down the center of the hexamer,
and bridge the extracellular space between the two neighboring plasma membranes. This configuration
produces a central pore with an average diameter of approximately 1.8 to 2.0 nm, which allows small
15
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molecules of up to 1.2 kDa to pass through uninhibited, but prevents proteins, nucleic acids and other
large structures from doing so (Garrett and Grisham, 1999; MUller et al., 2002). This central pore is an
aqueous channel that joins the cytoplasm of the adjacent cells and forms the primary structural unit of
the gap junctions that are found as closely packed groups (Krutovskikh and Yamasaki, 2000; Ahmad
and Evans, 2002).
A number of coordinated events have to take place for GJlC to assemble, whereby it is assumed that
different parts of the connexin molecule are implicated in regulating the various steps of the procedure.
Firstly, the newly formed connexin protein must be inserted into the membrane of the endoplasmic
reticulum (ER) accurately, where it is then assembled into a connexon. Secondly, the connexon has to
be correctly separated from the Golgi apparatus, which is then followed by its transportation into the
lateral plasma membrane of the cell. Finally, it has to find and dock with a correlating connexon in an
adjacent cell thereby producing an intracellular channel (Krutovskikh and Yamasaki, 2000).
It is important to be able to regulate metabolic intercellular communication, hence the gap junctions
have the ability to close under abnormal conditions thereby protecting neighbouring cells. This closure
of the central pore occurs by a twisting, sliding motion of the connexons produced by a localized
conformation change at the cytoplasmic ends of the connexins. Gap junctions appear to be sensitive to
membrane potentials, hormonal signals, pH changes and intracellular calcium (Ca) ion levels.
However, it has been suggested that Ca ions play an important role in the gating of the gap junction.
Under normal conditions the intracellular levels of Ca ions is less than 10.7 M, thereby signaling the
opening of gap junctions so that intracellular communication can take place. On the other hand, the gap
junctions are quickly closed if the Ca ion level reaches 10.5 M or higher (Garret and Grisham, 1999;
MUlier et al., 2002).
One of the most important functions of gap junctions is the regulation of the fluid and ion balance
within the cochlea, which is a unique system that allows for the separation of ions as well as their
transfer and transport during the process of hearing. This communication, which occurs via gap
junctions between bordering basal cells, sustains the endolymphatic potential by retaining the high
levels of potassium (K). This is achieved by removing K ions, which were released from the cochlear
hair cells into the extracellular space within the organ of Corti, by way of the gap junction network of
the epithelial cells. The K ions are then discharged in an area where the extracellular K concentration is
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lower. An example of a location with a lower extracellular K concentration would be the root cell
process. A brief summary of the process would be as follows: a mechanical vibration of the cochlear
leads to K ions entering the hair cell where it is then released basolaterally via the epithelial gap
junctions back to the stria vascularis (Engel-Yeger et al., 2002).
A number of research results have supported the vital role that gap junctions play in the auditory
process. Firstly, it has been shown that there are gap junctions present between the outer hair cells
(OHCs) and the supporting cells, which include melanocytes, within the ear. Secondly, the endothelium
of the scala media of the cochlea, which is separated from the endolymphatic space by tight junctions
in the marginal cell layer, has also been implicated in the manufacturing of a receptor response to
sound. Finally, gap junctions have been identified in both epithelial and connective tissue cells, which
are involved in the recycling of endolymphatic K ions, in the rat cochlea. This provides a
morphological basis for GJIC taking place in response to an auditory stimulus as well as for the electric
coupling of receptor cells (Zelante et al., 1997).
There is some debate as to how a mutation in the connexin that forms the gap junctions would affect
the auditory process. According to Engel-Yeger et al. (2002) the disrupted recycling ofK ions would
deprive the stria vascularis of K ions because they would not have been released into the scala media
where it would act as the dominant cation involved in carrying the hair cell receptor currents.
Therefore, the impaired recycling of K ions may hamper the establ ishment of the receptor potential that
is found in both the OHCs, which are sensitive to the displacement of the basilar membrane, and the
inner hair cells (IHCs), which are sensitive to the basilar membrane velocity. On the other hand,
Lefebvre and Van De Water (2000) maintain that the disturbed recycling of K ions would lead to the
local intoxication of the organ of Corti. This would occur due to the K ions not being removed from the
synapses at the base of hair cells and being transported via the supporting cells and fibroblasts to the
endolymph in the cochlear duct.
2.4.2 THE CONNEXIN PROTEIN FAMILY
Connexin proteins are involved in the formation of gap junctions that are found in glial, epithelial,
smooth and cardiac muscle cells (Estivill et al., 1998). Six connexin protein chains form a hexamer,
known as a connexon, which then links with another connexon in a neighboring cell to form a gap
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junction (Figure 2.2). A connexon can be made up of a number of different types of connexins, and a
variety of connexons can link to form various types of gap junctions. Therefore, linking of the same
connexons produces homotypic channels whereas when different connexons bond they result in
heterotypic channels. This ability allows gap junctions to have different distinct physiological
properties depending on the tissue they are present within, thereby determining which molecules or
ions can pass through (Jun et al., 2000; Kemperman et al., 2002).
To date, 21 members of the connexin family have been discovered in mammals as well as mammalian
isoforms in non-mammalian vertebrates (Muller et al., 2002). The family can be divided into at least
three subfamilies, a, ~, and y, according to evolutionary properties. However, it is more common to
name the different connexin proteins according to their molecular weights that vary from 25 - 62 kDa
(Krutovskikh and Yamasaki, 2000; Ahmad and Evans, 2002). Often the connexin genes are found as
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Figure 2.2: Schematic representation of a gap junction
connexon
Adapted from Kemperman et al., 2002.
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clusters on a chromosome. For example, genes for connexins 26, 30 as well as 46 are found on
chromosome 13q12 and it is thought that a fourth possible connexin gene may also be reside in the
same area.
Gap junctions are found as thousands of linked connexon pairs that are arranged into junctional plaques
that are planar, double-layered structures with clear borders. Connexins are membrane proteins that
display a conserved core that contains the intracellular N-terminus, four transmembrane domains and
two disulphide-linked extracellular loops. They also contain a variable section that is made up of the
cytoplasmic loop and intracellular C-terminus (Maestrini et al., 1999; Muller et al., 2002). Each area
of the connexin protein has a specific role to play in its correct functioning (Figure 2.3), which is
briefly summarized below (Kelley et al., 1998; Krutovskikh and Yamasaki, 2000):
.:. N-terminus (NT): is relatively small, approximately 20 residues. It plays a role, together with
Ml, in voltage gating of the central pore of gap junctions .
•:. Transmembrane domains (MI - M4): are thought to playa role in the formation of the central
pore and therefore they are important in the selective permeability of the gap junction. It is also
thought that these areas are crucial for the correct transportation of the connexin into the plasma
membrane .
•:. Extracellular loops (E1 and E2): are crucial for the correct linking of neighbouring connexons.
There are three cystines present, which are conserved among all the connexin family, that are
important for intramolecular stabilization. These areas are also involved in the selective
compatibility between different connexin types when forming heterotypic channels .
•:. Cytoplasmic loop (CL): is not highly conserved as it has a variable size and amino acid
composition amongst the connexin family. Together with the C-terminus it is implicated in pH
gating of the gap junctional channel.
.:. C-terminus (CT): is the most variable area amongst the connexin family and it has been
suggested that it is not important for normal functioning.
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The structure and function of connexins have been studied in great detail at the biochemical and
physiological levels by using mutant forms. It appears that connexins may be unique amongst other
integral multimeric membrane proteins, as it seems that they do not oligomerize within the ER but in
the trans-Golgi network (TON) instead, where an unknown TON chaperone may be involved. This is a
novel mechanism that is similar to that which is observed in the production of channels by a number of
bacterial toxin proteins, therefore it is implied that this is an evolutionary conserved membrane-
integration mechanism that has been retained in mammals. It has been suggested that the levels of most
of the different connexin types are linked to transcription or mRNA turnover as it seems to be rapid
(Kelley et al., 1998; Ahmad and Evans, 2002).
Figure 2.3: Schematic representation ofCx26 and some of its mutations
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The mutation studies of connexin proteins have also highlighted a number of conserved residues, which
indicate that these residues are very important for the correct functioning of the connexin no matter
what tissue-specific role it is in. There appears to be some evidence that connexin proteins also playa
role in other functions besides GJIC, such as the regulation of the expression of growth control genes,
cell differentiation, as well as the suppression of tumors (Krutovskikh and Yamasaki, 2000). This was
shown by Kartz (1995) who proposed that connexin expression might playa role in the production of
complex functional architecture during the development of the brain by preparing the basis of cortical
circuits that will mature by synapse formation. It was also shown that GJB2 is considered a class II
tumor-suppressor gene because it is down regulated in tumor tissue, whereas it is up regulated during
the S and G2 phases of the cell cycle (Kelley et al., 1998).
It was also discovered during mutation analysis studies that several mutations that had been detected in
different connexin genes, and were involved in different diseases, were in fact topologically similar. In
addition, all of the mutations were either in the transmembrane domains (mostly in M2) or situated
close to them. It is interesting to note that even though the expression of a mutated connexin occurs in
many tissue types, because all connexin mutations that lead to human diseases are caused by germ-cell
mutations, only certain functions of organs or tissue properties are affected. For example, the majority
of the mutations found in GJB2 lead to the complete absence of Cx26. However, the only clinical
symptom that develops is deafness, even though Cx26 is expressed in a number of different types of
tissue. It is suggested that this is possible because other connexins can act as a substitute for Cx26 in
the other tissues but not in the cochlea (Estivill et al., 1998; Krutovskikh and Yamasaki, 2000). It
appears that the connexin protein family plays an integral part in the process of normal hearing as it has
been discovered that a number of mutations found in different connexins have been associated with
hearing loss (Lin et al., 2001).
2.5 THE CONNEXIN 26 PROTEIN
In 1994 the first autosomal recessive non-syndromic deafness locus, DFNB1, on chromosome 13ql1
was identified by Guilford et al. This was followed in 1997 by the discovery of the gene, GJB2
(OMIM: 121011), that is linked to this locus (Figure 2.4). GJB2 belongs to a highly conserved family
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Figure 2.4: A schematic representation oj chromosome 13 indicating the position of the
DFNBI locus together with polymorphic markers
13,
12. D13S:17,S'
0[3S;141
DF~l
of genes that encode the polypeptides that make up gap junctions. More specifically GJB2 encodes
Cx26, which is a p-2 gap junction protein that is expressed in distinct areas of the cochlea (Griffith et
al., 2000; Jun et al., 2000; Houseman et al., 2001).
The GJB2 gene is small with a length of approximately 5.5 kb of which only 2.4 kb is mRNA that
translates into a protein consisting of 226 amino acids. The gene consists of two exons separated by a
single intron. The first exon is non-coding whereas the second exon codes for the Cx26 protein (Figure
2.5). The size of the non-coding exon 1 is 158 bp and its 3' end is situated 3170 bp upstream from the
Adapted from Scott et al., 1995.
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single intron. The first exon is non-coding whereas the second exon codes for the Cx26 protein (Figure
2.5). The size of the non-coding exon 1 is 158 bp and its 3' end is situated 3170 bp upstream from the
5' end of the coding exon 2 whose size is approximately 681 bp (Kiang et al., 1997; Denoyelle et al.,
1999; Kemperman et al., 2002; Pampanos et al., 2002).
Figure 2.5: Diagram ofGJB2 showing the single coding exon (Exon 2) and the non-coding
exon (Exon 1)
Cen Intron 1 3170 bp Tel
Adapted from Ferraris et al., 2002.
2.5.1 F UNCTIONS OF CONNEXIN 26
Cx26 gap junctions are found together with other connexins in numerous types of cells and tissues in
humans including alveolar cells, ependyma hepatocytes, intestine, keratinocytes, leptomeninges,
myometrium, pancreatic acinar cells and pinaelocytes (Scott et al., 1998A; Denoyelle et al., 1999). The
main area where Cx26 is expressed, as gap junctions, is in the inner ear within the cochlea non-sensory
epithelial and the connective tissue cells (Engel-Yeger et al., 2002.). The non-sensory epithelial cells
include the inner sulcus cells, interdental cells of the spiral limbus, supporting cells of the Organ of
Corti, outer sulcus cells, and the cells found within the root process of the spiral limbus (Figure 2.6).
On the other hand, the connective tissue cells include the fibrocytes of the spiral limbus and spiral
ligament, basal and intermediate cells of the stria vascularis as well as the mesenchymal cells found
lining the scala vestibuli (Kammen-lolly et al., 2001; Kenna et al., 2001).
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Figure 2.6: Structure of the cochlea indicating the various non-sensory epithelial
cells and connective tissue cells
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Adapted from Jun et al., 2000.
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While studying the immunoreactivity traits of Cx26 within rats the distribution of Cx26 was
discovered. The first indication of Cx26 activity is at the prenatal age of 11 weeks where it is then
maintained at a high level for 31 weeks of gestation. By fetal week 20 the distribution of Cx26 activity
appears similar to that of adults. It was found that the emergence of the Cx26 activity followed in
parallel with the start of development and histological maturation. It was also established that Cx26
activity plays a role in functional maintenance (Kammen-lolly et al., 2001).
Due to the presence of Cx26 within the different types of cells found in the inner ear, it was believed
that it is involved in the recycling of K ions during the process of hearing. This was assumed due to the
fact that gap junctions are necessary for maintaining the high K concentration found in the endolymph
of the inner ear (Kenna et al., 2001; Kemperman et al., 2002). It is understood that if there is a loss in
functioning of Cx26 molecules it will affect the proper working of gap junctions. This leads to a
disturbance in the flow of K ions through the network of gap junctions being produced, which will lead
to hearing loss occurring (Van Laer et al., 2001).
2.5.2 THE FREQUENCY OF DFNBl LINKED DEAFNESS
It is estimated that one in 3750 children in the general population is affected by autosomal recessive
non-syndromic deafness due to mutations occurring in the GJB2 gene. This figure was determined by
taking the accepted figures of one in 1000 children suffering from congenital hearing loss, together
with the two thirds of these that are due to a genetic cause. Also taken into account was the 80% that
have an autosomal recessive pattern of inheritance and the approximate half that are thought to be due
to mutations in GJB2. From this it could also be determined that the carrier frequency for GJB2
mutations is approximately 3.3% or one in 30 (Wilcox et al., 1999). However, the actual contribution
to non-syndromic hearing impairment by mutations found in the GJB2 gene varies from 0 - 40 %
between populations thereby demonstrating genetic heterogeneity (Pampanos et al., 2002).
High carrier rates of specific mutations, such as seen with those found in GJB2, are normally ascribed
to a founder effect that took place sometime in the past within the given population. To prove this
hypothesis one can study the conservation of haplotypes with the use of closely linked markers. In the
case of recessive genes, the high carrier rates are usually caused by bottlenecks taking place within a
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population, which causes the size of the population to reduce greatly. This leads to the conservation of
the haplotype around the mutation due to there being very few mutant chromosomes present in the
population when the bottleneck occurs (Morell et al., 1998).
The high carrier rate can also be caused by endogamy, which is the bias of individuals to marry within
their community. For example, if all deafness was due to recessive genes at a single locus and all those
that were deaf were to marry each other, it would lead to the frequency of hearing loss to double within
the first generation. At first it was assumed that this phenomenon would not play such a large role due
to hearing impairment being heterogenic, but due to the discovery that hearing loss due to GJB2
mutations is more common than previously thought, it had to be reconsidered. This is due to the fact
that in a population where random mating occurs the expected frequency of homozygotes would be the
square of the gene frequency for a specific type of recessive hearing loss. However, in the case of
marriages between two homozygotes with the same deafness, the frequency would equal to the fourth
power of the gene frequency (Nance et al., 2000).
2.5.3 THE CHARACTERISTICS OF AUTOSOMAL RECESSIVE NON-SYNDROMIC
HEARING LOSS INVOLVING MUTATIONS IN GJB2
The phenotypic features that have been linked to autosomal recessive non-syndrornic hearing loss due
to mutations in GJB2 include that the deafness is prelingual in onset, and has no associated syndromic
conditions or radiological abnormalities of the inner ear. There should also be no vestibular
irregularities, which would include walking taking place after 18 months, episodes of vertigo and
abnormal vestibular caloric test result (Jun et al., 2000; Marlin et al., 2001).
The degree of hearing impairment that is observed can be classified as mild, moderate, severe and
profound. However, it was noted that there was a characteristic loss amongst the high frequencies (4
000 - 10 000 Hz). Generally, the hearing loss was not progressive and it was associated with sloping or
flat audiometric curves, which were equal in both ears (Denoyelle ~tal., 1999; Wilcox et al., 2000).
Specifically, for 35delG homo zygotes it has been observed that there is no distortion product oto-
acoustic emissions (DPOAEs) except sporadically at 1 000, 8 000 and l O 000 Hz. Whereas, those
individuals with normal hearing have larger DPOAE responses at all frequencies than those individuals
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who are carriers of the 35deiG mutation. With auditory brainstem evoked potential (ABEP) tests it is
noticed that homozygotes have variable results but the majority show partial or absent ABEPs. This
therefore indicates that the function of the outer hair cells (OHCs) is affected by the 35deiG mutation
(Engel- Yeger et al., 2002).
Another characteristic of autosomal recessive non-syndromic deafness is interfamilial as well as
intrafamilial variation in the severity of the hearing impairment. This means that there is a difference in
the degree of hearing loss amongst families, generations as well as siblings. A possible reason for this
is that other factors affect the expression of the mutated GJB2 gene, for example, a second gene that
shares partial functioning together with GJB2 (Engel- Yeger et al., 2002). More specifically this
variation in the level of deafness could be caused by the variable expression of this second gene or its
polymorphic variants. Alternatively, the variation could be explained by the timing or the level of
expression of Cx26 or a second gene (Kelley et al., 1999).
Clinical evaluation at a microscopic level of temporal bones of those suffering from non-syndromic
autosomal recessive deafness revealed that no neural degeneration is present and that there is a healthy
collection of spiral ganglion cells. However, there is an almost complete deterioration of hair cells in
the organ of Corti, agenesis of the stria vascularis, as well as a severed and rolled-up tectorial
membrane. The condition of the tectorial membrane is possibly due to the near total lack of hair cells in
this area of the inner ear. Due to the neurons in the spiral ganglion still being preserved it is possible to
conduct successful cochlear implants for the rehabilitation of deaf patients with DFNB 1 linked hearing
impairment (Jun et al., 2000).
2.5.4 MUTATIONS OF GJB2 THAT ARE INVOLVED IN DFNBI HEARING IMPAIRMENT
Even though up to a 100 different genes have been identified that playa role in hearing impairment it is
now accepted that mutations in GJB2 account for up to 40% of all genetic cases. (Nance et al., 2000)
Altogether more than 70 mutations of GJB2 have been linked to deafness (Table 2.4), most of which
are found in the coding region of GJB2 encoded by a single exon of 681 bp (Simsek et al., 2001;
Shahin et al., 2002). It is assumed that those mutations that lead to missense, deletion or frameshift
changes are likely to be inactivating null mutations, which would lead to the formation of proteins that
are either non-membrane anchored or are missing their cytoplasmic tails (Carrasquillo et al., 1997). It
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has been estimated that the carrier frequency of any mutation found in the GJB2 gene is most likely
between 1:20 and 1:25 (Estivill et al., 1998).
Table 2.4: Sequence variations reported in GJB2
Autosomal recessive mutations that cause non-syndromic recessive deafness
Mutation name Description Effect Protein domain
IVSI+I G to A G to A at -3172 Splice site None
-3170G to A G to A at -3170 Splice site None
MIV A to G at I No protein production NT
T8M C to T at 23 Threonine into Methionine NT
31dell4 deletion of 14 nucleotides at 3 I Frameshift NT
31de138 deletion of 38 nucleotides at 31 Frameshift NT
GI2V G to T at 35 Glycine at 12 into Valine NT
35deiG deletion ofG at 30-35 Frameshift NT
35insG insertion ofG at 30-35 Frameshift NT
KI5T AtoCat44 Lysine at 15 into Threonine NT
51dell2insA deletion of 12 nucleotides and Frameshift NT
insertion of A at 51
SI9T G to C at 56 Serine at 19 into Threonine NT
I20T T to Cat 59 Isoleucine at 20 into Threonine NT
W24X G to A at 71 Tryptophan at 24 into a stop codon Ml
V27I+EI14G G to A at 79 + A to G at 341 Valine at 27 into Isoleucine and Glutamic MI +CL
acid at 114 into Glycine
R32C C to T at 94 Arginine at 32 into Cysteine Ml
R32H G to A at 95 Arginine at 32 into Histidine MI
M34T T to C at lOl Methionine at 34 into Threonine MI
V37I G to A at 109 Valine at 37 into Isoleucine MI
A40E C to A at 119 Alanine at 40 into Glutamic acid EI
W44X G to A at 132 Tryptophan at 44 into a stop codon EI
G45E G to A at 134 Glycine at 45 into Glutamic acid EI
E47X G to Tat 139 Glutamic acid at 47 into a stop codon EI
E47K G to A at 139 Glutamic acid at 47 into Lysine El
167deiT deletion of T at 167 Frameshift EI
Q57X C to T at 169 Glutamine at 57 into a stop codon EI
176-191de116 deletion of 16 nucleotides at 176 Frameshift EI
Y65X C to Gat 195 Tyrosine at 65 into a stop codon EI
W77R T to C at 229 Tryptophan at 77 into Arginine M2
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W77X G to A at 231 Tryptophan at 77 into a stop codon M2
235deiC deletion ofC at 233-235 Frameshift M2
L79P T to C at 236 Leucine at 79 into Proline M2
Q80P A to C at 239 Glutamine at 80 into Proline M2
182M C to G at 246 Isoleucine at 82 into Methionine M2
V84L G to C at 250 Valine at 84 into Leucine M2
S85P T to C at 253 Serine at 85 into Proline M2
L90P T to C at 269 Leucine at 90 into Proline M2
269insT insertion of T at 269 Frameshift M2
V95M G to A at 283 Valine at 95 into Methionine CL
Y97X not described Tyrosine at 97 into a stop codon CL
290-29I insA insertion of A at 290 Frameshift CL
HIOOY C to T at 298 Histidine at 100 into Tyrosine CL
299-3 OOdelAT deletion of AT at 299-300 Frameshift CL
302de13 deletion of AGA at 302 Deletion of Lysine at 102 CL
EIOIG A to G at 302 Glutamic acid at 101 into Glycine CL
3lOdeU4 deletion of 14 nucleotides at 3 10 Frameshift CL
312dell4 deletion of 14 nucleotides at 3 12 Frameshift CL
314de1l4 deletion of 14 nucleotides at 314 Frameshift CL
333-334delAA deletion of AA at 333-335 Frameshift CL
Sl13R T to G at 339 Serine at 113 into Arginine CL
delEl20 deletion of GAG at 360 deletion of Glutamic acid at 119-120 CL
Kl221 A to T at 365 Lysine at 122 into Isoleucine CL
Ql24X C to T at 370 Glutamine at 124 into a stop codon CL
Yl36X C to A at 408 Tyrosine at 136 into a stop codon CL
Sl39N G to A at 416 Serine at 139 into Glutamine CL
Rl43W C to T at427 Arginine at 143 into Tryptophan M3
El47K G to A at 439 Glutamic acid at 147 into Lysine M3
469deiG deletion of G at 469 Frameshift E2
486insT insertion of T at 486 Frameshift E2
Rl65W C to T at493 Arginine at 165 into Tryptophan E2
504insAAGG insertion of AAGG at 504 Frameshift E2
509de1I4 deletion of 14 nucleotides at 509 Frameshift E2
509insA insertion of A at 509 Frameshift E2
515de1I7 deletion of 17 nucleotides at 515 Frameshift E2
WI72X G to A at 516 Tryptophan at 172 into a stop codon E2
Pl75T C to T at 523 Proline at 175 into Threonine E2
V178A T to Cat 533 Valine at 178 into Alanine E2
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R184W C to G at 550 Arginine at 184 into Tryptophan E2
R184P G to C at 551 Arginine at 184 into Proline E2
572delT deletion ofT at 572 Frameshift E2
S199F C to Tat 596 Serine at 199 into Phenylalanine M4
1203K TC to AA at 608 Isoleucine at 203 into Lysine M4
N206S A to G at 617 Glutamine at 206 into Serine CT
631delGT deletion of GT at 631-632 Frameshift CT
L214P T to C at 641 Leucine at 214 into Proline CT
645-648de1T AGA deletion of TAGA at 645 Frameshift CT
Mutations with unknown modes of inheritance
Mutation name Description Effect Protein domain
IVSI-12C>T C to Tat -12 from exon 2 Unknown None
V84A T to C at 251 Valine at 84 into Alanine M2
Tl23N C to A at 368 Threonine at 123 into Asparagine CL
E129K G to A at 385 Glutamic acid at 129 into Lysine CL
R143Q G to A at 428 Arginine at 143 into Glutamine M3
Y155X T to A at 465 Threonine at 155 into a stop codon M3
Ml63V G to A at487 Methionine at 163 into Valine E2
A171T G to A at 511 Arginine at 171 into Threonine E2
A197S G to Tat 589 Alanine at 197 into Serine M4
Mutations of unknown effect (polymorphisms)
Polymorphism Description Frequency Protein domain
Exonl-493dell0 del of lOnt at 493 5' of exon 1 not determined 5'UTR
-3558T to C T to C at -3558 not determined 5'UTR
CIT at -15 C to T at -15 not determined 5' UTR
V271 G to A at 79 not determined Ml
BOl T to A or C at 90 not determined Ml
A40A A to C at 120 not described EI
S72C C to G at215 not determined El
F83L· C to G at 249 3/200 control chromosomes M2
L89L C to A at 267 not determined M2
E114G A to G at 341 not determined CL
Tl23A A to G at 367 not determined CL
R127H G to A at 380 not described CL
11281 C to T at 384 1% CL
V153I G to A at 457 4/367 controls (1%) M3
G160S G to A at468 2/200 control chromosomes E2
C169Y G to A at 506 not determined E2
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V182V G to? at 546 not determined E2
V190V C to Tat 570 not described E2
1203T T to C at 608 not determined M4
CIT at 682 Cor T at 682 not determined 3' UTR
CIT at 765 Cor T at 765 not determined 3' UTR
Adapted from the connexin homepage, 2003.
It has been reported in some studies that not all individuals suffering from hearing loss carry both
copies of the GJB2 mutation that are necessary for them to exhibit recessive deafness (Marlin et al.,
2001; Lalwani, 2002). There are a number of possible explanations for this phenomenon. Firstly, there
could be variants in the .non-coding region that could influence the gene expression of GJB2. This
however, is unlikely because further research in this area has not identified any such mutations.
Secondly, the single GJB2 mutation may only be present by chance and not be related at all to hearing
loss, however this explanation seems unlikely. Finally, the most likely explanation is that another gene
could be affecting the capability of GJB2 from functioning normally (Wilcox et al., 2000).
Interestingly, the GJB2 gene has also been implicated in disorders besides autosomal recessive non-
syndromic deafness: six mutations have been linked to DFNA3 and three have been linked to
syndromic disorders. These disorders include an autosomal dominant skin disease known as Clouston
hidrotic ectodermal dysplasia (HED, OMIM: 129500) and Vohwinkel's syndrome (VS, OMIM:
124500), which is characterized by mutilating keratoderma and hearing loss (KelseIl et al., 1997;
Maestrini et al., 1999; Kenna et al., 2001). This phenomenon of more than one disorder being linked to
the same region of a chromosome is possibly due to either the existence of two closely linked genes, or
a single mutation within a single gene presenting different symptoms depending on the genetic
background or other environmental factors. The most likely explanation is that different mutations
within the same gene produce different symptoms depending where they lie within the protein itself,
thereby, having an effect on the protein's structure or function (Scott et al., 1995).
It has been reported that different mutations of GJB2 play an important role in different populations,
for example, 35deiG in Caucasians, 167deiT in Ashkenazi Jews, 235deiC in Asians and R143W in
Africans (Pampanos et al., 2002). These four specific mutations will be discussed in further detail in
the following sections.
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2.5.4.1 THE 35deiG MUTATION
The GJB2 mutation, 35de1G, is formed due to a deletion of one guanine (G) from a set of six that are
located from nucleotide position 30 to 35. This leads to a frameshift mutation resulting in a premature
stop codon at nucleotide 38 (Pampanos et al., 2002). The Cx26 protein that is formed is significantly
shorter than in the wild type protein, and therefore it is unlikely to be inserted into the plasma
membrane.
This mutation is the most common mutation causing non-syndromic autosomal recessive deafness in
Caucasian populations. The frequency of 35deiG varies from greatly between ethnic groups such as 0.0
in Japan and 0.313 in Lebanon. The carrier frequency within the Mediterranean is estimated to be as
high as 1:31, however, it is lower or non-existent in other ethnic groups (Table 2.5). It can be deduced
from both the carrier frequency of GJB2 mutations as well as the prevalence of other mutations besides
35deiG in non-Caucasian populations that different variations will characterize those which are
common to these ethnic groups (Rickard et al., 2001).
Table 2.5: Carrier frequency of the 3SdeiG mutation within several populations
Population Carrier frequency
Northern and central Europe
Norway 0.005
Denmark 0.021
Estonia 0.044
United Kingdom 0.119
Germany 0.050
Belgium 0.012
Holland 0.022
France (Brittany) 0.010
France 0.103
Czech Republic 0.021
Slovenia 0.005
Austria 0.101
Bulgaria 0.006
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Southern Europe
Portugal
Spain
Italy
Italy (Sardinia)
Malta
Greece
Turkey
North America
White Americans
African Americans
Asian Americans (Indian, Japanese, Koreans)
Ashkenazi Jewish Americans
Other populations
Egypt
Arabs
Lebanon
Israel
Korea
Japan
Australia
Oman
0.022
0.023
0.122
0.034
0.028
0.121
0.116
0.019
0.0
0.0
0.007
0.0
0.017
0.313
0.147
0.005
0.0
0.041
0.0
Adapted from Van Laer et al., 2001; Kemperman et al., 2002; Pampanos et al., 2002.
There is a debate as to whether the high frequency of the 35delG mutation is due to a founder effect or
the presence of a mutational hotspot. There appears to be an equal amount of evidence supporting both
possibilities. A fluctuation in carrier frequencies for the 35delG mutation between different ethnic
groups together with the presence of other common mutations in these populations support the
hypothesis that the high frequency is due to a founder effect (Pampanos et al., 2002). If the theory that
the high frequency is due to a hypermutable region were correct, it would be expected that all ethnic
groups would have had roughly the same carrier frequency (Abe et al., 2000). Furthermore, haplotype
analysis has revealed the sharing of a very small chromosomal interval between patients that are
homozygous for the 35deiG mutation, thereby indicating that the common ancestor occurred
approximately 500 generations or roughly 10 000 years ago (Shahin et al., 2002). Conversely, the
information supporting the hypothesis that the high frequency is due to a mutational hotspot includes
that this nucleotide sequence has structural similarities to other known hypermutable regions within the
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genome. Further evidence is provided by the deletion of any of the six Gs resulting in the same
genotype (Kelley et al., 2000; Tekin et al., 2001).
If it is assumed that the high frequency of 35deiG is due to a founder effect it is then possible to explain
the spread of this mutation across Europe, the Mediterranean, the United States as well as other
countries due to the age of this variation. It was hypothesized that the mutation probably originated
somewhere in the Middle East from where it radiated throughout Europe along the two Neolithic
population movement lines, the first of which reached Italy and Spain by following the coast of the
Mediterranean Sea, whereas the second reached Northern Europe by following the Danube and Rhine
valleys. From Europe the mutation would have spread to the United States and other countries by
means of colonization and emigration (Van Laer et al., 2001).
2.5.4.2 THE i67delT MUTATiON
Mutation 167deiT in GJB2 is caused by a deletion ofa Thymine (T) at nucleotide 167, which leads to a
frameshift mutation to occur at amino acid 56, followed by a premature termination after a further 25
codons (Sobe et al., 1999). The Cx26 peptide that is formed is largely truncated and therefore it is not
expected to assemble correctly or show any functional activity as a gap-junction protein (Griffith et al.,
2000). From analyzing the haplotypes that flank the 167deiT mutation it was inferred that it had
originated from a single founder as there was a conservation of this region amongst patients (Morell et
al., 1998; Tekin et al., 2001).
The 167deiT mutation is the second most common mutation worldwide, but it is confined to the
Ashkenazi Jewish population at a carrier frequency of approximately 4% (Tekin et al., 2001). From this
high carrier frequency it has been roughly estimated that 1 in 1765 Asheknazi Jews are affected by
autosomal recessive non-syndromic deafness (Morell et al., 1998).
2.5.4.3 THE 235delC MUTATION
The range of mutations in GJB2 found within the Asian population is considerably different from those
that are found in other ethnic groups with an European background. For example, the 35deiG mutation
of GJB2 is not observed in the Japanese population, however, the .235de1C mutation is seen in the
34
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Japanese but not the Caucasian population (Abe et al., 2000, Kudo et al., 2000). The 235deiC mutation
is caused by a deletion of a Cytosine (C) at nucleotide position 235, which leads to a frameshift that is
followed by a premature stop codon.
The 235deiC mutation is the most common variant in Asia with a frequency amongst those suffering
from autosomal recessive non-syndromic deafness ranging from 1% in Japan to 5% in Korea (Park et
al., 2000; Houseman et al., 2001). These high frequencies together with the fact that they are limited to
a specific ethnic background suggests that the 235deiC mutation is the result of a founder effect,
similar to the I 67delT mutation which occurs in the Ashkenazi Jewish population (Abe et al., 2000).
2.5.4.4 THE R143W MUTATION
In Ghana the RI43W mutation in GJB2 was identified at a frequency of 90%, making it the most
common GJB2 mutation linked to autosomal recessive non-syndromic hearing loss in that population
(Hamelmann et al., 2001). This high frequency is most likely due to a founder effect, because
haplotype analysis has revealed that the region around the mutation has been conserved and the
mutation probably occurred 60 generations ago (Brobby et al., 1998).
The R143W mutation is caused by the substitution of a T by a C base at nucleotide position 427, which
leads to the exchange of amino acids from a Tryptophan to an Arginine at codon 143. This mutation
therefore falls in the M3 domain of the Cx26 protein, which would influence the selective permeability
of the central pore (Brobby et al., 1998). Interestingly, when comparing the pattern of Ghananian
GJB2 mutations to other populations, a number of differences are noted (Hamelmann et al., 2002):
.:. Compared with European countries where mutations in GJB2 cause 30-50% of all deafness
in childhood, in Ghana this is only true for 16%. The reason for this could be due to other
causes having a greater influence, such as meningitis that has a higher incidence rate in
Africa .
•:. Nonsense and frameshift mutations found within GJB2 predominate around the world but
they are very rare in the Ghanaian population .
•
•:. Mutations tend to cluster in the C-terminal half of the Cx26 protein within the Ghanaian
population whereas in other populations the majority of mutations are found in the N-
terminal half.
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2.6 THE CONNEXIN 30 PROTEIN
While screening families with autosomal recessive non-syndromic deafness it was noticed that there
were some cases where the DFNB1-linked family members did not exhibit the expected GJB2
mutations. This lead to the suggestion that another gene in the same region could be responsible for
these cases as only about 75% of the predicted mutations were detected (Grifa et al., 1999; Kelley et
al., 1999). The candidate gene that was suspected of also playing a role in autosomal recessive non-
syndromic hearing loss was connexin 30 (Cx30) as Lauterman et al. (1998) had discovered the
expression of both Cx26 and Cx30 in the inner ear. He suggested that connexin 30 formed homotypic
channels in the cochlea, but not sufficiently enough to prevent the loss of hearing. Therefore Cx30 does
not provide a substitute to the loss of functioning Cx26 (Engel- Yeger et al., 2002).
Further research concernmg Cx30, ap-class connexm, revealed that the GJB6 gene maps to
chromosome 13qI2, roughly 35 kb from GJB2 (Figure 2.7). The GJB6 gene encodes a protein that is
261 amino acids in length and is the fourth connexin linked to hearing loss (Grifa et al., 1999; Pallares-
Ruiz et al., 2002). The Cx30 protein shares 77% homology with the Cx26 protein, but has 35 additional
amino acids at its C-terminus (Kelley et al., 1999).
Figure 2. 7: Diagram ofGJB6 (Cx30) in relation to GJB2 (Cx26) and GJA3 (Cx46)
~45 kb 786 bp35 kb
Adapted from Pallares-Ruiz et al., 2002.
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2.6.1 THE FUNCTIONS OF CONNEXIN 30
Research conducted in 1996 by Dahl et al. found that mouse Cx30 was expressed predominantly in the
brain and to a lesser degree in the eyes, skin, lungs, testis and uterus. In later studies it was reported that
human Cx26 and Cx30 were both expressed in the same cells of the cochlea. Specifically they were co-
expressed in the spiral limbus, spiral ligament, basal region of the stria vascularis, and between the
supporting cells of the organ of Corti (Kelley et al., 1999). It was also noted that because Cx26 and
Cx30 are structurally highly related (Figure 2.8), they could be co-expressed in the inner ear forming
homo- and/or hetero-channels. It was thought that this expression may be a prerequisite for the
maturation of the cochlea (Pallares-Ruiz et al., 2002).
Figure 2.8: Comparison of the amino acid sequence ofCx26 and Cx30
Connexin Amino Acid Sequence
Cx26 M D W G T L Q TIL G G V N K HST SIG K I W LTV L F I F RIM I L V V A A K E V W G D
Cx30 M D W G T L H T FIG G V N K HST SIG K V W JT V I F I F R V MIL V V A A Q E V W G D
C~6 EQADFVCNTLQPGCKNVCYDHYFPJSHIRLWALQLIFVSTPALLVA
Cx30 E QED F V C N T L Q P G C K N V C Y D H F F P V S H I R L WAL Q L I F V S T PAL L V A
Cx26 M H V A Y R RH E K K R K FIK G E J K S E F K DIE EIK T Q K V R lEG S L W W T Y T
Cx30 M H VA Y Y RH E T T R K F R R GEK R N D F K DIE DIK K H K V R lEG S L W W T Y T
Cx26 S SIF F R V I F E A A F M Y V F Y V M Y D G F S M Q R L V K C N A W PCP N T V D C F V S
Cx30 S SIF F R I I F E A AF M Y V F Y FLY N G Y HLP W V L K C G 1 D PCP N L V D C FIS
Cx26 R PTE KTV F T V F M I A V S G I C J L L N V TEL C Y L L I R Y C S G K S K P V - - - -
Cx30 R PTE KTV FT 1 F MIS A S V lCM L L N V A E L C Y L L LKV C F R R S K R A Q T Q K
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Cx30 N H P N HAL K E S K Q N E M NEL r D S G Q N AlT G F P S
Variations in amino acid sequence are indicated by red text (X) and the absence of an amino acid is indicated by a
red dash (-). Adapted from the sequences deposited in the NCB! with accession number NM_004004 for Cx26 and
NM 006783 for Cx30.
2.6.2 MUTATIONS OF GJB6 THAT ARE INVOLVED IN DFNBl HEARING IMPAIRMENT
To date, only two mutations in GJB6 (OMIM: 604418) linked to autosomal dominant deafness have
been identified together with six polymorphisms (Table 2.6). The number of mutations in GJB6 that
cause non-syndromic autosomal recessive hearing loss is relatively low (Kelley et al., 1999). The only
mutation in GJB6 that has been linked to recessive non-syndromic deafness is a large deletion, known
as ~(GJB6-D13S1830) that involves the loss of approximately 342 kb of DNA (Connexin Homepage,
2003), which is discussed in detail in Section 2.6.2.1.
Table 2.6: Sequence variants that have been identified in GJB6 in autosomal dominant
deafness
Mutation name Description
Mutations that cause non-syndromic autosomal dominant deafness
Protein domainEffect
T5M C to T at 14
63deiG deletion of G at 63
Polymorphisms Description
A39A T to C at 117
P58P G to A at 174
L132L G to A at 396
Sl39G A to G at 415
Ll63L G to A at489
S199T T to A at 595
Threonine at 5 into Methionine
Frameshift
NT
El
Variants of unknown effect (polymorphisms)
Frequency Protein domain
not described
not described
not described
not described
not described
not described
Ml
El
M3
M3
E2
M4
Adapted from the connexin homepage, 2003.
The GJB6 gene has also been implicated in causing HED, which is also referred to as Clouston
syndrome. This syndrome is an autosomal dominant skin disorder that is characterized by palmoplantar
hyperkeratosis, nail hypoplasia and deformities, as well as hair defects. GJB6 is also involved in
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autosomal dominant non-syndromic hearing loss (Lamartine et al., 2000). This again is an example of
how different mutations found within connexins result in various disorders. Another case is the
mutations found in the GJR3 gene that encodes connexin 31 (Cx31). Mutations in this gene are
responsible for autosomal dominant deafness as well as for the skin disorder erythrokeratodemia
variabilis (EKV, OMIM: 133200 and 605425.001). From these findings it could be assumed that
different mutations in the connexin genes can result in either skin disorders or deafness depending on
where the mutations are located within the gene (Maestrini et al., 1999).
2.6.2.1 THE L1(GJB6-DJ3S1830) MUTATION
A deletion of 342 kb, known as ~(GJB6-DI3S1830), was first identified in the Spanish population.
This deletion dissects the GJB6 gene but does not affect the GJB2 gene and is usually observed
together with mutations found in GJR2 (Del Castillo et al., 2002). A second deletion of approximately
140 kb was identified in the Ashkenazi Jewish population as well as in the French population (Lerer et
al., 2001; Pallares-Ruiz et al., 2002). Again, it was noted that these deletions dissected GJB6 hut did
not affect GJR2 (Lerer et al., 2001; Pallares-Ruiz et al., 2002). In the past there was confusion as to
whether these deletions were distinctly different but it has been shown in a recent study that all the
patients in the previous studies contained the same deletion breakpoint junction, thereby confirming
that all the cases were those of the ~(GJR6-DI3S1830) mutation. Using the latest sequencing
information it has also been established the ~(GJB6-D13S 1830) mutation is 309 kb long and not the
previously estimated size of342 kb (Del Castillo et al., 2003).
Within the Spanish population the ~(GJR6-D13S1830) deletion is the second most frequent mutation
causing non-syndromic autosomal recessive deafness, after 35de1G, in GJR2 (Del Castillo et al., 2002).
The frequency of this deletion has also been determined in a number of other populations as is shown
in Table 2.7. Itmust be noted that there is a relatively low number of ~(GJR6-D13S1830) homozygous
cases. This is the result of the incidence rate of this mutation being too low to cause a high frequency of
patients with the homozygous genotype to be present in any of the populations studied (Del Castillo et
al.,2003).
"
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Table 2.7: Allelefrequency of L1(GJB6-D13S1830) within several populations.
Popoulation Allele Frequency (%)a
Spain (Madrid) 7.6
Spain (Barcelona) 9.7
Italy 0.0
France 8.2
Belgium 1.4
United Kingdom 5.9
Israel (Tel Aviv) 7.1
Israel (Jerusalem) 6.0
USA (Virginia) 4.5
Israel (Iowa) 1.6
Brazil 7.1
Australia 1.3
a Calculated from the number of Ll(GJB6-D 13S 1830) alleles identified divided by the total number of DFNB 1
alleles, which only included those cases were both the DFNB I alleles had been identified.
Adapted from Del Castillo et al., 2003.
It was unclear as to whether the ~(GJB6-D13S1830) mutation was due to a founder effect or the
presence of a mutational hotspot in that area of the chromosome. The latest findings, involving
haplotype analysis, have indicated that the mutation is the result of a founder effect especially amongst
the Ashkenazi Jewish population. It also appears that there is a common ancestor responsible for this
deletion amongst those populations found within those countries of Western Europe. The haplotypes
that were obtained from the Ashkenazi patients with non-syndromic deafness showed a similarity along
a 464 kb region. When this was compared with those that were obtained from Western Europe it was
noted that there was more diversity amongst those individuals from Western Europe, suggesting that
there was an older founder for this mutation as well as the possibility of various points of origin
amongst these countries (Del Castillo et al., 2003).
There are various ways in which this large deletion could result in non-syndromic autosomal recessive
hearing impairment (Del Castillo et al., 2002; Pallares-Ruiz et al., 2002):
.:. A digenic mode of inheritance is the result of either the removal of two doses of GJB6 or the
removal of one dose of GJB6 together with one dose of GJB2. This would lead to the reduction
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in the number of homomeric or heteromeric connexons present in the inner ear and therefore
there would be insufficient transportation of K ions .
•:. A monogenic mode of inheritance due to the removal of the regulatory elements that are
essential for the expression of GJB2 in the cochlea. This regulatory element would be found far
upstream of the GJB2 gene and the deletion would result in the suppression of the expression of
Cx26. However, this regulatory element of GJB2 is still hypothetical, as no such element has
been identified .
•:. The resulting phenotype of hearing loss is probably due to a combination of both mechanisms.
2.7 OTHER CONNEXIN PROTEINS
Due to connexins being distributed in many organs and systems it has been observed that mutations in
connexin genes affect these areas of the body causing different disorders. It has even been noted that
the same connexin gene can be associated with different diseases. Mutations in connexins have been
predominantly linked to alterations in the auditory system, peripheral nerves and the skin (Rabionet et
al.,2002).
Besides GJB2 and GJB6, there are other connexin genes that are associated with hearing loss. Firstly,
there is GJB3 (Cx31) that has been linked to both non-syndromic autosomal recessive deafness as well
as non-syndromic autosomal dominant deafness. The dominant form is characterized by bilateral high-
frequency hearing impairment. Secondly, a missense mutation in GJA2 (Cx43) that encodes an u-
connexin has been reported as the cause of autosomal recessive deafness in several African-American
families (Rabionet et al., 2002).
From research conducted, it appears that gap junction communication plays an important part in the
coordinated control of epidermal keratinocyte differentiation. It has also been reported that all known
p-connexin genes are expressed in human skin cells. The first connexin gene to be reported to cause the
autosomal dominant skin disorder EKV is GJB3. All mutations in this gene are missense changes that
affect several domains of the protein and lead to variable clinical symptoms. A second gene GJB4
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(Cx30.3) has also been found to co-segregate with EKV, associated with erythem gyratum repens
(Rabionet et al., 2002).
There are several types of Charcot-Marie- Tooth (CMT, OMIM: 302800) an inherited peripheral
neuropathy caused by different genes. Two connexin genes, GJBI (Cx32) and GJB3, have been linked
to this disorder. Mutations in GJBI lead to the X-linked form that has a pattern of inheritance that is
both dominant and recessive, where males have a more severe phenotype than their carrier female
counterparts who show a milder form of the disease. This disorder has characteristic features of
progressive atrophy of distal muscles, a decreased number of myelinated fibers as well as the formation
of onion bulbs, which consist of supernumerary, flattened Schwann cells. To date, more than 240
mutations have been identified in GJBI since the gene was discovered in 1993. Only recently a
dominant mutation in GJB3 was reported to cause a rare type of peripheral neuropathy that is
characterized by a wide range of disease severity. These features can range from asymptomatic cases or
individuals with persistent skin ulcers on their feet and osteomyelitis, which leads to amputations.
Symptoms of mild, asymmetrical hearing loss have also been reported together with the neuropathy in
some patients (Krutovskikh and Yamasaki, 2000; Rabionet et al., 2002).
Finally, connexm genes have also been reported to play a role in the formation of cataracts.
Specifically, mutations in GJA3 have been linked to autosomal dominant congenital cataracts and Cx50
appears to playa role in human "zonular pulverulent" cataracts (Krutovskikh and Yamasaki, 2000).
2.8 GENETIC COUNSELLING FOR NON-SYNDROMIC AUTOSOMAL
RECESSIVE HEARING IMPAIRMENT
Autosomal recessive non-syndromic deafness is relatively common with a frequency of 1 in 1 000.
This rate can be compared with other common disorders such as Down syndrome (1 in 600 - 800), cleft
lip and palate (1 in 750) and cystic fibrosis (1 in 3 500 Caucasians or I in 17 000 African-Americans)
in the United States (Kenna et al., 2001). Due to the high frequency of hearing loss, there has been an
increasing demand for a fast and precise screening service for the detection of the various mutations in
the GJB2 gene. This service needs to be population based so that it can provide the most accurate
results possible in the shortest amount of time with the least expenses being incurred (Rickard et al.,
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2001; Najmabadi et al., 2002). The screening of GJB2 for mutations was the first genetic test clinically
available for autosomal recessive non-syndromic hearing impairment (Lench et al., 1998).
There are a number of reasons why many families want to know why their children are suffering from
hearing impairment. This includes how it will affect their educational plans for the child, the method of
communication chosen, what type of hearing device or other aid should be considered, as well as
whether a cochlear transplant is a viable option. Another important reason for genetic counselling is to
determine whether there is a chance of having further children with hearing loss (Kenna et al., 2001).
According to current information it has been estimated that the chance of a normal-hearing couple
having a second child with hearing loss is between 15 and 20%. If the diagnosis determines that the
cause of deafness was not due to GJB2 mutations this risk drops to 14%, whereas if it was determined
that GJB2 was the cause the risk factor is raised to 25% (Green et al., 1999; Prasad et al., 2000).
The manner in which people determine if a condition is senous depends on their culture, SOCiO-
economic status, religion and personal experience. Therefore, these factors differ amongst populations
as well as communities (Pampanos et al., 2002). In the case of the deaf community there as some
individuals that do not consider that having a hearing impairment should be considered a serious
medical condition whereas the majority of those outside the community see it as a major handicap.
Therefore, the challenge to those that are providing a genetic counselling service is that they must be
sympathetic and sensitive to all points of view (Wilcox et al., 1999).
2.8.1 EVALUATION OF HEARING IMPAIRMENT
The standard tests that are conducted to determine the cause of deafness when a child is newly
diagnosed includes thyroid, renal, liver and immunologic function tests as well as assessments for
syphilis, toxoplasmosis and cytomegalovirus. The child can also be referred to ophthalmology and
neurology specialists. Recently advances in medicine have lead to more accurate diagnostic techniques
being developed for the use in hearing impairment identification. These new techniques include high-
resolution topography and magnetic resonance imaging (MR!) of the temporal bone (Kenna et al.,
2001).
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Previously, genetic testing was limited to dysmorphologic examinations together with a detailed
evaluation of the families' medical history. These inaccurate methods that were used in the past are
now making way for more accurate assessments based on the identification of the genes that are
involved in syndromic or non-syndromic deafness. This has lead to genetic counseling becoming an
important tool in the early diagnosis of hearing loss. (Kenna et al., 2001).
There is some debate as to where in the evaluation procedure the genetic testing for GJB2 mutations
should be placed as well as to who should be considered for such testing. On the one hand it has been
suggested that it should be the first test to be conducted, as all further tests would be unnecessary if a
positive result for GJB2 mutations is obtained, thereby saving time as well as resources. Conversely, it
has been suggested that genetic analysis of GJB2 should just be one of a number of tests conducted
thereby ensuring accurate results, i.e. preventing false positives or negatives (Figure 2.9).
When it comes to determining whom should benefit from the investigation of the GJB2 gene for
mutations, it has been proposed that only those children who show the specific phenotypic features of
DFNB 1 should undergo testing. The other possibility is that all children showing possible non-
syndromic hearing loss should be tested as deafness due to GJB2 mutations has a high frequency
amongst children and there is also such a variation in phenotypes that it is possible to incorrectly
classify a case (Denoyelle et al., 1999; Kenna et al., 2001).
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Figure 2.9: Diagnostic algorithm/or sensorineural hearing loss (SNHL) in children.
History/Physical Examination! Audiological
Diagnosis Readily Apparent
(Autosomal Dominant SNHL,
Meningitis, Trauma) Diagnosis Uncertain
I >40 dB I Mild
I Unilateral IAppropriateTreatment
Bilateral
I
Cx26 Testing
Preferential
Seating Repeat
Audiograms
Computed
Tomography Repeat
AudiogramsAbnormal No Mutations
I I
Computed Tomography
Urine Analysis
(Other Tests as Needed*)
Counselling
I
Visual Acuity Check
Hearing Aids and/or Cochlear
Amplification
* Indicates other tests: thyroid function; fluorescent treponemal antibody; erythrocyte sedimentation rate and/or Western
blot analysis; platelet analysis; Pendred syndrome and bronchio-oto-renal syndrome; genetic studies; and
electrocardiogram.
Adapted from Greinwald and Hartnick, 2002.
2.8.2 AVAILABLE TREATMENT FOR HEARING LOSS
The possible steps that can be taken for the treatment of hearing impairment include early speech and
language developmental programs as well as the use of listening devices such as hearing aids and FM
systems. Recent progress in technology has lead to the development of digital and programmable
hearing aids together with improvements being made in the analog hearing aids (Kenna et al., 2001).
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The level of deafness in those suffering from autosomal recessive non-syndromic deafness due to
mutations in the GJB2 gene, often prevents the successful use of hearing devices. The option of a
cochlear transplant is considered as a viable alternative. However, for this method to be successful
there has to be surviving as well as electrically sensitive spiral ganglion cells and cochlear nerves. Both
of these are present in patients with GJB2 related deafness and cochlear implantation is now a regular
alternative for those children that suffer from bilateral severe or profound deafness who would not
sufficiently benefit from the use of another hearing device (Jun et al., 2000; Kenna et al., 2001).
Further evidence supporting the use of cochlear transplants for GJB2 non-syndromic autosomal
recessive hearing loss has been reported by Fukushima et al (2002). He conducted a study that focused
on the performance of patients with GJB2 deafness compared to those patients with non-GJB2 deafness
who had received an implant. Itwas discovered that those with mutations in GJB2 had better language
development and cognitive ability after the transplant compared with those that were deaf due to other
causes.
2.8.3 WHOLE GENE VERSUS 35deIG SCREENING
There is some debate as to whether the whole GJB2 gene or just the 35deiG mutation should be
screened. There are a number of reasons supporting and disputing both suggestions. The high
frequency of the 35deiG mutation of GJB2 supports the idea of only screening for this mutation as
complete results will be obtained in this manner for a number of individuals suffering from autosomal
recessive non-syndromic hearing impairment (Greinwald and Hartnick, 2002). The 35deiG mutation is
also easy to detect as a number of methods have been developed recently for this purpose and it would
be practical because it saves both time as well as resources (Denoyelle et al., 1999).
However, in some populations only between 30 and 60% of children with non-syndromic autosomal
recessive hearing loss are homozygous for the 35deiG mutation found in the GJB2 gene. Therefore, in
these cases it would be necessary to screen the entire GJB2 gene for other contributing mutations that
could be found either in the coding, non-coding or promoter regions of GJB2 (Denoyelle et al., 1999;
Wilcox et al., 2000). It is possible to use direct DNA sequencing as a method to detect other possible
mutations other than 35delG, since the GJB2 gene is relatively small in size. This is the preferred
technique as it is more accurate than other methods (Simsek et al., 2001).
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2.8.4 ADVANTAGES AND DISADVANTAGES OF CONDUCTING GENETIC TESTS FOR
AUTOSOMAL RECESSIVE NON-SYNDROMIC DEAFNESS
The advantages of genetic screening of GJB2 in children with autosomal recessive non-syndrornic
hearing loss are numerous. Below is a summary of a few of the most important reasons that have been
provided for conducting such testing (Marlin et al., 2001; Greinwald and Hartnick, 2002; Kemperman
et al., 2002):
.:. Genetic testing of children who are deaf would increase the number of those that are accurately
diagnosed for autosomal recessive non-syndromic deafness. Previously they would have
remained undiagnosed, due to there being no method for this type of hearing impairment.
Currently between 25 and 52% of patients have undiagnosed non-syndromic hearing loss .
•:. Target testing for mutations that are population specific, such as 35delG, allows for a quick and
accurate diagnosis that may prevent the need for further testing .
•:. Genetic analysis would also greatly help in identifying the cause of deafness in cases where
there is no clear family history, in other words sporadic cases of autosomal recessive non-
syndromic hearing loss. It has been estimated that a third of these cases would be explained .
•:. Genetic testing for GJB2 mutations provides an opportunity for the families of affected children
to get the appropriate genetic counseling that would provide them with the correct information,
and which would help in making suitable decisions about treatment and education. Early
diagnosis leads to treatment being attained earlier, which provides better results in the long term
especially in the case of cochlear transplants .
•:. Genetic counselling would be able to provide important information concerning the risks of
future offspring who may also suffer from autosomal recessive non-syndrornic deafness.
A number of disadvantages have also been suggested concerning the genetic analysis of the GJB2 gene
in those suffering from autosomal recessive non-syndromic hearing impairment. The following list is a
summary of the most important points that have been raised concerning such screening (Green et al.,
2000; Prasad et al., 2000; Greinwald and Hartnick, 2002):
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.:. High rates of false-positives and false-negatives have been recorded. In the case of the detection
of the 35deiG mutation a frequency of 2.6 and 3.1% respectively has been recorded. This is
mainly due to the screening methods used, therefore the results can be improved by using
automated DNA sequencing .
•:. The unclear relationship between genotype and phenotype can produce misleading results that
may lead to incorrect genetic counselling .
•:. It is still difficult to determine whether certain missense mutations do in fact result in deafness
or if the variation in the DNA sequence is just a benign polymorphism .
•:. A major ethical issue that has been raised concerns the possibility of parents wanting to
terminate a pregnancy due to prenatal genetic tests indicating the likelihood of having a child
who will suffer from autosomal recessive non-syndromic hearing loss. The final decision will
have to take into account that there is a large variation in the degree of hearing loss that is
experienced by those suffering from deafness related to GJB2 mutations and that this variation
even occurs between family members.
2.9 METHODS USED FOR MUTATION DETECTION
The procedures used for the detection of mutations can be divided into two steps: firstly, the
identification of changes in the primary DNA structure by the variation of the physical or enzymatic
properties due to the presence of a mutation, and secondly, the visualization of this change. The
different methods used in mutation analysis (Table 2.7) can be divided according to whether they are
founded on the presence of prior knowledge of the characteristics of the mutation or whether the
methods are used to screen for unknown mutations (Kristensen et al., 2001).
48
Stellenbosch University http://scholar.sun.ac.za
49
CHAPTER 2: LITERATURE REVIEW
Table 2.7:Mutation detection techniques based on (A) prior knowledge of the variant
or (B) information available
(A) Analysis of known variants (B) Screening for unknown variants
Restriction fragment length polymorphism (RFLP) Single-strand conformation polymorphism (SSCP) and
heteroduplex analysis (HA)
DNA sequencing
Random amplified polymorphic DNA (RAPD) or arbitrarily
primed PCR (AT-PCR)
Direct termination PCR (DT-PCR)
Amplified fragment length polymorphism (AFLP)
Cleavage fragment length polymorphism (CFLP), enzymatic
mutation detection (EMD)
Microarrays "gain of signal"
Minisequencing
Allele specific oligonucleotide analysis (ASO-PCR)
Invasive cleavage of nucleotide probes
Ligation-based assays
Double-strand conformation analysis (DSCA)
Molecular beacons
Microarrays "loss of signal"
Fluorescence resonance energy transfer (FRET)
Adapted from Kristensen et aI., 200 I.
A number of different techniques have been used to detect the various mutations found within the
GJB2 gene and specifically the 35deiG mutation. These methods include amplification-resistant
mutation screening (ARMS), allele specific oligonucleotide analysis (ASO), allele-specific polymerase
chain reaction (PCR) and PCR-mediated site-directed mutagenesis. All these methods that have been
used have some or other disadvantage, be it expense, time or limited sensitivity (Smith and Van Camp,
1999; Antoniadi et al., 2000; Lin et al., 2001).
One of the techniques that has been relatively successful in the detection of mutations in GJB2 is the
single-stranded conformation polymorphism (SSCP) method, which involves the electrophoretic
discrimination of allelic variants (Kelley et al., 1998; Carrasquillo et al., 1997). The standard process of
SSCP analysis entails the denaturing of PCR-amplified fragments into single strands followed by the
formation of sequence-specific secondary and tertiary structures that are produced in a non-denaturing
solution during gel electrophoresis. The three-dimensional structure that forms is dependent on the
nucleotide sequence and determines the mobility of the molecule. Those strands that differ even by a
single base have distinct conformations that can be visualized by the variation in migration pattern. The
advantages of SSCP analysis include that it is simple, relatively inexpensive and highly sensitive (80%)
for fragments up to 300 bp (Hayashi and Yandell, 1993). However, this technique does have its
disadvantages, which include that the sensitivity decreases with an increase in fragment length,
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therefore the sizes of the fragments screened are limited. There is a low detection rate of G to C
transitions (Orita et al., 1989; Ganguly et al., 1993; Kristensen et al., 2001; Sambraak and Russell,
2001).
Automated DNA sequencing is considered the ultimate mutation detection method that can be used to
identify both known and unknown changes in the DNA arrangement as it is the most accurate
technique developed to date (Kristensen et al., 2001). This technique involves the use of four different
dyes as labels in base-specific reactions. The labels can either be connected to base-specific ddNTPs or
to the primer, in which case there have to be four sets of primers to correspond to the four different
reactions. A laser beam is focused on a specific point on the gel during electrophoresis so that as the
DNA fragments migrate past this point, the laser can pick up the specific wavelengths of the different
fluorescent dyes. The information that is generated is then stored electronically in a computer database
(Strachan and Read, 1999). This is the ideal method to use in the screening of GJB2 mutations, because
the GJB2 gene is small. It is therefore a relatively fast procedure because the entire coding region can
be analyzed in a single reaction. Another advantage of using sequencing as a screening tool is that it
can detect all mutations present, even those that are rare (Green et al., 1999; Wilcox et al., 2000;
Kemperman et al., 2002). The main disadvantage of this technique is that it is not easily applicable in
routine diagnostic laboratories because it is expensive and time consuming (Storm et al., 1999;
Antoniadi et al., 2000).
The techniques that have been used successfully with regards to the detection of mutations within
GJB6 that playa role in non-syndromic autosomal recessive deafness include SSCP and hetroduplex
analysis. These techniques were used together with direct automated DNA sequencing to identify the
specific variants that were produced (Grifa et al., 1999; Kelley et al., 1999 and Gabriel et al., 2001).
These same techniques have also been used successfully for the identification of mutations that result
in non-syndromic autosomal recessive hearing loss involving other connexin genes, such as GJB3,
GJAI and GJB4 (Liu et al., 2000 and 2001; López-Bigas et al., 2000, 2001 and 2002)
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2.10 OBJECTIVES OF THIS STUDY
The identification of the GJB2 and GJB6 mutations in the South African population that underlie
autosomal recessive non-syndromic deafness will lead to the broadening of our understanding of the
biological role of the GJB2 and GJB6 gene mutations. This information would also provide an answer
for families and individuals as to the cause of their deafness and improve the genetic counselling that is
offered to families and individuals at risk of developing non-syndromic hereditary hearing impairment.
The specific aims of this study were:
1. The investigation of the entire coding region of GJB2 to identify any mutations that result in non-
syndromic autosomal recessive deafness in the Caucasian and Mixed Ancestry populations of South
Africa.
2. The investigation of the entire coding region of GJB6 to identify any mutations that result in non-
syndromic autosomal recessive deafness in the Caucasian and Mixed Ancestry populations of South
Africa.
3. The application of three SSCP gel electrophoresis systems to determine which was best suited for
use in mutation screening of GJB2 in a standardised diagnostic program. The three systems that
were tested included a mini PAGE procedure, a SSCP-urea procedure and a two buffer system.
4. The determination of the frequencies of mutations detected in GJB2 and GJB6 amongst the
Caucasian and Mixed Ancestry populations of South Africa. This information indicates which
mutations are common to these populations, therefore allowing for a population specific diagnostic
program to be put in place in the future.
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The Ethics Review Committee of the Faculty of Health Sciences, Stellenbosch University approved the
study presented in this thesis (Project number 99/125). Prior to the collection of blood samples, written
informed consent was obtained from all individuals included in this study.
3.1 SAMPLE COLLECTION
The families studied in this project were referred mainly from the Carl du Toit Centre, the De La Bat
School and Aftercare Centre as well as the Nuwe Hoop Centre situated in the Western Cape. However,
three families were recruited from the Bartemeu School in the Free State and one family from the Wits
Clinic in Gauteng. For families to be entered into the project they had to provide written informed
consent (Appendix A), and both the parents and children had to undergo audiological tests. In the case
of the familial group there preferably had to be two unaffected parents and two affected children
present.
Mrs Muller (Division of Audiology, Tygerberg Hospital) conducted the clinical evaluations, which
included the audiology tests. The pedigree analysis and prenatal history of the affected children was
conducted by Dr. G de Jong of the Division of Human Genetics, University of Stellenbosch,
Tygerberg. Using the same specialist for all the clinical examinations prevented the possibility of
diagnostic bias. The individuals who participated in this study received genetic counseling as well as
information regarding the results of the molecular screening.
A total of 44 families were recruited, and 125 individuals were screened for mutations in the GJB2 and
GJB6 genes. These families were divided into two groups, either familial or sporadic, according to the
definition that a case was familial if the condition was found in a number of members of a family
whereas sporadic cases were those that occurred only in isolated individuals (Oxford Concise Medical
Dictionary, 2000). The familial group comprised 16 families and the sporadic group was made up of28 .
families. The familial group predominantly contained Caucasian families except for families 12 and 13
who were of Mixed Ancestry (consisting of Khoi San, Malay, African and European Caucasian
ancestry). Again, the sporadic group was also primarily Caucasian except for families 9, 18,22 and 28
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who were of Mixed Ancestry; families 14, 15 and 16 who were African; and families 10, Il and 21
who were of Indian origin.
The age of the affected individuals who were screened for GJB2 and GJB6 mutations varied from four
months to 44 years, however, all were diagnosed with hearing impairment before the age of two years.
All those affected by non-syndromic hearing loss had hearing difficulty ranging from severe to
profound deafness.
Control samples obtained from non-related individuals who appeared to have normal hearing were also
screened in this study. In total, 50 Caucasian and 50 Mixed Ancestry control samples were screened for
mutations in both GJB2 and GJB6 genes.
3.2 DNA EXTRACTION
DNA was extracted from 5-10 ml whole blood samples that had been collected in tubes containing
ethylendediamine tetraacetic acid (EDTA, CIOHI6N20g) as the preservative. The method used was a
modification of the one described in 1998 by Miller et al. This method involved adding 30 ml cold
lysis buffer [155 mM ammonium chloride (NH4CI), 10 mM potassium hydrogen carbonate (KHC03),
0.1 mM EDTA - pH 7.4) to each whole blood sample that had been transferred to 40 ml centrifugation
tubes [Greiner Labortechnik, Kremsmuenster, Austria]. This solution was kept on ice for 15 minutes
until the red blood cells had undergone lysis, then the cell suspension was centrifuged at 201 x g for 10
minutes at 4°C [Beckman AvantiJO™, Beckman Coulter, Inc, Fullerton, CA, USA]. The supernatant
was removed and the pellet was resuspended in 10 ml cold phosphate buffered saline solution (PBS) [6
mg/ml potassium chloride (KCI), 24 mg/ml sodium chloride (NaCl), 3.42 mg/ml di-sodium hydrogen
orthophosphate anhydrous (Na2HP04) and 0.6 mg/ml potassium dihydrogen orthophosphate
(KH2P04)]. This solution was centrifuged at 201 x g for 10 minutes at 4°C and the supernatant was
once again removed. The intact pellet was resuspended in 3 ml nucleic lysis buffer [10 mM
Tris(hydroxymethyl)aminomethane (Tris-HCI) ((CH20H)3CNH2-CI), 400 mM NaCl, 2 mM EDTA -
pH 8.2] together with 150 III 20% (w/v) sodium dodecyl sulphate (SDS) and 30 III proteinase K (10
mg/ml) [Roche Diagnostics Corporation, Indianapolis, IN, USA]. This solution was incubated
overnight in a water bath at 50°C.
Stellenbosch University http://scholar.sun.ac.za
54
CHAPTER 3: MATERIAL AND METHODS
Following after overnight incubation, 1 ml of saturated 6 M NaCI was added and the solution was
shaken vigorously for one minute, followed by centrifugation at 559 x g, at 21°C for 15 minutes. The
supernatant containing the DNA was transferred to a clean 40 ml centrifugation tube, with care taken to
leave the foam and pellet behind. The supernatant was then centrifuged at 559 x g, at 21°C for 15
minutes. The supernatant was transferred to a 30 ml glass Porex tube [QSp® (Quality Scientific
Plastics) Porex Bio Products Group, Fairburn, GA, USA] and the volume was noted. To this, two times
the volume of ice-cold 100% (v/v) ethanol (EtOH) was added and the solution was covered with
Parafilm'" [American National Can™, Menasha, WI, USA] and left at room temperature for 30 min to
allow the DNA to precipitate. The precipitated DNA was transferred, to a clean 1.5 ml Safe Lock
Eppendorf'" tube [Eppendorf, Hamburg, Germany] with an innoculation needle [Looplast", LP Italiana,
SPA, Milan, Italy]. The DNA was washed with 300 !lI ice-cold 70% (v/v) EtOH to remove any excess
salt. This solution was centrifuged at 17 530 x g for 15 minutes at 4°C [Beckman GS-15R, Beckman
Coulter, Inc, Fullerton, CA, USA] followed by the careful removal of the excess EtOH. The DNA was
left to air dry at room temperature. This DNA pellet was dissolved in 250 ul double distilled (ddH20)
SABAX water [Adcock Ingram, Johannesburg, RSA] overnight at room temperature after which the
DNA was stored at 4°C until further use.
3.2.1 DETERMINATION OF EXTRACTED DNA CONCENTRATION
To determine the concentration of the genomic DNA (gDNA) that was extracted from the whole blood
samples a concentration gel was resolved. This involved the loading of the extracted gDNA samples
onto a horizontal 2% (w/v) agarose gel. 5 ul of gDNA was mixed to an equal volume of 6X loading
dye [0.25% (w/v) bromophenol blue (C14HIOBrOsS), 0.25% (w/v) xylene cyanol FF
(C2sH27N2N~06S2Na) and 30% (w/v) glycerol (C3H803)]. A concentration gradient was made up of
lambda (A) DNA [Promega Corporation, Madison, WI, USA] of varying concentrations, ranging from
10 - 70 ng. The 2% (w/v) agarose gel was resolved in IX TBE buffer [10.8 mg/ml Tris, 5.5 mg/ml
Boric acid (H3B03) and 0.7445 mg/ml EDTA - pH 8.3] for two hours at 120 V after which it was
visualized under ultraviolet (UV) light and photographed using the GelDoc system [BioRad, Hercules,
CA,USA].
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3.3 POLYMERASE CHAIN REACTION AMPLIFICATION
3.3.1 POLYMERASE CHAIN REACTION AMPLIFICATION OF GJB2
The coding region of the GJB2 gene was first amplified by producing five overlapping fragments
(fragments 1,2,4,5 and 6), which were used in SSCP analysis (Table 3.1 and Figure 3.1). The fragments
were produced because SSCP analysis is most effective if smaller fragments are used. Fragment 3,
which covers the entire coding region of GJB2 was used for DNA sequencing.
Table 3.1: Primers used in amplifying the coding region of the GJB2 gene
Fragment Fragment Primer Primer Sequence Tm Annealing
Number Size (bp) Name (DC) Temperature (DC)
350 lA (F) 5'-TCT ITT CCA GAG CAA ACC GC-3' 60 60
IB (R) 5'-GAC ACG AAG ATC AGC TGC AG-3' 62
2 500 2A (F) 5'-CCA GGC TGC AAG AAC GTG TG-3' 64 60
2B (R) 5'-GGG CAA TGC GTT AAA CTG GC-3' 62
3 750 lA (F) 5'-TCT TIT CCA GAG CAA ACC GC-3' 60 60
2B (R) 5'-GGG CAA TGC GTT AAA CTG GC-3' 62
4 490 4A (F) 5'-AGG CCG ACT ITG TCT GCA ACA-3' 64 66
4B (R) 5'-GTG GGC CGG GAC ACA AAG-3' 60
5 110 5A (F) 5'-CGA AGC CGC CIT CAT GTA CG-3' 64 60
4B (R) 5'-GTG GGC CGG GAC ACA AAG-3' 60
6 520 4A (F) 5'-AGG CCG ACT TTG TCT GCA ACA-3' 64 66
2B (R) 5'-GGG CAATGC GTT AAA CTG GC-3' 62
Primers synthesized by ID~ [Integrated DNA Technologies, Inc, Coralville, lA, USA].
The melting temperature (Tm) for each of the primers was calculated according to the equation
described by Thein and Wallace (1986). The equation is as follows:
Tm= 2(A + T) + 4(G + C)
PCR conditions were optimized for each primer set with regard to the annealing temperature and the
magnesium chloride (MgCh) concentrations.
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The peR reactions were prepared in a total volume of 25 JlI in 0.2 ml thin wall peR tubes [QSp®
(Quality Scientific Plastics) Porex Bio Products Group, Fairburn, GA, USA]. Before use the PCR
reagents were thawed on ice and thoroughly mixed by vortexing. For fragments 2, 4, 5 and 6, the PCR
was performed in reactions containing approximately 100 ng of gDNA that was extracted from the
EDTA blood samples, 0.03 JlM of the forward primer (Table 3.1), 0.03 JlM of the reverse primer
(Table 3.1), 50 JlM of each 2' -deoxynucleotide (dNTP) [Promega Corporation, Madison, WI, USA],
0.25 U of Taq polymerase [BIOTAQ™ DNA Polymerase, Bioline, Springfield, Nl, USA] and a final
concentration ofO.75 mM MgCb.
The standard PCR program that was used for fragments 2, 4, 5 and 6 began with denaturation at 95°C
for five minutes. This was followed by 34 cycles consisting of denaturation at 95°C for one minute,
annealing at the optimized temperature (Table 3.1) for two minutes and extension at 72°C for ten
minutes. A final step of ten seconds at 25°C ensured that all PCR products were cooled to room
temperature. All peR reactions were performed in a Perkin Elmer GeneArnp PCR system 9600 [PE
Applied Biosystems, Warrington WA, Great Britain].
In the case of fragment 1 the PCR was performed in reactions containing a total volume of 25 JlI. Each
reaction contained approximately 100 ng gDNA, 0.06 JlM of the forward primer lA, 0.06 JlM of the
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Figure 3.1: Schematic representation ofGJB2 indicating the position of the various primers
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reverse primer IB, 50 11Mof each dNTP, 0.5 U of Taq polymerase and a final concentration of 0.75
mMMgCI2.
The PCR program that was used for fragment I began with denaturation for two minutes at 95°C. This
was followed by 40 cycles of denaturation at 95°C for 30 seconds, annealing at 60°C for 45 seconds
and extension at 72°C for 30 seconds. A final extension of five minutes at noc followed by a further
ten seconds at 25°C ensured that all the PCR products were full length products.
For fragment 3, which covers the entire coding region of GJB2, the PCR reactions were prepared in a
total volume of 25 Ill. The PCR was performed in reactions containing approximately 100 ng gDNA,
0.03 11Mof the forward primer lA, 0.03 11Mof the reverse primer 2B, 50 11Mof each dNTP, 0.25 U of
Taq polymerase and a final concentration ofO.75 mM MgCh.
The standard PCR program that was used for fragment 3 began with denaturation at 95°C for two
minutes. This was followed by 40 cycles consisting of denaturation at 95°C for 30 seconds, annealing
at the optimized temperature of 60°C for four seconds and extension at noc for 30 seconds. A final
extension of 72°C for five minutes allowed for all PCR products to reach their full length. This was
followed by ten seconds at 25°C to ensure that all the samples returned to room temperature.
3.3.2 POLYMERASE CHAIN REACTION AMPLIFICATION OF GJB6
The coding region of the gene that encodes Cx30 was amplified as a single fragment. Due to this region
being so small, only 786 bp, it was not necessary to divide it into smaller fragments for successful
automated DNA sequencing to occur. The primers that were used to accomplish the amplification were
primers Cx30.1 and Cx30.8 (Table 3.2 and Figure 3.2) previously published by Del Castillo et al.
(2002). PCR amplification of GJB6 was only conducted in those individuals where either one or both
mutant alleles for non-syndromic autosomal recessive deafness had not been identified during GJB2
mutation analysis.
The primers GJB6-IR and BKR-I, indicated in Table 3.2 and Figure 3.2, which produced the Del
fragment, were used to identify those samples that could possibly contain the ~(GJB6-D13SI830)
Stellenbosch University http://scholar.sun.ac.za
Fragment
Cx30
CHAPTER 3: MATERIAL AND METHODS
mutation that involves GJB6 (Del Castillo et al., 2002). PCR conditions were optimized with regard to
the annealing temperature and the MgCh concentration.
Table 3.2: Primers used in amplifying the coding region of the GJB6 gene
Fragment Fragment Primer Primer Sequence Tm Annealing
Name Size (bp) Name (0C) Temperature (0C)
Cx30 850 Cx30.1 5'-TCA GGG ATA AAC CAG CGC AAT-3' 58 56
Cx30.8 5'-GTT GGT ATT GCC TTC TGG AGA AGA-3' 54
Del 700 GJB6- 5'-TTT AGG GCA TGA TTG GGG TGA TTT-3' 68 50
IR
BKR-l 5'-CAC CAT GCG TAG CCT TAA CCA TTTT-3' 72
Primers synthesized by IDT® (Integrated DNA Technologies, Inc, Coralville, 10, USA).
Figure 3.2: Schematic representation ofGJB6 indicating the position of the various primers
CEN
Cx30.8
t
BKR-l TEL
~
Fragment
Del
Genomic DNA obtained from the extraction from the EDTA blood samples was used as template for
amplification. The PCR reactions of fragment Cx30 were prepared in a total volume of 25 JlI in 0.2 ml
thin wall PCR tubes. Before use, the PCR reagents were thawed on ice and thoroughly mixed by
vortexing. The PCR was performed in reactions containing approximately 100 ng of gDNA, 0.04 JlM
of the forward primer Cx30.l, 0.04 JlM of the reverse primer Cx30.8, 50 JlM of each dNTP, 0.25 U of
Taq polymerase and a final concentration ofO.75 mM MgCh.
In the case of the PCR amplification of the Del fragment, the reactions were prepared in a total volume
of 25 JlI in 0.2 ml thin wall PCR tubes. Before use the reagents were thawed on ice and thoroughly
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mixed by vortexing. The PCR was performed in reactions containing approximately 100 ng of gDNA,
0.6 ~M of the forward primer GJB6-1R, 0.6 flM of the reverse primer BKR-I, 50 uM of each dNTP,
0.25 U of Taq polymerase and a [mal concentration of2 mM MgCI2.
The standard PCR program that was used for the fragments Cx30 and Del started with denaturation at
95°C for two minutes. This was followed by 40 cycles consisting of denaturation at 95°C for 30
seconds, annealing at the optimized temperature (Table 3.2) for 45 seconds and extension at 72°C for
30 seconds. A final extension of 72°C for five minutes followed by ten seconds at 25°C ensured that all
PCR products were at their full length and the samples were returned to room temperature.
3.3.3 AGAROSE GEL ELECTROPHORESIS OF PCR AMPLICONS
After PCR amplification was completed the reactions were tested to determine if successful
amplification had occurred. If this could not be done immediately the PCR products were stored at 4°C.
Electrophoresis was performed using a horizontal 2% (w/v) agarose gel containing 0.01% (v/v) EtBr
for staining purposes. An equal volume of 6X loading dye was mixed with 5 ul of PCR product. A 100
bp DNA ladder [Promega Corporation, Madison, WI, USA] was loaded on the gel, together with the
PCR products, to be used as a molecular size marker. The 2% (w/v) agarose gel was resolved in IX
TBE buffer for one hour at 100 V after which it was visualized under UV light and photographed using
the GelDoc system. Successfully amplified PCR products were stored at 4°C until further use.
3.4 COMPARISON OF GEL ELECTROPHORESIS SYSTEMS
At first it was decided to screen for mutations in GJB2 using different SSCP gel electrophoresis
systems to determine which is more effective at detecting all the different mutations found with in the
coding region of the gene. The various procedures used included a mini polyacrylamide gel
electrophoresis (PAGE) system, a 12% (w/v) polyacrylamide-urea SSCP system and finally, a two
buffer system.
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3.4.1 SINGLE-STRAND CONFORMATION POLYMORPHISM GEL ELECTROPHORESIS
3.4.1.1 MINI POLYACRYLAMIDE GEL ELECTROPHORESIS
The SSCP analysis using the mini polyacrylamide (PAA) gel electrophoresis system involved a 103 X
98 mm vertical gel with a composition of a 10% (w/v) PAA. The gel stock solution contained 5 ml of a
40% (w/v) acrylamide-bisacrylamide (19:1) mixture, 3 ml 5X TBE [54 mg/ml Tris, 27.5 mg/ml Boric
acid and 3.7225 mg/ml EDTA - pH 8.3] and 2 ml dH20. A catalyst [60 III TEMED (C6HI6N2)] and an
oxidising agent [600 J.lIof a 10% (w/v) ammonium persulphate solution (APS)] were added to the gel
to achieve polymerization of the 0.75 mm thick gel. Once polymerization had occurred the gel was
placed in the gel apparatus [Mighty Small, Hoefer Pharmacia Biotech Inc, BioRad, Hercules, CA,
USA] that contained fresh 1.5X TBE (16.2 mg/ml Tris, 8.25 mg/ml Boric acid and 1.116 mg/ml EDTA
- pH 8.3) buffer in the buffer chamber. All the fragments except for fragment 6 were screened on this
system.
The PCR products were prepared for electrophoresis by adding 10 III of formamide loading buffer
[98% (v/v) formamide (CH3NO), 10 mM EDTA, 0.05% (w/v) xylene cyanol FF and 0.05% (w/v)
bromophenol blue] to 20 III of the PCR product. This solution was heat denatured for five minutes at
95°C and then placed on ice until loading. Approximately 10 III of the denatured solution was loaded
onto the gel.
Electrophoresis of the amplicons of fragment 1, 2 and 4 was performed at 200 V and 15°C for four
hours, whereas for fragment 5 it was performed for two hours. After electrophoresis, the gels were
dismantled and stained in IX TBE containing 0.01% (v/v) EtBr for ten minutes and destained in dH20
for approximately three minutes followed by visualization under UV light and photographed using the
GelDoc system.
3.4.1.2 SSCP-UREA GEL ELECTROPHORESIS
In this SSCP system a 37 X 16.5 cm vertical gel with a composition of 12% (w/v) PAA, supplemented
with urea [CH4N20] was used. The gel stock solution contained 18 ml of a 40% (w/v) acrylamide-
bisacrylamide (19:1) mixture, 4.5 g urea, 18 ml 5X TBE and 24 ml dH20. An oxidizing agent (600 III
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of 10% (w/v) APS) and a catalyst (60 fll TEMED) were added to the gel solution to achieve
polymerization of the 0.75 mm geL Once the gel had polymerized it was placed in the gel apparatus gel
[Duel Slab Gel Unit, C.RS. Scientific Co., Del Mar, CA, USA] that contained fresh 0.5X TBE buffer
(5.4 mg/ml Tris, 2.75 mg/ml Boric acid and 0.37225 mg/ml EDTA - pH 8.3) in the lower chamber and
fresh 1.5X TBE buffer in the upper chamber. All the fragments were screened using this gel
electrophoresis system.
The amp licons of fragments 1, 2, 4 and 5 were prepared as before, by adding 10 fll formamide loading
buffer to 20 fll PCR product. This solution was heat denatured for five minutes at 95°C and then placed
on ice until 15 fll of the denatured solution was loaded onto the gel. In the case of fragment 6, it was
first digested overnight with the restriction enzyme MnlI [Roche Diagnostics Corporation,
Indianapolis, IN, USA (recognition sequence: 5' ... CCT(N)?/6... 3')] before adding the loading buffer
and heat denaturing. In each reaction 10 ul PCR product was utilized together with 2 ul Buffer 2,0.2 ul
bovine serum albumin (BSA) and 5 U MnlI. Finally, ddH20 was added to a total volume of20 ul in 1.5
ml Eppendorf" tubes and were incubated overnight in a 37°C water bath. After digestion, 20 fll of the
digested fragment 6 together withl0 ul loading buffer was heat denatured for five minutes at 95°C.
Electrophoresis of the amplicons of fragments 1, 2, 4 and 6 was performed at 300 V for approximately
18 hours at 4°C, whereas for fragment 5 it was performed for seven hours. Following electrophoresis,
the gels were dismantled and stained in IX TBE containing 0.01% (v/v) EtBr for ten minutes and
destained in dH20 for approximately three minutes after which the DNA fragments were visualized by
UV light and photographed using the GelDoc system.
3.4.1.3 TWO BUFFER POLYACRYLAMIDE GEL ELECTROPHORESIS
The two buffer PAGE system used for this SSCP analysis involved producing a 37 X 16.5 cm vertical
gel [Duel Slab Gel Unit, C.RS. Scientific Co., Del Mar, CA, USA] with a 12% (w/v) composition of
PAA supplemented with glyceroL The gel solution contained 12.5 ml of a 40% (w/v) acrylamide-
bisacrylamide (19:1) mixture, 20 ml Tris-formate buffer [0.75 M Tris base and Formic acid, CH202-
pH 9.0] and 7 ml glyceroL To achieve polymerization of the 0.75 mm gel a catalyst (60 fll TEMED)
and an oxidizing agent [600 ul of 10% (w/v) APS] were used. Once the gel had completely
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polymerized it was placed into the gel apparatus that contained fresh Tris-formate buffer in the upper
chamber and fresh Tris-borate buffer (125.9 g Tris base, 17.31 g Boric acid, 1 000 ml dH20 - pH 9.0)
in the lower chamber. Again, the PCR products of all the fragments were tested on this system.
The amplicons were prepared by adding 10 ~l of formamide loading buffer to 20 ul PCR product. This
solution was heat denatured for five minutes at 95°C and then placed onto ice until 10 ~l of the
denatured solution was loaded onto the gels. As before, fragment 6 was first digested with the
restriction enzyme Mnll before the loading buffer was added and heat denaturing occurred. This
involved adding 2 ~l Buffer 2, 0.2 ~l BSA and 5 U Mnllto 10 ,..rl PCR product. The digestion solution
was left overnight to incubate in a 37°C water bath. After digestion, 20 ul of digested fragment 6
together with 10 ul Ioading buffer was heat denatured for five minutes at 95°C.
Electrophoresis of the amplicons of all the fragments was performed at 350 V at 12 - 15°C for
approximately two hours. Following electrophoresis, the gels were dismantled and stained in IX TBE
containing 0.01% (v/v) EtBr bromide for ten minutes and destained in dH20 for approximately three
minutes after which the DNA fragments were visualized by UV light and photographed using the
GelDoc system.
3.5 AUTOMATED DNA SEQUENCING
The amplicons that were to be sequenced were purified using a QIAquick™ PCR Purification Kit
[QIAGEN, GmbH, Hilden, Germany]. Fifty microliters Buffer PB was added to 10 ~l PCR product. To
bind the DNA, the sample was placed in a QIAquick™ spin column that was placed within a 2 ml
collection tube. This was centrifuged for one minute at 10 000 x g. The flow-through was discarded
and the spin column was placed back into the collection tube. To wash the DNA, 0.75 ml Buffer PE
was added and centrifuged again at 10 000 x g for one minute. The flow-through was again discarded
and the spin column was placed back into the collection tube. Nothing was added and the samples were
centrifuged for a further minute at 10 000 x g. Finally, to elute the DNA, the spin column was placed
into a clean 1.5 ml Eppendorf'" tube and 50 ~l ddH20 was added. This was followed by centrifugation
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at 10 000 x g for one minute. The purified PCR product was stored at 4°C until it was needed for
sequencing.
Prior to sequencing the Del fragments it was required to purify the fragments in the gel as they had
been sliced from a 2% agarose gel. The purification of the DNA from the fragments in the gel involved
the use of a GFX PCR DNA and gel band purification kit [Amersham Biosciences, Buckinghamshire,
England]. A gel slice was removed from the 2% agarose gel and cut into smaller pieces using a clean
razor blade. The pieces were then placed into a 1.5 ml Eppendorf" tube to determine the weight of the
gel slice to the nearest 10 mg (maximum limit of 300 mg). 10 ul of capture buffer for each 10 mg of
gel slice was added to the 1.5 ml Eppendorf'" tube. The tube was vortexed to mix the contents before
placing it in a heating block at 60°C for approximately 15 minutes, to allow for the agarose to
completely dissolve. To collect the sample at the bottom of the tube it was centrifuged briefly, after the
agarose had melted. The sample was then transferred to a GFX column, which had been place in a
collection tube, and left to incubate at room temperature for one minute. The flow-through was
discarded from the collection tube after centrifugation at full speed in a microcentrifuge for 30 seconds.
The GFX column was placed back into the collection tube and 500 ul of wash buffer was added. The
sample was then centrifuged again at full speed for 30 seconds. The collection tube and flow-through
were both removed, whereas the GFX column was placed in a clean 1.5 ml Eppendorf'" tube. To elute
the DNA, 30 fll of ddH20 was added to the column. This was left to incubate at room temperature for
one minute. Finally the sample was centrifuged at full speed for one minute to recover the purified
PCR product.
Before the sequencing reaction could be performed the concentration of the purified PCR products had
to be determined. This was accomplished by the electrophoresis of a horizontal 2% (w/v) agarose gel
containing 0.01% (v/v) EtBr for staining purposes. A A DNA concentration series, covering the range
of 40 ng - 100 ng was prepared. Five microliters of the purified PCR product was mixed with 5 fll
loading buffer and loaded onto the gel, which was resolved at 60 V for approximately one hour in 1X
TBE buffer and visualized via UV light and photographed using the GelDoc system. The
concentrations of the purified PCR products were estimated and where necessary the purified
amplicons were diluted with ddH20 to obtain the correct concentration (Table 3.3).
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Table 3.3: Concentration of DNA required for sequencing according to PCR product size
PCR Product Size (bp) Concentration Required (ng/!!I)
100 -200
200 - 500
500 -1000
1000 - 2000
3.3
6.6
13.3
Automated DNA sequencing was performed according to the chain termination protocol using a Perkin
Elmer BigDye™ Terminator Cycle Sequencing kit [PE Applied Biosystems, Warrington WA, Great
Britain]. The purified PCR products were used as templates in the sequencing reaction together with
the same primers that were used in the PCR reaction earlier (Table 3.1 and Table 3.2). To 3 ul of the
purified and diluted PCR product, 4 f-llof the sequencing reaction solution was added to make a final
reaction volume of 7 ul in 0.2 ml thin wall PCR tubes. This sequencing reaction solution contained 1 ul
termination ready reaction mix, 2 ul ddH20 and 1 ul of either the forward or reverse primer (1.1
pmol/ul). Cycle sequencing followed, conducted in a Perkin Elmer GeneAmp PCR system 9600 kit
[PE Applied Biosystems, Warrington WA, Great Britain]. An initial denaturation at 96°C for two
minutes was followed by 25 cycles consisting of denaturation for ten seconds at 96°C, annealing at
55°C for five seconds and an extension at 60°C for four minutes.
The products were loaded onto the ABI 3100 automated sequencer [PE Applied Biosystems,
Warrington WA, Great Britain]. Analysis of electropherograms, following electrophoresis, was
performed using the programs Sequence Analysis (V3.07) and BioEdit Sequence Alignment Editor
(Hall, 1999). The sequences were compared with the sequence obtained for GJB2 (accession number:
NM_004004), GJB6 (accession number: NM_006783) and clone RPll-501K3 on chromosome 13
(accession number: AL355984) from the NCB! Database.
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In this chapter the screening of GJB2 and GJB6 within South African families with non-syndromic
autosomal hearing impairment as well as the comparison of different SSCP gel systems is presented.
Results indicated in this chapter have been presented at several national and international conferences
(Appendix B).
4.1 GENOMIC DNA QUANTIFICATION
To determine the concentration of the gDNA that was extracted from the whole blood, DNA samples
were resolved by gel electrophoresis and the intensity of each band compared with a DNA
concentration standard. This involved the loading of the extracted gDNA samples onto a 2% agarose
gel together with a concentration gradient made up of A DNA of varying concentrations, ranging from
50 - 200ng, for comparison purposes (Figure 4.1).
Figure 4.1: Representative photograph of an agarose gel used in gDNA quantification
A 2% agarose gel used for the determination of the concentration of extracted gDNA. The samples were resolved
for one and a half hours at IOOV in IX TBE buffer and stained with EtBr. The first nine lanes contain samples of
extracted gDNA whereas the remaining three lanes contain the A DNA concentration gradient.
From the gel photographs it was determined that on average the aliquot that was loaded contained
approximately 200 ng of extracted gDNA when compared with the A DNA concentration gradient. It
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was also determined from the 2% agarose gels that the samples contained high molecular weight DNA
and there was no RNA present.
4.2 POLYMERASE CHAIN REACTION AMPLIFICATION
4.2.1 POLYMERASE CHAIN REACTION OF GJB2 and GJB6
PCR amplification was conducted on gDNA to produce the overlapping fragments 1, 2, 4, 5 and 6 that
cover the 678 bp of the coding exon 2 of GJB2 (refer to Table 3.1 and Figure 3.1). Fragment 3 covered
the entire coding region of GJB2 and was used for automated DNA sequencing whereas the other
fragments were used in SSCP analysis.
Fragments of Cx30 were produced by PCR amplification of gDNA. The fragment of 786 bp covered
the entire coding exon of GJB6 and was small enough to accomplish successful automated DNA
sequencing in a single reaction. This gene was not screened using the different SSCP gel systems,
therefore GJB6 did not have to be amplified as a number of overlapping fragments. Amplification of
GJB6 was only conducted on those samples that had either one or both mutant alleles unidentified
during GJB2 analysis. PCR amplification was also used to amplify the Del fragment to screen for the
i1(GJB6-D13S1830) mutation, ofGJB6. This fragment is only visible when the mutant allele is present
in a patient as the large deletion allows for the primers to move within range of each other for
amplification to occur. Refer to Table 3.2 and Figure 3.2 for the sequence and position information
concerning the primers used to produce the Cx30 and Del fragments.
The annealing temperatures for the different primer sets were calculated using the equation reported by
Thein and Wallace (1986). The optimized conditions, including the calculated and optimized annealing
temperatures, as well as the fragment sizes produced by the primer sets are given it Table 4.1.
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Table 4.1: Optimized conditions for the fragments that covered GJB2 and GJB6
Gene Fragment Fragment Calculated Tm of Calculated Tm of Optimized Tm eq
Name Name Size (bp) Forward Primer eq Reverse Primer eC)
GJB2 350 60 62 60
GJB2 2 600 64 62 60
GJB2 3 750 60 62 60
GJB2 4 490 64 60 66
GJB2 5 110 60 64 60
GJB2 6 600 64 62 66
GJB6 Cx30 850 58 54 56
GJB6 Del 700 68 72 50
All PCR amplicons for fragments 1 to 6 of GJB2 were verified on a horizontal 2% agarose gel to
determine if successful amplification had occurred (Figure 4.2) before proceeding with SSCP analysis
or DNA sequencing. No negative controls are shown in Figure 4.2, as this gel was resolved only as an
example of the various fragment sizes produced during PCR amplification of GJB2.
Figure 4.2: Representative photograph of peR amplicons ofGJB2fragments 1 - 6
2% Agarose gel electrophoresis of fragments 1 - 6, which covers the coding region of GJB2, that were produced
using PCR. The 2% agarose gel was resolved for I hour at 100V in 1X TBE buffer and stained with EtBr.
M = 100 bp DNA ladder.
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Agarose gel electrophoresis was used to determine if PCR amplification had been successful III
producing the amplicons of GJB6. In the case of the Del fragment, agarose gel electrophoresis was
used for the detection of the absence or presence of the L1(GJB6-D13S1830) mutation that involves the
partial deletion of GJB6 (Figures 4.3 A - B). Theoretically, this was possible due to the fragment only
being produced in the presence of the large deletion as it resulted in the primers being within the
necessary distance for amplification to occur. An amplicon should not be produced when the large
deletion was not present, as the two primers would be located too far apart for successful amplification
to occur. PCR amplification is not possible in the absence of the deletion because a limiting factor of
this method is that it can only produce a fragment if the primers are within 0.1 - 5 kb of each other
(Strachan and Read, 1999). Therefore, if the deletion is not present, the primers will be over 300 kb
apart. No negative control was shown in Figure 4.3 A - B but they were resolved.
Agarose gel electrophoresis of the PCR amplified fragments Cx30 and Del that cover the coding region of GJB6
and the d(GJB6-DI3S1830) mutation involving two different primer sets (Table 3.2 and Figure 3.2). The 2%
agarose gels were electrophoresed for 1 hour at 100V in 1X TBE buffer and stained with EtBr. M = 100 bp DNA
ladder.
Three different SSCP gel electrophoresis systems were selected for testing for their effectiveness in
detecting mutations in GJB2. The effectiveness of the system was determined by the ability of the
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Figure 4.3 A - B: Representative photographs of peR amplicons ofGJB6 for fragments
Cx30andDel
[A] Fragment Cx30 [BJ Fragment Del
850 bp
0(
700 bp
)
4.3 COMPARISON OF SSCP GEL SYSTEMS
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system to accurately detect the mutations present in GJB2. The three systems that were chosen
included a mini PAGE system, a 12% (w/v) SSCP-urea system and a two buffer system. These
methods were favoured as the equipment was readily available in the laboratory.
4.3.1 SINGLE-STRAND CONFORMATION POLYMORPHISM GEL ELECTROPHORESIS
4.3.1.1 MINI POLYACRYLAMIDE GEL ELECTROPHORESIS
The first SSCP system that was tested by identifying mutations in the coding exon 2 of GJB2 was the
mini PAGE technique. This method was conducted on the heat denatured PCR products of all the
fragments except for fragment 6. It was assumed that if a mutation were present in this fragment it
would not be visible because the digested pieces that make up fragment 6 are too similar in size to be
separated on this gel system. Representative photographs of the gels obtained during mini PAGE
analysis for each fragment, except fragment 6, are shown in Figure 4.4A - D. The positive controls that
were used were samples that were known to contain specific mutations within the fragments whereas
the negative controls were samples that were obtained from normal hearing individuals and were
known to be negative for all disease causing mutations and benign polymorphisms within GJB2.
For fragment 1 (Figure 4.4A) no variation in banding pattern could be detected, even in the positive
control, P, which was known to contain the 35deiG mutation. This was unexpected, as there should
have been a high frequency of variants present, including the common 35deiG mutation located within
this fragment. With the subsequent DNA sequencing of the samples it was determined that there were a
large number of individuals who had been assigned negative status with mini PAGE analysis and who
were in reality positive for the 35delG mutation. For example, in Figure 4.4A all the individuals
appeared to be negative for any variants. With DNA sequencing it was determined that only sample
6079 was a wild type individual whereas samples 9, 6865 and 6078 were heterozygous carriers and
samples 10 and 11 were homozygous for the 35deiG mutation.
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Figure 4.4A - D: Representative photographs of peR amplification of GJB2 fragments
analyzed by mini polyacrylamide gel electrophoresis
[A] Fragment 1 [B] Fragment 2
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[C] Fragment 4 [D] Fragment 5
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Mini polyacrylamide gel electrophoresis of fragments 1,2,4 and 5. The 10% polyacrylamide gels were resolved in
IX TBE buffer at 200V for four hours (fragments 1, 2 and 4) or two hours (fragment 5), and stained with EtBr. P =
positive control and N = negative control.
It was, however, possible to detect variations in banding patterns in fragments 2, 4 and 5. Figure 4.4B
contains an example of the results obtained for fragment 2. The positive control, P, was known to
contain the 312del14 mutation, therefore producing the extra band lower on the gel during
electrophoresis. It appeared that the mini PAGE analysis system was effective in detecting this specific
mutation as samples 620, 625, 6078 and 6079 tested normal and samples 43 and 67 tested positive for
312de114. However, when these results were confirmed with automated DNA sequencing it was
discovered that samples 625 and 6079, showing a low concentration on the gel, were actually
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heterozygotic individuals, therefore indicating that equal quantities of PCR amplicons should be used.
It was also observed that from these gels it was not possible to assign homozygous or heterozygous
status for a specific mutation.
The positive control, P, in fragment 4 (Figure 4.4C) was also known to contain the 312de114 mutation
as fragments 2 and 4 overlapped in this area of GJB2. The positive control produced two extra bands
lower on the gel during electrophoresis using the mini PAGE system. Again it was thought that the
mini PAGE system was effective in detecting the 3I2de114 mutation as it appeared that samples 619,
618, 617, 88 and 89 were wild type individuals and 625 was positive for the 312de114 variant.
However, when these results were tested with automated DNA sequencing it was determined that
samples 618 and 617 were not wild types but heterozygous individuals for mutation 312de114. Once
again the low concentration of these two samples on the gel probably caused this phenomenon.
In fragment 5 (Figure 4.4D) the positive control, P, contains the VI53! polymorphism. This variation
was characterized by the extra band that was produced above the normal banding pattern on the gel
during electrophoresis. It was assumed that this system is successful at detecting this variant as the
positive control was clearly visible and those samples that appeared normal during gel electrophoresis
were later confirmed as such during automated DNA sequencing. However, this needs to be tested
further as none of the samples that were tested contained the V153! polymorphism and therefore
further samples that are known to contain the variation need to be screened using this system.
4.3.1.2 SSCP-UREA GEL ELECTROPHORESIS
The second SSCP system that was tested was a 12% (w/v) PAA gel containing 7.5% (w/v) urea. This
method was conducted on the heat denatured PCR products of all the fragments that cover exon 2 of
GJB2. These samples were run on a larger gel (37 X 16.5 cm) so that electrophoresis could be
performed for longer thereby allowing for the screening of fragment 6, which consisted of two
relatively similar sized fragments. This system also allowed for the analysis of the dsDNA bands, as
they were still present on the gel after electrophoresis. Representative photographs of the gels that were
obtained of all the fragments during the SSCP-Urea gel analysis are presented in Figure 4.5A - E. The
positive controls that were used were samples that were known to contain specific mutations within the
fragments whereas the negative controls were samples that were obtained from wild type individuals
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and were known to be absent for all disease causing mutations and benign polymorphisms within
GJB2.
For fragment 1 (Figure 4.5A) it was not possible to detect any variation in band partem. This was
surprising since the detection of the common 35deiG mutation was expected in the positive control, P.
For example, it was later confirmed, with automated DNA sequencing, that the samples 230, 231 and
224 (Figure 4.5A) were actually heterozygous for the 35deiG mutations and not wild type individuals
as the SSCP-urea analysis had indicated.
It was possible to identify the variation in banding pattern caused by mutations present in fragments 2,
4 and 5. In fragment 2 (Figure 4.5B) the mutation caused two extra bands to form lower down from the
normal three bands as was shown by the positive control (P), which was known to contain the 3I2delI4
mutation. All the samples that are indicated in this example were assigned as wild types during SSCP-
urea analysis and this deletion variant was later confirmed with automated DNA sequencing to be
accurate.
The example of fragment 4 shown in Figure 4.5C indicates all the samples to be wild types for the
expected mutation, 3I2de114. Subsequent confirmation using automated DNA sequencing determined
these results to be correct. The SSCP-urea system was able to detect the 3I2de114 mutation even
though this is not indicated in this example.
In fragment 5 (Figure 4.5D), the positive control (P) was known to contain the VI53I polymorphism.
The variation was visible during gel electrophoresis as extra bands above and below the normal band
pattern. It appears that this system was successful in detecting this variation, as the positive control was
clearly distinguishable from the negative control (N).
The positive control, P, in fragment 6 (Figure 4.5E) was also known to contain the 3I2de1l4 mutation
as this fragment overlapped with fragment 2 and 4. However, using this system it was not possible to
detect a variation between the positive control and those samples that were wild type.
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Figure 4.5A - E: Representative photographs of SSCP-urea gel electrophoresis ofGJB2
fragments
[A] Fragment 1 [B] Fragment 2
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SSCP-urea gel electrophoresis of fragments 1,2,4,5 and 6. The 12% polyacrylamide gels were resolved in
O.5X and 1.5X TBE buffer at 300V for 18 hours (fragments 1, 2, 4 and 6) or seven hours (fragment 5). They
were stained with EtBr. P = positive control and N = negative control.
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4.3.1.3 TWO BUFFER POLYACRYLAMIDE GEL ELECTROPHORESIS
The final SSCP analysis technique tested was the two buffer gel electrophoresis system. Again a 12%
(w/v) PAA gel was used but this time it contained 7.5% (w/v) glycerol instead of 7.5% (w/v) urea.
Another difference was that it was run in Tris-Formate and Tris-Borate buffer instead of 0.5X TBE and
1.5X TBE. This method was used for the analysis of heat denatured PCR products of all the fragments
of GJB2 and the gel apparatus used produced gels that were 30 cm long. Figures 4.6A - Dare
representative photographs of the gels obtained for all the fragments that were screened using this
system. The positive controls that were used were samples that were known to contain specific
mutations within the fragments whereas the negative controls were samples that were obtained from
normal hearing individuals and were known to be absent for all disease causing mutations and benign
polymorphisms within GJB2.
Using the two buffer SSCP analysis system, it was once again not possible to identify any variations in
band pattern resulting from mutations present in fragment 1 (Figure 4.6A). Even the positive control
(P) that was known to contain the 35deiG mutation appeared to be wild type. With automated DNA
sequencing it was determined that, in this example, samples 56, 616 and 625 were in fact heterozygous
individuals for the 35deiG mutation.
For fragment 2 a positive control (P) containing the 312del14 mutation was used. In Figure 4.6B it was
observed that the two buffer SSCP system was able to detect this mutation as the variation of an extra
band was visible in both the positive control and sample 29. Automated DNA sequencing later
determined that this result was correct however it also determined that sample 31 was a homozygous
individual for the 312del14 mutation, which was not detected using the two buffer SSCP system.
In fragment 4 a positive control (P) for the 312del14 mutation was used and the variation was visible
although it is not shown in this example (Figure 4.6C). Even though the positive control was detected
successfully, the variation was not always clear as was observed with sample 618, which appeared
normal during two buffer SSCP analysis, but was determined to be a heterozygous individual with
automated DNA sequencing.
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The gels containing fragment 5 (Figure 4.6D) showed no variation in banding pattern. Even the
positive control, P, (not shown in this example) that was known to contain the V153I polymorphism
showed no distinct difference from those samples that contain the wild type allele. This was an
unexpected result as this polymorphism was detected with all the other gel systems used.
Figure 4.6A - D: Representative photographs of two buffer gel electrophoresis analysis of
GJB2 fragments
[A] Fragment 1 [B] Fragment 2
z
[C] Fragment 4 [D] Fragment 5
0\
r-o 00
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00-'0 0\00 Mo
V)
M
00 z
dsDNA
(
Two buffer SSCP gel electrophoresis of fragments 1,2,4 and 5. The 12% polyacrylamide gels were resolved in
Tris-Formate and Tris-Borate buffer at 350V for two hours and were stained with EtBr. P = positive control and
N = negative control.
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The concentration of the PCR amplicons corresponding to both GJB2 and GJB6 had to be determined
before automated DNA sequencing could commence. This was performed because a specific
concentration of the PCR amplicon was required (dependent on the size of the fragment) for successful
sequencing (Table 3.3). To achieve this a 2% agarose gel was used, whereby a concentration gradient
of A DNA, ranging from 50 - 100 ng, was resolved together with the PCR amplicons (Figure 4.7).
A 2% agarose gel used for the quantification of the PCR amplicons. The gel was resolved for two hour at I20V in
IX TBE buffer and stained with EtBr. The first four lanes contain the 'A DNA concentration gradient whereas, the
remaining lanes contain samples ofPCR amplicons to be sequenced.
In the case of fragments 1 and 5 the final concentration of the PCR amplicons had to be 3.3 ng/ul
before successful DNA sequencing could take place whereas, for fragments 2, 3, 4, 6, Cx30 and Del
the concentration needed was 6.6 ng/ul. Therefore, those samples that contained a higher PCR
amplicon concentration were first diluted to the required concentration before DNA sequencing.
4.4 AUTOMATED DNA SEQUENCING
4.4.1 DNA CONCENTRATION DETERMINATION OF AMPLICONS
Figure 4.7: Representative photograph of the quantification of amp/icons
'A DNA
~
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4.4.2 AUTOMATED DNA SEQUENCING OF SSCP GEL ELECTROPHORESIS VARIANTS
Automated DNA sequencing was first conducted on all the PCR products of fragment 1 of GJB2 due to
no results being obtained during SSCP analysis. It was expected that there would be a high frequency
of individuals with the most common mutation, 35de1G, which causes non-syndromic autosomal
recessive hearing loss. The specific results pertaining to this mutation are discussed later in section
4.4.3.1.
DNA sequencing was also conducted on the samples that showed a variation in SSCP band patterns,
due to the presence of a possible mutation. The mutation was confirmed by DNA sequencing to be the
312del14 mutation that is found in both fragment 2 and 4 due to these fragments overlapping in this
area of the sequence. Again the specific results regarding this mutation are discussed later in section
4.4.3.2.
4.4.3 SCREENING OF GJB2
It was decided that any further analysis of samples obtained from families with non-syndromic
autosomal deafness would be conducted using only automated DNA sequencing of GJB2 for possible
mutations. The reasons for this decision were firstly, that it was noted that none of the SSCP gel
electrophoresis systems were successful in detecting all the mutations within the GJB2 gene. Secondly,
the only way to detect the common 35delG mutation was by automated DNA sequencing. Finally,
those samples that showed a change in mobility during SSCP analysis had to be sequenced to
determine the specific mutation that was present.
A total of seven different disease-causing mutations and four benign polymorphisms were detected in
the GJB2 gene. These mutations included the common Caucasian mutation, 35delG as well as a novel
mutation, N62I. All the mutations and polymorphisms that were encountered are discussed in further
detail in the following sections.
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4.4.3.1 THE 35deiG MUTATION
The 35deiG mutation of GJB2 was detected in homozygous form, 35de1G/ 35de1G, (Figure 4.8C) in
three familial and one sporadic family. It was also encountered in a compound heterozygous form
(Figure 4.8B) in three familial and four sporadic families. In compound heterozygote state it was
observed together with other GJB2 mutations, which included 312de114, W24X and N62I. None of the
control samples from either the Caucasian or Mixed Ancestry populations had any individuals
harbouring the 35deiG mutation. Refer to Section 4.5.1 for further information concerning the
statistical analysis of the 35deiG mutation with regards to the frequencies of this mutation within the
different study groups.
Figure 4.8 A - C: Representative electropherograms of the GJB2 mutation 35delG
[A] Wild Type [B) Heterozygous
CC'rGGGGGGTGT'G~
40
TCC TG GGGGKGGK.RA MA___ 40
t: ,,". . . '.' .,'
'. .' .' ".' ',' ' .
[C] Homozygous
Tee TGG G G G TG T G AA CAA10
~
, , . - ,
, . --' - -, .
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The 35deiG variant is a recessive mutation that is caused by a deletion of a single G from a set of six
found at nucleotide position 30 to 35. This deletion results in a frameshift mutation that leads to a
Valine substituting for a Glycine at amino acid 12, followed by a premature stop codon at nucleotide
38 (amino acid 13). This causes the formation of a significantly shorter protein that is unlikely to be
inserted into the plasma membrane as this mutation lies within the N-terminus region of the connexin
26 protein.
For more information concerning the 35deiG mutation, including the frequency of this mutation within
other populations as well as the origin of the mutation, refer to Section 2.5.4.1.
4.4.3.2 THE 312de114 MUTATION
The 312de114 variant is a recessive mutation that was detected in GJB2 as the result of the deletion of
14 nucleotides starting at position 312, leading to a frame shift mutation that eventually forms a
premature stop codon. This mutation results in a significantly shorter Cx26 protein that is unable to
perform its function as the mutation lies within the cytoplasmic loop.
The 312de114 mutation of GJB2 was identified in homozygous form, 312de114/ 312de114, (Figure
4.9B) in two familial and one sporadic family. Itwas also encountered in compound heterozygous form
(Figure 4.9C) in two familial and four sporadic families. In compound heterozygote state it was only
encountered with the GJB2 mutation 35de1G. This mutation was only detected in heterozygous form in
a single Caucasian individual from the control paneL
The 312de114 mutation was first reported in 2000 by Rabionet et al., in a Spanish and an Italian
population. However, he assumed that this mutation was possibly the same as a previously reported
mutation, 31Ode114, which was found in the same protein region. In 2001, Lin et al. also detected the
312de114 mutation in a study involving an American population from various backgrounds. Here the
312de114 mutation was found in a heterozygous state at a frequency ofO.026 amongst those with non-
syndromic recessive hearing loss and therefore was considered as a separate recessive mutation from
the previously described 310de114. Refer to Section 4.5.1 for further information concerning the
statistical analysis of the 312del14 mutation with regards to the frequencies that this mutation was
detected in the different study groups.
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Figure 4.9 A - C: Representative electropherograms of the GJB2 mutation 312de114
[A] Wild Type [B] Heterozygous
, ?c.-
.GAG GAAGT T CAT CAA
~10 320
.GAAGAGG:Rl\ RKWYAWM AAG
o 320 3
[CJ Homozygous
11n 11f
CATC AI) A1>.O A.<\3 1>.C IJ I)G AC AT
4.4.3.3 THE W24X MUTATION
The W24X mutation of GJB2 was only detected twice in this study. It was identified in a compound
heterozygous form (Figure 4.10B) together with the GJB2 mutation 35deiG in a sporadic family of
Mixed Ancestry. The second case was in an individual from the Mixed Ancestry control group (Section
The W24X mutation that was detected in GJB2 was a recessive nonsense mutation, which was the
result of the conversion of a G to an A at nucleotide position 71. This mutation was caused by the
conversion of a non-polar, hydrophobic Tryptophan (TGG) into a stop codon (TGA) at the amino acid
position 24. The W24X mutation produces a significantly shorter Cx26 protein that is unlikely to be
inserted into the plasma membrane since the mutation lies within the first transmembrane domain.
4.5.1).
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The W24X mutation was first detected in two Pakistani families in 1997 (Kelsell et al., 1997). This
was followed shortly by its detection in two Indian families in a homozygous as well as a compound
heterozygous state. It was noticed that the W24X allele was always associated with the same closely
linked marker alleles and therefore the mutation may have arisen from a single ancestral variation
(Scott et al., 1998B). The W24X mutation has been reported in a heterozygous state at a frequency of
0.026 amongst an American population, of varied ancestry, suffering from non-syndromic autosomal
recessive deafness (Lin et al., 2001). The W24X variant has also been reported in the Spanish and
Italian populations (Rabionet et al., 2000). However, it appears to be predominantly found in
individuals from the Indian subcontinent (India, Pakistan and Bangladesh). This, therefore, suggests
that the W24X mutation may be a common mutation to this ethnic group (Rickard et al., 2001). Refer
to Section 4.5.1 for further information concerning the statistical analysis of the W24X mutation with
regards to the frequencies that this mutation was detected within the different study groups.
The M34T mutation of GJB2 was only detected in a single individual from the Caucasian control group
and therefore it was only encountered in its heterozygous form (Figure 4.l1B).
The M34T mutation that was detected in GJB2 was a recessive missense variant that was the result of
the conversion of a T to a C at nucleotide position 101. This mutation caused the conversion of a non-
polar, hydrophobic Methionine (ATG) into a polar, hydrophilic Threonine (ACG) at amino acid
Figure 4.10 A - B: Representative electropherograms of the GJB2 mutation W24X
[A] Wild Type [B] Heterozygous
7n ~l
AAA(J ATG"": 3- C' C TCAC C
70 ~O
A.6,.AO _c.."": ~T lt CJ C T C AC CO
4.4.3.4 THE M34T MUTATION
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position 34 but still resulted in a full-length product. The M34T mutation was assumed to alter the
shape of the first transmembrane domain due to a large amino acid being replaced by a smaller one
(Kelsell et al., 1997). It was determined that this altered protein conformation, caused by the M35T
variant, hindered radial oligomerization of the subunits into connexons. A resultant decrease in the
number of homomeric M34T connexons was noted due to connexon movement from the intracellular
space to the plasma membrane requiring oligomerization. Those connexons that did form were
functionally abnormal as their voltage sensor gating was changed (Prasad et al., 2000). It was
determined that the Methionine amino acid at codon 34 played an important role in connexin
functioning as this residue was conserved in Cx26 and Cx32 of different species (Kelsell et al., 1997).
Kelsell et al. first detected the M34T variant in 1997, and described it as causing an autosomal
dominant form of hearing loss. Since then there has been continued debate as to whether this variant
was the cause of autosomal dominant or recessive deafness or even possibly a benign polymorphism. A
number of studies, which are discussed briefly below, have supported the various theories. However,
according to the Connexin Homepage (2003) the M34T variant is classified as a mutation that is
responsible for non-syndromic recessive deafness.
After the discovery of the M34T variant in 1997, Kelley et al. (1998) also detected it amongst an
American population group and described it as a recessive mutation since it was observed amongst
individuals with normal hearing. However, the possibility that it was a polymorphism was not ruled out
Figure 4.11A - B: Representative electropherograms of the GJB2 mutation M34T
[A] Wild Type [B] Heterozygous
lOC 110
TTT~ rCC-CATTAT OATCCTCO'
100 110
~rTTTcaCATTANCArCC7CG
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due to the fact that no homozygous individuals had yet been identified. Three possible explanations
were given as to how the M34T variant can be present in an individual with no signs of hearing
impairment. They were as follows (Scott et al., 1998B):
.:. The M34T variant was possibly the cause of non-syndromic recessive deafness in only some
individuals and not expressed in all, however this was unlikely due to a number of individuals
with normal hearing being hetetrozygous carriers .
•:. Some individuals were possibly carrying a change that compensated for the effect of the M34T
variant, however no such change had been identified .
•:. The M34T variant was a polymorphism that was only found within a small percentage of the
general population.
A study involving the injection of Xenopus laevis oocytes with in vitro-transcribed complementary
RNA that encoded either wild type human Cx26, M34T Cx26 or a combination of both was used to
determine the role of the M34T variant in non-syndromic deafness. Itwas shown that the M34T variant
did not bring about coupling between paired oocytes and the combination of both the M34T variant and
the wild type produced an inhibition in intercellular coupling. Therefore, the M34T variant caused
hearing loss by dominant inhibition of the activity of the wild type Cx26 (White et al., 1998).
Finally, in 2001 a homozygous individual for the M34T variant was identified amongst a sample
population collected from the UK and Ireland who suffered from non-syndromic autosomal recessive
hearing loss. Due to the identification of a M34T/M34T individual with mild hearing loss it was
determined that the M34T variant is responsible for non-syndromic autosomal recessive mild hearing
loss (Houseman et al., 2001). Even with this discovery that seemed to finally classify the M34T
variant, in the same year, two individuals in a French population with normal hearing were discovered
to harbour the M34T/35delG genotype. This again, indicated that the M34T allele was a benign
polymorphism (Marlin et al., 2001). Currently, the M34T variant is classified as a recessive mutation
that leads to non-syndromic hearing impairment (Connexin Homepage, 2003).
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Table 4.2: Frequency of the M34T allele ofGJB2 in various populations
Spanish/Italian
Japanese
French
French
Israeli
British/Irish
Australian
American
American
American
American
American
0.001
0.0
0.0
0.0
Houseman et al., 2001
Houseman et al., 2001
Houseman et al., 2001
Marlin et al., 2001
Houseman et al., 2001
Houseman et al., 200 I
Wilcox et al., 2000
Kelley et al., 1998
Green et al., 1999
Prasad et al., 2000
Kenna et al., 200 I
Lin et al., 2001
0.009
0.0
0.032
0.100
0.020
0.042
0.080
0.079
0.015
0.025
0.023
The sample group sizes in some of the studies were small therefore, the estimated frequencies of the M34T allele
should be treated with caution.
The frequency of the M34T variant has been determined amongst a number of different populations
(Table 4.2). It appears to be most common amongst the American, British, Irish and Australian
populations. However, in other populations such as the French, Spanish, Italian and Japanese it is
present at a low frequency or not at all. This suggests that a single ancestral mutational event took place
to form the M34T allele in either the UK or Ireland that was then carried over to the USA and Australia
by colonization of these countries by the British (Houseman et al., 2001). Refer to Section 4.5.1 for
further information concerning the statistical analysis of the M34T mutation and the frequencies
determined for this variation within this study.
4.4.3.5 THE V371 MUTATION
The V371 mutation of GJB2 was only detected in a single Indian sporadic family in a compound
heterozygous patient (Figure 4.12B).
The V371 missense mutation that was detected in GJB2 was the result of the conversion of a G to an A
at nucleotide position 109. This mutation leads to the change from a non-polar, hydrophobic Valine
(GTT) to a non-polar, hydrophobic Isoleucine (ATT) at the amino acid position 37. This Valine is
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conserved amongst all ~-connexins whereas, it is found as a Serine, Alanine or Glycine amongst the (1.-
connexin family (Kelley et al., 1998; Rabionet et al., 2000). This indicates that this Valine is important
for the correct functioning of Cx26, which is a ~-connexin. The V37I mutation most likely alters the
shape of the first transmembrane domain due to the difference in size of the amino acids.
Figure 4.12 A - B: Representative electropherograms of the GJB2 mutation V371
At first there was uncertainty as to the effect of the V371 variant. When it was first detected it was
classified as a benign polymorphism due to it only being detected once amongst a control group of
individuals with normal hearing (Kelley et al., 1999). In 2000, Abe et al., reported that the V371
variant frequently cosegregated, in a Japanese population, with non-syndromic recessive hearing loss
and therefore it was possible that this variant could be disease-causing. At the same time a homozygous
individual with non-syndromic autosomal recessive deafness was reported in the USA. However, there
was still confusion because in the same study, a family was identified where both parents with normal
hearing had genotypes V37IN271 and V37I1Wild Type. Their two deaf children had the genotypes
V37IN371 and V27I1Wild Type respectively. This therefore, suggested that neither mutation caused
deafness and that one child (V27I/Wild Type) represented a phenocopy (Prasad et al., 2000). Further
examples of homozygous individuals for the V371 variant were identified in Spanish/Italian and
Australian populations and the V371 allele was thus described as a recessive mutation that causes mild
non-syndromic autosomal recessive deafness (Rabionet et al., 2000 and Wilcox et al., 2000). The
Connexin Homepage (2003) currently confirms this classification of the V371 variant.
[A) Wild Type [B) Heterozygous
110
ÁTCCT~GT TGTGGC GATCCTCRTTGTGGCTGC
110 120
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Population V37I Frequency
(Deaf Individuals)
Japanese 0.057
Japanese
Japanese 0.014
American 0.017
American Homozygous = 0.079
Heterozygous = 0.052
Australian 0.150
French 0.036
V37I Frequency
(Control Individuals)
Reference
CHAPTER 4: RESULTS AND DISCUSSION
The frequency of the V371 variant has been determined in a few populations, including the Japanese,
American, Australian and French (Table 4.3). The V37I variant is found at relatively high frequencies
amongst all these groups. These high frequencies can be due to some of the studies using relatively
small sample groups. Refer to Section 4.5.1 for further information concerning the statistical analysis
of the V371 mutation with regards to the frequencies at which this variation was detected within this
study.
Table 4.3: Frequency of the V371 allele ofGJB2 in various populations
0.010
0.030
0.010 - 0.030
Abe et al., 2000
Kudo et al., 2000
Marlin et al., 2001
Prasad et al., 2000
Lin et al., 2001
0.009
Wilcox et al., 2000
Marlin et al., 2001
4.4.3.6 THE W44X MUTATION
The W44X mutation of GJB2 was only detected in a single individual within the Caucasian control
group (Section 4.5.1) in its heterozygous form (Figure 4.13B).
The W44X nonsense mutation that was detected in GJB2 was the result of the conversion of a G to an
A at nucleotide position 132. This mutation caused the conversion of a non-polar, hydrophobic
Tryptophan (TGG) into a stop codon (TGA) at the amino acid position 44. The W44X mutation
produces a significantly shorter Cx26 protein that is unable to function correctly as the mutation lies
within the first extracellular loop.
The W44X variant is classified on the Connexin Homepage (2003) as a disease-causing mutation that
leads to non-syndromic autosomal recessive hearing impairment. The W44X mutation was reported in
a study involving an American population at a frequency of 0.017 amongst those that suffered from
non-syndromic autosomal recessive deafness (Prasad et al., 2000). Refer to Section 4.5.1 for further
~6
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[A] Wild Type [B] Heterozygous
information concerning the statistical analysis of the W44X mutation with regards to the frequencies
that this variation was detected within this study.
Figure 4.13 A - B: Representative electropherograms of the GJB2 mutation W44X
130 I~O
~c- GT ar c G G c AI} AT (
l1n Ian
CaT CT G ac G Aa AT c Aa
4.4.3.7 THE N62I MUTATION
The N62I mutation of GJB2 was only detected in a single Caucasian family from the familial patient
group of samples (Section 4.5.1). This mutation was observed in compound heterozygous form with
the GJB2 35deiG mutation (Figure 4.14B).
Figure 4.14 A - B: Representative electropherograms of the GJB2 mutation N621
A CA CGT T CT T GeAG C CT GGC' A CAe G W ''1' CT T G C A G-
Sd 60 i 70
[A] Wild Type [B] Heterozygous
-. ; 1
The N62I missense mutation that was detected in GJB2 was a novel mutation and was the result of the
conversion of an A to a T at nucleotide position 185. This mutation causes the change from a polar,
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hydrophilic Asparagine (AAC) to a non-polar, hydrophobic Isoleucine (ATC) at amino acid position
62. It was determined that the N62I variation was a disease causing mutation that results in non-
syndromic autosomal recessive hearing impairment because it was the only variation, other than
35de1G, that was detected in the individual with non-syndromic autosomal recessive deafness. The
N62I mutation likely alters the shape of the first extracellular loop due to the difference in size of the
amino acids. The change will also likely affect the correct functioning of this domain due to the
difference in chemical properties of these amino acids.
4.4.3.8 THE V27I POLYMORPHISM
The V27I polymorphism of GJB2 was detected in two individuals. These individuals were identified in
the Caucasian and Mixed Ancestry control groups (Section 4.5.2). The electropherogram of this
polymorphism is shown in Figure 4.15B.
Figure 4.15 A - B: Representative electropherograms o/the GJB2 polymorphism V271
The V27I benign polymorphism that was detected in GJB2 was the result of the conversion of a G to
an A at nucleotide position 79. This polymorphism resulted from the conversion of a non-polar,
hydrophobic Valine (GTC) to a non-polar, hydrophobic Isoleucine (ATC) at the amino acid position
27. The Valine amino acid residue lies in the first transmembrane domain of the protein and is found to
be conserved in all connexin proteins (Kelley et al., 1998). Even though the amino acid at this position
is conserved it is unlikely to play an important role in the correct functioning or construction of the
Cx26 protein since individuals that have normal hearing and are homozygotic for the V27I variant have
[BJ Polymorphism
(AJ Wild Type
&0
C l' C AC I;J '1 C crc '1 ','
oj
GeT C AC CGT CC"": -::T T
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been identified (Wilcox et al., 2000). However, it has been observed that when the V27I polymorphism
is present together with a second GJB2 polymorphism, E114G, the resultant autosomal non-syndromic
recessive deafness phenotype does present. It has been suggested that V27I together with El14G
produces a dominant negative effect possibly due to interfering with the function of wild type Cx26
(Park et al., 2000).
From the time that the V27I variant was reported it has been classified as a benign polymorphism
(Kelley et al., 1998). Since then extensive evidence has arisen to support this classification of the V27I
variant. This evidence was generated in the form of results from a number of studies that were
conducted worldwide, where the V27I variant was found in the heterozygotic state as well as the
homozygotic form in many individuals with normal hearing (Kenna et al., 2001).
The frequency of the V27I variant has been determined in a number of populations, including the
Japanese, Korean, American, French and Iranian (Table 4.4). The V27! polymorphism appears to be
very common in the Japanese and Korean populations therefore, suggesting a common ancestor.
However, these high frequencies could be inaccurate due to some of the studies using relatively small
sample groups. Refer to Section 4.5.2 for further information concerning the statistical analysis of the
V27I polymorphism with regard to the frequencies determined for this variation within this study.
Table 4.4: Frequency of the V271 allele ofGJB2 in various populations
Population V271 Frequency V27I Frequency Reference
(Deaf Individuals) (Control Individuals)
Japanese 0.390 Abe et al., 2000
Japanese 0.360 Kudo et al., 2000
Korean 0.200 Park et al., 2000
American 0.025 Prasad et al., 2000
American 0.158 Lin et al., 2001
French 0.017 Marlin et al., 200 I
Iranian 0.012 Najmabadi et al., 2002
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4.4.3.9 THE A40A POLYMORPHISM
The A40A polymorphism of GJB2 was only encountered in a single individual from the Mixed
Ancestry control group (Section 4.5.2). The electropherogram ofthis polymorphism is shown in Figure
4.168.
The A40A polymorphism that was detected in GJB2 was the result of the conversion of an A to a G at
nucleotide position 120. This polymorphism lead to the wobble effect occurring, where there is no
change in amino acid, as the amino acid at position 40 remains a non-polar, hydrophobic Alanine and
only the translation codon changes from GCA to GCG. This change therefore, has no effect on the
correct functioning or construction of the Cx26 protein even though the A40A polymorphism lies in
the first extracellular loop.
4.4.3.10 THE R127H POLYMORPHISM
The R127H polymorphism of GJB2 was encountered in three unrelated individuals, all of whom
belonged to the Mixed Ancestry control group (Section 4.5.2). The electropherogram of this
polymorphism is shown in Figure 4.178.
The R127H polymorphism that was detected in GJB2 was the result of the conversion of a G to an A at
nucleotide position 380. This polymorphism lead to the conversion of a positively charged, polar
Figure 4.16 A - B: Representative electropherograms of the GJB2 polymorphism A40A
(A] Wild Type (B) Polymorphism
lao 1501~0 1~0
TO C AAAO G ,6,.0CT GT I o GC TC CO AAG GAG
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[A] Wild Type [B) Polymorphism
Arginine (CGC) to another positively charged, polar Histidine (CAC) at amino acid position 127. It has
been noted that the Arginine residue at codon position 127 is conserved in the B2, A2, A3, A4 and A8
connexins of all species that have been studied to date, however, a histidine residue has been found in
other members, such as Al, A5 and Bl (Estivill et al., 1998). The R127H polymorphism occurred in
the cytoplasmic loop, which plays a role in pH gating of the Cx26 protein (Rabionet et al., 2000).
However, this change had no effect on the correct functioning or construction of the Cx26 protein
possibly due to both amino acids being similar in chemical properties and size.
Figure 4.17 A - B: Representative electropherograms of the GJB2 polymorphism R127H
At first it was not known what role the R127H variant played in non-syndromic autosomal recessive
hearing impairment as it was restricted to patients suffering from deafness in Spanish, Italian and
Greek populations. Therefore, it could not be determined if this variation was a disease-causing
mutation or a benign polymorphism (Estivill et al., 1998 and Antoniadi et al., 2000). Only when the
R127H variant was detected together with the 35deiG mutation in a normal-hearing individual in
France, was the classification of the variant as a polymorphism made (Marlin et al., 2001).
The frequency of the R127H variant has since been determined in a number of populations, including
the Spanish, Italian, Geek, American, French and Iranian (Table 4.5). The R127H polymorphism
appears to be common in the Greek and Iranian populations. However, these high frequencies could be
due to the studies using relatively small sample groups. Refer to Section 4.5.2 for further information
1~n 10n
~AGC ':'C:; GCA ':' GG AhC J
3S0 ~90
AAJJT CC IJC ATC 0 Moa
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concerning the statistical analysis of the Rl27H polymorphism with regards to the frequencies with
which this variation was detected within this study.
Table 4.5: Frequency of the R127H allele ofGJB2 in various populations
The V153I polymorphism of GJB2 was identified in one Caucasian and one Indian family from the
sporadic patient group. The electropherogram of this polymorphism is shown in Figure 4.18B.
Population R127H Frequency R127H Frequency Reference
(Deaf Individuals) (Control Individuals)
Spanish/Italian 0.012 0.0 EstiviIJ et al., 1998
Greek 0.038 Antoniadi et al., 2000
American 0.008 Prasad et al., 2000
French 0.010 Marlin et al., 2001
Iranian 0.024 Najmabadi et al., 2002
4.4.3.11 THE V153I POLYMORPHISM
Figure 4.18 A - B: Representative electropherograms of the GJB2 polymorphism VlS3]
[A) Wild Type [B) Polymorphism
45C
Jl. TG r AC G T C T ~ C TA TGTACRTCTTCTATGTCATG TAC
460 470
The V153I polymorphism that was detected in GJB2 was the result of the conversion of a G to an A at
nucleotide position 457. This polymorphism resulted in the change from a non-polar, hydrophobic
Valine (GTC) to another non-polar, hydrophobic Isoleucine (ATC) at the amino acid position 153. This
polymorphism occurred in the third transmembrane domain of the Cx26 protein. However, this change
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had no effect on the correct functioning or construction of the Cx26 protein possibly due to both amino
acids being similar in chemical properties and size.
At first it was unclear as to the role that the V 1531 variant played in non-syndromic autosomal
recessive deafness since it had only been identified in heterozygotic form amongst individuals suffering
from hearing loss (Prasad et al., 2000 and Kenna et al., 2001). Later, two individuals with normal
hearing were identified with the VI53I variant together with the 35deiG mutation of GJB2. Therefore,
the VI53I variant was classified as a benign polymorphism with no significant no role in non-
syndromic austosomal recessive deafness (Marlin et al., 2001).
Table 4.6: Frequency of the Vi53! allele ofGJB2 in variouspopulations
Population VIS31 Frequency VIS31 Frequency Reference
(Deaf Individuals) (Control Individuals)
American 0.025 Prasad et al., 2000
American 0.011 Kenna et al., 2001
French 0.021 Marlin et al., 2001
Iranian 0.060 Najmabadi et al., 2002
The frequency of the VI53I variant has been determined in a few populations, including the American,
French and Iranian (Table 4.6). The VI53I polymorphism appears to be fairly common in all these
populations, especially the Iranian population. However, these high frequencies that have been reported
could be due to the studies using relatively small sample groups. Refer to Section 4.5.2 for further
information concerning the statistical analysis of the VI53! polymorphism with regards to the
frequencies with which this variation was detected within this study.
4.4.4 SCREENING OF GJB6
A number of samples that were screened for Cx26 (GJB2) mutations exhibit none or only one disease
causing mutation and it was decided to screen these samples for mutations in GJB6. The Cx30 gene
was chosen because of the role it plays together with GJB2 in hearing. Another reason for choosing the
GJB6 gene was that mutations within this gene have been implicated in non-syndromic autosomal
recessive deafness (especially the large deletion, ~(GJB6-DI3SI830) mutation). To screen GJB6,
automated DNA sequencing was selected because it is the most effective and sensitive method used to
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detect mutations. Another advantage of using DNA sequencing is that the coding region of the GJB6
gene is relatively small (786 bp) and therefore mutation screening can be accomplished in a single
DNA sequencing reaction. To detect the ó(GJB6-DI3S1830) mutation, PCR amplification involving
specific primers followed by agarose gel electrophoresis was used.
4.4.4.1 THE S199T POLYMORPHISM
The only variation identified by DNA sequencing, was the S199T polymorphism, which was
encountered in a single individual of the Mixed Ancestry control group (Section 4.5.2). The
electropherogram of this polymorphism is shown in Figure 4.19A-B.
The S199T polymorphism that was detected in GJB6 was the result of the conversion of a T to an A at
nucleotide position 595. This polymorphism resulted from the conversion of a polar, hydrophilic Serine
(TCT) to another polar, hydrophilic Threonine (ACT) at the amino acid position 199. This
polymorphism occurred in the fourth transmembrane domain of the Cx30 protein. However, this
change had no effect on the correct functioning or construction of the Cx30 protein possibly due to
both amino acids being similar in chemical properties and size.
Figure 4.19 A - B: Representative electropherograms of the GJB6 polymorphism S199T
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4.4.4.2 THE ~(GJB6-D13S1830) MUTATION
There have been three reports concerning a large deletion in GJB6 (Lerer et al., 2001; Pallares-Ruiz et
al., 2002; Del Castillo et al., 2002). The first study reported a deletion of at least 140 kb that was
identified in seven patients from four unrelated Ashkenazi Jewish families (Lerer et al., 2001). It was
noted that the deletion acted in trans with GJB2 mutations, 35deiG and 167delT. It was suggested that
the deletion caused non-syndromic autosomal recessive deafness either by a digenic mode of
inheritance that involved GJB2 and GJB6, or it removed control elements that were important for the
expression of GJB2. Itwas also demonstrated that all the patients had the same haplotypic background,
therefore it was assumed that the 140 kb deletion was due to a founder mutation. The frequency of the
140 kb deletion was determined to be less than 0.005 amongst the general population, but relatively
common amongst those with non-syndromic autosomal recessive deafness, at a frequency of 0.037
(Lerer et al., 2001).
The second study reported a deletion of 150 kb in five French patients with non-syndromic autosomal
recessive hearing loss who had previously been identified as carrying a single GJB2 mutation or were
linked to DFNB 1 but no mutations in GJB2 had been identified (Palleres-Ruiz et al., 2002). It was
shown that in these patients the 150 kb deletion was acting in trans with the GJB2 mutations 35deiG
and E47X. The 150 kb deletion was also observed in homozygotic state. Therefore, it was concluded
that the 150 kb deletion, which involves GJB6, is a recessive mutation but it was not known whether it
was of ancestral or recurrent origin or even a combination of both (Pallares-Ruiz et al., 2002).
Finally, a 342 kb deletion involving GJB6 was reported in a Spanish and Cuban population (Del
Castillo et al., 2002). The 342 kb deletion was identified in homozygous and heterozygous states in
patients with non-syndromic autosomal recessive hearing impairment. It was not known whether the
342 kb deletion encompassed the 150 and 140 kb reported deletions since the breakpoints for the
)
smaller deletions had not been reported. The frequency of the 342 kb deletion was determined at 0.048
amongst the Cuban and 0.088 amongst the Spanish non-syndromic autosomal recessive deafness
patients. It was not detected in any of the 200 samples collected from individuals with normal hearing
(Del Castillo et al., 2002). In a recent study it has been determined that the three large deletions that
were identified in various populations overlap and consists of a deletion of approximately 309 kb,
known as the ~(GJB6-D13S1830) mutation (Del Castillo et al., 2003) ..
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In the current study, agarose gel electrophoresis was used for the detection of the absence or presence
of the ~(GJB6-D13S1830) mutation (Figure 4.20). Theoretically a fragment would only be produced in
the presence of the large deletion as it resulted in the primers being within the necessary distance for
amplification to occur. An amplicon would not be produced when the large deletion was not present,
since the two primers would be too far apart for successful amplification to occur.
Figure 4.20: Representative photograph of peR amp/icons obtained during Lt(GJB6-
D13S1830) mutation screening
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Agarose gel electrophoresis of the PCR amplified fragment Del that covers the ~(GJB6-D13S1830) mutation.
The 2% agarose gels were electrophoresed for I hour at 100V in IX TBE buffer and stained with EtBr. M =
100 bp DNA ladder [Promega Corporation, Madison, WI, USA].
For the ~(GJB6-D13S1830) mutation screening a Del fragment of 460 bp was expected (Del Castillo et
al., 2002). However, in the current study a fragment of approximately 700 bp was observed instead. It
was therefore, assumed that this fragment could possibly indicate the presence of a smaller deletion of
approximately 140 kb. If a fragment of 460 bp was present it would indicate the presence of the larger
deletion of 324 kb as the primers are brought closer together than if there was only a 140 kb deletion,
thereby producing a 700 bp fragment instead. This 700 bp fragment together with a smaller 400 bp
fragment, which was occasionally observed, was purified from the gel and sequenced to determine the
breakpoints of the deletion.
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During the determination of the breakpoints a number of interesting observations were made. Firstly, it
was discovered that when the fragment of approximately 700 bp was compared against the NCBI
database, using the BLAST algorithm, a number of matches were obtained throughout the genome. The
predominant hit was that with the human DNA sequence from clone RPll-501K3 on chromosome 13
(accession number: AL355984). The fragment was positioned from nucleotide 43 075 - 43 722 on this
clone, within the vicinity of GJB6. However, it was not expected that over 300 matches would be
obtained in both the complementary and reverse complementary orientation. These matches included
correspondence with clones from almost all the chromosomes, including the X chromosome, as well as
the protein S (alpha) (PROSl) gene, part of a novel gene (IMOGEN 38), the FSH primary response
homolog 1 (FSHPRHl) pseudogene, the menage a trios 1 (CAK assembly factor) (MNATl) gene and
the glypican 3 (GPC3) gene. A possible reason for this result is that the sequence of the 700 bp
fragment is that of a genome-wide repeat i.e. a long interspersed nuclear element (LINE). LINEs are
classified, together with short interspersed nuclear elements (SINEs), as retroposons since they contain
a reverse transcriptase-like gene that possibly plays a role in retro transposition. Retroposons and LTR
elements, which contain long terminal repeats at either end that are involved in transposition, are
known as retro elements. These retro elements are known features of eukaryotic genomes. These
sequences are found often throughout the genome, as is seen in the example of LINE-l that is 6.1 kb in
length and is found 3 500 times within the human genome (Brown, 1999).
Secondly, when the second fragment of approximately 400 bp was compared against the NCB!
database it was reported to have a match with the human DNA sequence from clone RP5-1 033H22 on
chromosome Ip21.2-22.2 (accession number: ALI09613) was obtained. This clone contains part of a
novel gene (KlAA0554) and the BCAR3 (breast cancer anti-estrogen resistance 3) gene. The 330 bp
fragment was located at nucleotide position 39 047 - 39 277 within this clone. It is unclear as to why
this fragment was produced but it could possibly be due to the sequence being similar to enough to the
~(GJB6-D13S1830) sequence, which allows for the non-specific binding of the primers used during
PCR amplification.
Due to the result obtained from the NCB I database analysis of the 700 bp and 400 bp fragments it was
decided to perform a homology search with the sequences of the primers used to amplify these
fragments. Again a number of interesting observations were made.
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The results of the NCB I database analysis of the forward primer, GJB6-1R, indicated that the sequence
of this primer had homology with three locations within the human genome: Firstly, as expected, in the
complementary orientation within GJB6 (accession number: NM_006783) at nucleotide position 687 _
710 of the sequence of this gene. Secondly, the sequence matched, in the forward orientation, to the
THYR01000678 clone (accession number: AK075247) at nucleotide position 1 140 _ 1 163. This is
not unexpected as this clone is that of a Homo sapiens cDNA sequence that is highly similar to the
GJB6 gene. Finally, the sequence was also found in the reverse complementary orientation within the
RP11-501K3 clone on chromosome 13 at nucleotide position 20 612 _ 20 635. This could possibly
explain why a 700 bp fragment was obtained instead of the expected 460 bp. The reason could be that
the GJB6-1 R primer acts as both a forward and reverse primer to produce the 700 bp fragment in the
presence of the ~(GJB6-D13S1830) mutation since the primers are in closer proximity to one another.
The 460 bp fragment would be the result of amplification between the correct primers, GJB6-1R and
BKR-I, when the ~(GJB6-DI3S1830) mutation is present.
When the reverse primer BKR-1 was analyzed using the NCBI database it was again noted that the
primer matched a number of sequences within the human genome both in the forward and reverse
complement orientation. This primer matched predominantly with the RPll-476H16 clone on
chromosome 13 (accession number: AL590096). The primer was found to be located in the reverse
complementary orientation at nucleotide position 62 369 _ 62 393. This result was expected as the
clone is situated close to GJB6. However, it was not expected that the primer would also match
sequences found in two other clones. Firstly, the primer was found to show 92% similarity with the
forward DNA sequence of clone RP11-11KI5 on chromosome 5 (accession number: AC091888) at
nucleotide position 9 0154 _ 90178. Secondly, the primer showed a 92% match at nucleotide position
3 3704 _ 3 3728 in the reverse orientation to the sequence of clone RP3-52202 on chromosome 6q21
(accession number: HS52202). It is not thought that these matches have an influence on the sensitivity
of the PCR amplification as they are not located on chromosome 13 and they are not completely
complementary to the genomic sequence.
Due to the information discovered during the NCBI analysis of the PCR fragments and primers raising
questions as to the accuracy of the screening method, it was decided not to include the result obtained
from the screening for the ~(GJB6-D13S1830) mutation. Another reason for excluding the results was
the latest report by Del Castillo et al (2003) that only the ~(GJB6-D13S 1830) mutation of
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approximately 309 kb exists and not any of 140 or 150 kb. A final reason for the exclusion of the
results was that there was no reproducibility of results for the ó(GJB6-D13S1830) mutation as there
was inconsistent PCR amplification.
4.4.5 INACCURACIES IN THE NCBI DATABASE
During the analysis of the sequences of GJB2 and GJB6 a few inaccuracies within the NCBI database
sequences were noted. This was not expected, since the sequences in the NCB I database are those from
Caucasian samples and in this study many Caucasians were included. The first variation was detected
when the GJB2 sequence (accession number: NM_004004) on the NCBI database was compared with
the sequences that were obtained from the screening of the samples from patients and controls. It was
noted within all these samples that they contained the S86T variation, which involves the inversion of a
GC to a CG at nucleotide position 257 and 258, which leads to the amino acid conversion of a serine to
a threonine. Therefore, it was assumed that the NCBI database sequence represents a rare variant and
not the wild type.
The second inaccuracy within the NCBI database was detected in the GJB6 sequence (accession
number: NM_006783). The L36L variant was observed in all the patient and control samples that were
screened for GJB6 mutations. This variation involves the conversion of an A to a C at nucleotide
position 108, which results in no change in amino acid as both variants lead to the formation of a
leucine at this position. The third inaccuracy was also observed in the GJB6 sequence as the HI24Q
variant. This change in the sequence of a C to a G at nucleotide position 372 results in the amino acid
conversion of a histidine to a glutamine. It was therefore assumed that the sequence on the NCB I
database does not represent the wild type allele but rather a rare variant.
4.5 THE STATISTICAL ANALYSIS OF DATA
The statistical analysis of the data collected during this research project included the determination of
the allele frequencies of the specific disease-causing mutations and benign polymorphisms that were
detected in both GJB2 and GJB6 for the different population groups that were studied. Also included in
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the statistical analysis was the determination of the success rate achieved in identifying the causative
mutations. A summary of the results of the molecular analysis of GJB2 and GJB6 is presented C.
4.5.1 ALLELE FREQUENCIES OF THE DISEASE-CAUSING MUTATIONS DETECTED IN
GIB2 AND GIB6
4.5.1.1 FAMILIAL GROUP ALLELE FREQUENCIES
Allele frequencies were determined for the mutations in GJB2 within the familial study group. This
was achieved by using the mutation analysis results of the proband for each of the families.
Table 4.7 displays the number of alleles observed for each of the GJB2 mutations for each of the
specific families that were classified as familial cases. The 35delG mutation of GJB2 was the most
common mutation within this study group, with an allele frequency of 0.281 (of 32 alleles). The GJB2
mutation 312de114 was also detected at a high frequency of 0.188 within this study group. The only
other mutation that was identified amongst the familial cases was the novel N62I mutation of GJB2,
which was found in a single family.
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Table 4.7: Allele frequencies of the mutations detected in GJB2 in the familial study cohort
of 16families
4.5.1.2 SPORADIC GROUP ALLELE FREQUENCIES
The allele frequencies of the mutations that were detected in GJB2 were also calculated for the
sporadic study group (Table 4.8). The calculation was achieved by using the mutation analysis results
obtained for the proband of each of the families.
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Table 4.8: Allele frequencies of the mutations detected in GJB2 in the sporadic cohort of 28
families
The GJB2 mutations 35deiG and 312de114 were found at high frequencies of 0.107 and 0.125
respectively, with the 312de114 being the most common mutation amongst this group. The total
number of alleles screened was 56. The only other mutations observed were W24X and V37I. Both
these mutations were only observed in single families, and therefore at a very low frequency.
When comparing the sporadic group (Table 4.8) to the familial group (Table 4.7) it can be noted that
the 140 kb deletion of GJB6 was more common amongst the sporadic cases whereas the 35delG
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mutation was more common in the familial group. The GJB2 mutation 312del14 was found at
relatively the same frequency amongst both groups. It appears as if there were more variation in the
type of mutations amongst the sporadic cases since a missense (V37I) and a nonsense (W24X)
mutation was detected in this group whereas, in the familial group only a single missense (N62I)
mutation was observed.
4.5.1.3 TOTAL ALLELE FREQUENCIES
When the total allele frequencies (Table 4.9) for the mutations observed involving GJB2 were
calculated, using all the groups studied in this project, it was observed that the most common mutation
was the 35deiG mutation with a frequency of 0.052, which was followed by the 312de114 at a
frequency ofO.049. This was calculated from a total of288 alleles that were screened during this study.
The remaining GJB2 mutations were encountered at relatively low frequencies and are therefore
apparently not common to the South African population
Table 4.9: Allelefrequencies of the mutations detected in GJB2 in the entire study group
Familial 9/32 6/32 0/32 0/32 0/32 0/32
Sporadic
Caucasian
Controls
Mixed 0/100 0/100 1/100 0/100 0/100 0/100 01100
(0.0) (0.0) (0.010) (0.0) (0.0) (0.0) (0.0)
4.5.1.4 POPULATION-BASED ALLELE FREQUENCIES
The allele frequencies for each of the mutations that were detected in GJB2 were also determined for
the Caucasian and Mixed Ancestry population groups of South Africa. The results that were calculated
for the Caucasian population group are indicated in Table 4.10.
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From a total of 164 alleles that was screened it was determined that the 312del14 and 33deiG mutations
were the most common with frequencies ofO.085 and 0.073, respectively. The W44X, M34T and N62I
mutations were observed at very low frequencies. The remaining two mutations W24X and V37I were
not present in this population group. Therefore, these variations are apparently uncommon specifically
in the South African Caucasian population.
Table 4.10: Allelefrequencies of the mutations detected in GJB2 in the South African
Caucasian population
The total allele frequencies for the mutations observed in GJR2 also calculated for the Mixed Ancestry
population of South Africa (Table 4.11). The most common mutation detected at a frequency of 0.027
(112 alleles) was the 35deiG mutation. The only other mutation that was detected amongst the Mixed
Ancestry population was the W24X variation, which was found at a low frequency of 0.018.
Interestingly, the GJR2 mutation 312de1l4 that was observed amongst the Caucasian South African
population (0.085) was not detected at all amongst the Mixed Ancestry population of South Africa.
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Table 4.11: Allelefrequencies of the mutations detected in GJB2 in the South African
Mixed Ancestry population
The allele frequencies for all the mutations that were detected in GJB2 compared with the frequencies
that have been previously reported. The results of this are discussed briefly below:
.:. For the GJB2 mutation 35deiG it was noted that the allele frequency obtained in the Caucasian
population (0.073) in this study was higher than any that had been previously reported (Table
2.5), however, this could be the result of using a relatively small study group. The allele
frequency that was obtained for the 35deiG mutation for the Mixed Ancestry population (0.027)
was similar to those that had been reported in the general population of countries such as
Belgium, France and USA (Americans of European ancestry) .
•:. The 312de114 mutation of GJB2 was only detected in the Caucasian population in this study at
a frequency of 0.085. This frequency appears to be relatively high compared with the
previously reported frequency of 0.026 in an American population with non-syndromic
autosomal recessive deafness (Lin et al., 2001). Therefore, it appears that the 312de114
mutation is possibly specific to the South African Caucasian population, however it must be
taken into consideration that a relatively small sample size was used in this study. Refer to
Section 4.4.3.2 for more information concerning the 312del14 mutation .
•:. The GJB2 mutation W24X was only detected in the Mixed Ancestry population (0.018). When
compared with previously reported cases, this result is not surprising as it has been observed
that the W24X mutation is not frequently found but it is predominantly detected amongst
individuals from the countries of India, Pakistan and Bangladesh (Rickard et al., 2001). Refer to
section 4.4.3.3 for more information concerning the W24X mutation.
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.:. The M34T mutation of GJB2 was only detected in the Caucasian population at a frequency of
0.006, which is similar to that reported in a French population. This frequency is relatively low
compared with some of the other reported frequencies in populations such as the British/Irish,
Australian and American (Table 4.2) .
•:. The GJB2 mutation V37I was not detected in either the Caucasian or Mixed Ancestry
populations of South Africa however, it was detected in a single family of Indian ancestry. This
was surprising since the V37I mutation has been reported at relatively high frequencies amongst
various other populations such as the Japanese, American, Australian and French (Table 4.3).
A possible reason for the low number ofV37! mutants detected in this study could be due to the
sample size .
•:. The nonsense mutation W44X of GJB2 was only detected at a frequency of 0.006 amongst the
South African Caucasian population in this study, which is similar to the previously reported
frequency of 0.017 that was observed in an American group with non-syndromic autosomal
recessive deafness (Prasad et al., 2000). Refer to Section 4.4.3.6 for further information
concerning the W44X mutation .
•:. The N62I mutation of GJB2 that was detected in a single Caucasian family was a novel
mutation and therefore, there are no previously reported frequencies to compare this mutation
to.
4.5.2 ALLELE FREQUENCIES OF BENIGN POLYMORPHISMS DETECTED IN GJB2 AND
GJB6
4.5.2.1 FAMILIAL GROUP ALLELE FREQUENCIES
The allele frequencies of the polymorphisms that were detected in GJB2 and GJB6 were also
determined for the different groups studied in this research project. There were no polymorphisms
detected amongst familial cases but this is possibly due to the small sample size screened.
4.5.2.2 SPORADIC GROUP ALLELE FREQUENCIES
The results obtained for the calculation of the allele frequencies for the polymorphisms that were
detected in GJB2 and GJB6 amongst the sporadic study group are indicated in Table 4.12. Again only a
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single variation was detected in this study group; GJB2 polymorphism VI53I that was observed at a
high frequency of 0.071 amongst a total of 56 alleles. This was a small population size therefore, the
frequency has a high probability of being inacurrately estimated.
Table 4.12: Allelefrequencies of the polymorphisms detected in GJB2 and GJB6 in the
sporadic study cohort of 28 families
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4.5.2.3 TOTAL ALLELE FREQUENCIES
The total allele frequencies of the polymorphisms that were detected in GJB2 and GJB6 were
calculated (Table 4.l3). The combining of all the groups studied, increased the number of alleles
screened to a total of 276. It was observed that GJB2 polymorphisms V27I and V153I were the most
common at a frequency of 0.015 each. The second most common variation was R127H of GJB2. The
remaining polymorphisms were observed at a lower frequency of 0.003 and therefore are assumed to
be uncommon to the South African population.
Table 4.13: ALlelefrequencies of the polymorph isms detected in GJB2 and GJB6 in the
entire study group
2/100
(0.02)
0/100
(0.0)
21100
(0.02)
2
4.5.2.4 POPULATION-BASED ALLELE FREQUENCIES
The allele frequencies were also calculated for each of the population groups studied to determine if
any polymorphism involving GJB2 or GJB6 are specific to that group. The results of determination of
the allele frequency for the Caucasian population of South Africa are indicated in Table 4.14. It was
observed that no single polymorphism was specific to this group however two GJB2 variations were
detected, which included V27I and V153I, at a frequency of 0.012 and 0.006 respectively from 164
alleles screened.
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01100
(0.0)
Table 4.14: Allelefrequencies of the polymorph isms detected in GJB2 and GJB6 in the
South African Caucasian population
2/100
(0.02)
DilDO
(0.0)
6/100
(0.06)
6
0/100
(0.0)
O.
0/36
DilDO
(0.0)
o
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The allele frequencies of the polymorphisms observed in GJB2 and GJB6 were also determined for the
Mixed Ancestry population of South Africa as is indicated in Table 4.15. In this group a GJB2
polymorphism, R127H, does appear to be specific as it was detected at a frequency of 5.357% amongst
a total of 112 alleles screened. Other variations were observed at a low frequency of 1.786%. These
polymorphisms included the GJB2 variations V27I and A40A as well as the GJB6 polymorphism
SI99T. The V 1531 polymorphism of GJB2 was not detected amongst the Mixed Ancestry population
of South Africa.
Table 4.15: Allelefrequencies of the polymorph isms detected in GJB2 and GJB6 in the
South African Mixed Ancestry population
The allele frequencies for all the polymorphisms that were detected in GJB2 and GJB6 were compared
with the frequencies that have been previously reported ..The results of.this.are discussed briefly below:
2/100
(0.02)
CHAPTER 4: RESULTS AND DISCUSSION
.:. The allele frequency of the GJB2 variation V271 was similar in both the Caucasian and Mixed
Ancestry population groups at a frequency of 0.012 and 0.018 respectively. When compared
with previous reports it was noticed that the Caucasian group had a similar frequency to that
which has been detected in the Iranian population whereas the Mixed Ancestry population is
similar to that which was determined in a French study. The V271 polymorphism has been
detected at very high frequencies amongst the Japanese and Korean and it has been assumed
that this polymorphism is a founder variation for the Asian populations (Table 4.4) .
•:. The A40A polymorphism of GJB2 was only detected in a single individual from the Mixed
Ancestry control group. It was not possible to find any information concerning the frequency of
this variation therefore the allele frequency that was determined in this study could not be
compared with previous reports .
•:. The R127H polymorphism of GJB2 was not detected in the Caucasian population however it
was observed at a relatively high frequency amongst the Mixed Ancestry population of South
Africa. The frequency of 0.054 was also relatively high when compared with the frequencies
reported in various other studies involving a number of populations. The only similar frequency
was that of 0.038 which was detected in a Greek study (Table 4.5). The frequency that was
observed in this study could be inaccurate, as the sample size was relatively small.
.:. The GJB2 polymorphism of VI531 was only detected in the South African Caucasian
population and not in the Mixed Ancestry population in this study. It was observed at a
relatively low frequency of 0.006, which is lower than any of the other previously reported
frequencies determined using a number of different populations (Table 4.6). The frequency for
VI531 is possibly inaccurate as the sample size used in this study was relatively small .
•:. The S199T polymorphism of GJB6 was only detected in the Mixed Ancestry population of
South Africa at a frequency of 0.018. Itwas not possible to find any information concerning the
frequency of this variation, therefore the allele frequency that was determined in this study
could not be compared with previous reports.
4.5.3 SUCCESS RATE OF MUTATION DETECTION
The success rate of detecting mutations within GJB2 and GJB6 was calculated for both the familial and
the sporadic study groups, which contained families with non-syndromic autosomal recessive deafness.
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These two study groups were also divided according to population, so that the success rate could also
be determined for the various populations (Table 4.16).
Table 4.16: Total success rate a/mutation detection within GJB2 and GJB6 according to
population and study group
From a total of 32 alleles found within the familial group a success rate of 50% was achieved in the
detection of the deafness causing mutations within these families. This group contained individuals
from the South African Caucasian and Mixed Ancestry population groups, which had a success rate for
mutation detection of 50% each. It has been previously noted that when screening for GJB2 mutations,
10 - 42% of the individuals tested have only one mutation that results in hearing loss (Del Castillo et
al., 2002). This figure corresponds to those what was observed in this study (50% of the non-
syndromic autosomal recessive deafness causing mutations have not been identified in the familial
group).
Amongst those individuals who were classified in the sporadic group a success rate of only 26.8% was
achieved from 56 alleles that were screened for mutations that lead to hearing loss. In this group there
were individuals from various South African populations including Caucasian, Mixed Ancestry,
African and Indian. The best success was achieved amongst the Caucasians of this group as 33% of all
deafness mutations were identified. A success rate, for mutation detection during screening, of 25%
and 16.7% was obtained respectively for the Mixed Ancestry and Indian populations. For the African
(0.50) (0.0) (0.50) (0.33) (0.0) (0.33) (0.41 )
2/4 0/4 2/4 2/8 0/8 2/8 4/12
(0.50) (0.0) (0.50) (0.25) (0.0) (0.25) (0.33)
0/0 0/0 0/0 0/6 0/6 0/6 0/6
(0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0)
0/0 0/0 0/0 1/6 0/6 1/6 1/6
(0.0) (0.0) (0.0) (0.17) (0.0) (0.17) (0.17)
16/32 0/32 16/32 IS/56 0/56 IS/56 31/88
(0.50) (0.0) (0.50) (0.27) (0.0) (0.27) (0.35)
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group there were no mutations detected during screening. This however, was expected as it was noted
in a previous study involving a Ghanaian population that GJB2 mutations only contribute to 16% of the
cause of non-syndromic autosomal recessive deafness and it was thought that other factors such as the
environment played a larger role (Hamelmann et al., 2001). This could also be the reason as to why no
mutations were detected in either GJB2 or GJB6 for any of the African individuals in this study. The
frequency of unidentified mutations is 73.2% amongst the sporadic group studied, which is higher than
the expected 10 - 42%.
A total success rate of 35.2% was therefore attained from the 88 alleles that were screened for
mutations found within GJB2 and GJB6, which result in non-syndromic autosomal recessive deafness.
When comparing the two study groups it was observed that the best results were obtained in the
familial group, which had a success rate of 50% compared with the sporadic group's rate of 26.8%.
When comparing the different populations it was observed that the best success was obtained in the
Caucasian population (40.6%) followed by the Mixed Ancestry (33.3%) and the Indian (16.7%)
populations. It is expected that the success rate will increase with the inclusion of an accurate screening
procedure for the ~(GJB6-D13S1830) mutation of GJB6, as it has been estimated that this deletion
could be the cause of non-syndrornic autosomal recessive deafness in 15 - 35% of all cases (Del
Castillo et al., 2003).
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Hearing loss is the most common inherited sensory disorder (Kelley et al, 1998). It has been
estimated that 80% of all congenital inherited deafness cases are the result of autosomal recessive
inheritance or sporadic mutational events (Estivill et al., 1998). Itwas decided to conduct a study on
the role of GJB2 as the cause of deafness in South Africa since studies have indicated that
mutations involving this gene, which encodes Cx26, is a major contributor to autosomal non-
syndromic recessive deafness (Antoniadi et al., 2000). It has been estimated that the screening for
two specific mutations, 35deiG and 167deiT of GJB2 is expected to diagnose up to 50% of familial
and 10 - 40% of sporadic cases in Caucasian populations of European descent (Estivill et al., 1998;
Tekin et al., 2001). The information generated in this study would be useful in setting up a
population specific diagnostic and counselling program for autosomal non-syndromic deafness in
South Africa as no such study has been conducted involving this population.
The first aim of the study was to investigate the entire coding region of GJB2 to identify any
mutations that result in non-syndromic autosomal recessive deafness in the Caucasian and Mixed
Ancestry populations of South Africa. This was achieved by the PCR amplification of the entire
coding region and subsequently, SSCP analysis and automated DNA sequencing.
In total seven different non-syndromic autosomal recessive deafness mutations and five benign
polymorphisms were detected within GJB2 during screening of 44 families belonging
predominantly to the Caucasian and Mixed Ancestry populations of South Africa. The mutations
that were detected included the common Caucasian mutation (35deIG), other mutations that have
been previously reported (3I2de114, W24X, M34T, V3.7I and W44X), as well as a novel mutation
(N62I). The four benign polymorphisms that were detected have all been reported previously and
include V27I, A40A, R127H and VI53!. The 167deiT mutation of GJB2 was not detected in this
study. This was expected as it has been shown that this mutation is specific to Ashkenazi Jews and
in this study group there were no individuals from this genetic background. This therefore reflects
that every population should be screened for population specific mutations and the ancestral
background of the individuals being screened should also be taken into consideration.
The second aim of the study was to investigate the entire coding region of GJB6 to identify any
mutations that result in non-syndromic autosomal recessive deafness in the Caucasian and Mixed
Ancestry populations of South Africa. This was achieved by the PCR amplification of the entire
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region as a single fragment that was analysed by automated DNA sequencing. Screening for the
~(GJB6-D13S1830) mutation was attempted using a simple PCR technique that included agarose
gel electrophoresis to identify those individuals that were possibly homozygous, heterozygous or
wild type normal for the large deletion that involved the GJB6 gene.
Only a single benign polymorphism was detected in GJB6 during mutation analysis. The
polymorphism, S199T, has been reported before. It has been previously noted that not many
mutations causing non-syndromic autosomal recessive deafness have been identified in GJB6,
therefore it appears that this gene is not as susceptible to the occurrence of mutations as compared
with GJB2, which has more than 70 reported mutations (Connexin Homepage, 2003). Another
possible explanation for the low number of mutations identified to date within GJB6 could be due to
potential lethality in the embryo. This phenomenon has been reported for GJB2 knockout mice and
it is assumed the same may possibly occur for GJB6 knockout mice, since both genes are highly
similar in structure. However, this lethality may carryover to humans for GJB6 and not for GJB2
(Kelley et al., 1999).
During the screerung for the ~(GJB6-DI3S1830) mutation a number of questions arose that
concerned the accuracy of the method used. Due to this, some of the results that had been obtained
during this study were excluded. The specificity of the primers used was brought into question, as it
was noted during NCBI database analysis that the sequences of the primers were found in a number
of places throughout the human genome. Specifically the forward primer, GJB6-1R, could possibly
result in non-specific amplification as it is found in the forward and reverse complement orientation
on chromosome 13. Also during NCBI database analysis it was discovered that the fragments
obtained during PCR amplification were in fact localised throughout the genome on various
chromosomes as the sequence is possibly that of a genome-wide repeat, known as a LINE. Finally,
a recent report clarified the fact that only the deletion of approximately 309 kb exists and not a
smaller deletion of roughly 140 kb (Del Castillo et al., 2003). This information influenced our
results as it was assumed that the South African population harboured the smaller deletion of 140
kb. Therefore, it was decided that a positive control, containing the ~(GJB6-D13S1830) mutation,
was required. Inquires have been made for obtaining such a sample from studies previously
conducted within other countries. One such sample has been obtained and it will be used to
optimise the PCRconditions for ~(GJB6-D13S1830) mutation screening. Further verification may
be conducted with Southern blotting (Del Castillo et al., 2002), depending on the results obtained
during the analysis of the South African population with the PCR technique. This work will form
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part of the ongoing study of non-syndromic autosomal recessive deafness in the South African
population.
The third aim of this study was to analyse the effectiveness of three SSCP gel electrophoresis
systems in the detection of mutations in GJB2. Three systems that were chosen included a mini
PAGE, a SSCP-urea gel electrophoresis and a two buffer gel electrophoresis procedure. It was
determined from the results that none of the SSCP gel electrophoresis techniques were effective,
because none could detect the most common mutation, 35de1G, of GJB2. A possible reason for this
could be that the fragment size screened was too large, as the sensitivity of SSCP analysis decreases
with the increase of fragment sizes over 200 bp. The size of this fragment was 350 bp, and this
could have influenced results obtained. Also the position of the mutation within the fragment can
also influence the sensitivity of the method. The 35deiG mutation lay within the first 40 bp of
fragment 1, therefore the SSCP method may detect this mutation successfully if it lay within the
middle of the fragment instead. With regards to the detection of other mutations it was determined
that the two buffer system was the most effective at detecting mutations within fragment 2 as it
clearly demonstrated the 312de114 mutation. Another reason for the two buffer system being
regarded as the most efficient system is that more samples can be screened per experiment. This,
therefore, means that more samples can be screened per day, which is a great advantage for a
diagnostic program.
In the present study optimisation of the different SSCP gel electrophoresis systems did not occur as
it was decided that it was necessary to first determine which mutations were the most common to
the South African populations. Therefore, a future study could be conducted whereby the different
SSCP gel electrophoresis systems could be optimised to specifically detect the common mutations.
It is believed that with specific optimisation the different SSCP gel electrophoresis systems will be
able to detect the 35deiG mutation of GJB2 as it has been shown to be possible in other studies that
have been conducted elsewhere (Kelley et al., 1998). This therefore, should give a more accurate
assessment as to whether the two buffer gel electrophoresis system is in fact the best suited for use
in a large scale diagnostic program of non-syndromic autosomal recessive deafness. It is still
debatable as to whether the SSCP gel electrophoresis system should be used in a screening program,
as it is not a completely sensitive technique even when it is fully optimised because novel mutations
may still be missed. The percentage of patients that do not contain the previously reported
mutations will have to be taken into account. This will determine the possible number of samples
that will have to undergo further screening using automated DNA sequencing to determine the
deafness causing mutations present. If DNA sequencing technology becomes more cost effective in
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the future it could become the method of choice for mutation screening. On the other hand DNA
chips may be designed to contain the most common mutations and thereby provide a reliable and
time effective method for screening for a large number of mutations in a single reaction.
The fourth and final aim of the study was to determine the allele frequencies of those mutations
detected in GJB2 and GJB6 amongst the Caucasian and Mixed Ancestry populations of South
Africa. This information indicates which mutations are common in these populations and therefore
can be used in the establishment of a diagnostic program in the future.
From the results obtained it was determined that the most common mutations amongst the familial
study group was the GJB2 mutation 35de1G. The 312de1l4 ofGJB2 was also common in this group.
With regards to the sporadic study group the 312de114 and 35deiG mutations were observed at a
high frequency. Therefore, in total the most common mutation that was detected within the South
African population was the 35deiG mutation. To determine if there were different mutations
relating to specific South African populations, the result were further analysed for the specific
population groups. It was observed that the 35deiG mutation was the most common in both the
Caucasian and Mixed Ancestry populations. However, the 35deiG mutation was more common in
the Caucasian population than in the Mixed Ancestry group. This result was expected since the
Caucasian population of South Africa is of European descent and the Mixed Ancestry group
descends from the Khoi San, Malay, African and Caucasian populations. Interestingly, the Cx26
mutation, 312de1l4, was only observed in the Caucasians and not in the Mixed Ancestry
population. This is also the first time that this mutation has been reported at such a high frequency,
which could possibly be due to a founder gene effect. The frequency of the different polymorphisms
that were observed in GJB2 and GJB6 was also determined and compared to those detected
amongst the controls. However, the sample SIze was relatively small which resulted in the
frequency being insignificant. The success rate of mutation detection was also determined (35 %),
which can be considered as relatively successful since it has been reported that between 10 - 50%
of all the cases with non-syndromic autosomal recessive hearing loss have at least one mutant allele
remaining unidentified when only GJB2 mutation screening is performed (Del Castillo et al., 2003).
This therefore indicates that if a diagnostic program for autosomal recessive non-syndromic
deafness were to be put in place, focusing only on the mutations of GJB2 and GJB6, a high rate of
success in identification of the causative mutations would not be achieved. However, if screening
for the ~(GJB6-D13S 1830) mutation were included it could lead to an increase in sensitivity by 17
- 34% (Del Castillo et al., 2003).
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Future studies should include other population groups of South Africa, such as the different African
tribes as well as the South African Indian population. This will mean increasing the sample
collection area to include the other provinces of the country instead of just focusing predominantly
on the Western Cape province as was done in this study. For this to be achieved, better co-operation
and understanding about the heritability of non-syndromic autosomal recessive deafness and the
potential benefits of the project will have to be communicated between the researchers and the deaf
community so that a sufficient number of samples can be collected.
The inclusion of additional individuals and population groups will lead to a better understanding of
the role that GJB2 and GJB6 play in South Africa. Another possible area of study would be to
determine whether the common mutations that have been observed in the South African populations
are derived from a common ancestor. This could be achieved with the use of haplotype studies that
would include various polymorphic markers that surround GJB2 and GJB6.
The study could be expanded further by the inclusion of other genes, such as GJAI (Cx43) and
GJB3 (Cx31), since it has been reported that these genes are also involved in non-syndromic
hearing loss (Liu et al., 2000; Liu et al., 2001). This is important, since it has been shown that
mutations in GJAI playa role in non-syndromic autosomal recessive deafness amongst the African
population of South Africa (Kabahuma et al., 2003). This should help in the identification of the
mutations that lead to non-syndromic autosomal recessive deafness in those unexplained cases.
Eventually, this knowledge would further improve the impact of a population specific diagnostic
program for the detection of non-syndromic autosomal recessive hearing loss in South Africa.
With regards to the establishment of a diagnostic and genetic counselling program for non-
syndrornic autosomal recessive deafness it is recommended that:
1. Further research be conducted to optimise the various SSCP gel electrophoresis systems so that
the most efficient system can be determined. The optimisation of the systems should focus on
common mutations, which include the GJB2 mutations 35deiG and 312de114. Conversely,
research could be conducted into other screening techniques that are possibly more efficient at
detecting mutations and also cost effective.
2. Future studies should include other population groups of South Africa, such as the various
African groups as well as the South African Indian population, thereby improving the diagnostic
and counselling service that is offered to all populations in the country.
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3. The sample size of the various study groups should be increased so that a more accurate
frequency of the different mutations related to non-syndromic autosomal recessive deafness in
South Africa can be determined. This will again lead to a more accurate diagnostic and genetic
counselling service being offered.
4. In screening, patient ethnicity and cultural background should be considered since this will
provide a more time effective screening program because population specific mutations can be
focused on initially. It will also allow for more accurate risk assessment that is given to the
family with non-syndromic autosomal recessive deafness.
5. Other genes that lead to non-syndromic autosomal recessive deafness should also be studied.
These genes would include GJAI (Cx43) and GJB3 (Cx31) as they have been reported to playa
role in this disorder. Analysis of these genes could then possibly be included into the diagnostic
screening when the identification of GJB2 and/or GJB6 mutations have failed to provide an
answer as to the cause of non-syndrornic autosomal recessive deafness within a family or
individual.
118
119
REFERENCES
REFERENCES
Abe S., Usami S., Shinkawa H., Kelley P.M. and Kimberling W.l. Prevalent connexin 26 gene (GJB2)
mutations in Japanese. Journal of Medical Genetics 37, 41-43, 2000.
Ahmad S. and Evans W.H. Post-translational integration and oligomerization of connexin 26 in plasma
membranes and evidence of formation of membrane pores: implications for the assembly of gap
junctions. Biochemistry Journal 365, 693-699, 2002.
Antoniadi T., Grenskov K., Sand A., Pampanos A., Brendum-Nielsen K. and Petersen M.B. Mutation
analysis of the GJB2 (connexin 26) gene by DGGE in Greek patients with sensorineural deafness.
Human Mutation 16, 7-12, 2000.
Baris I., Kline M.O. and Tolun A. Frequency of the 35deiG mutation in the connexin 26 gene in
Turkish hearing-impaired patients. Clinical Genetics 60, 452-455, 2001.
Ben Arab S., Hmani M., Denoyelle F., Boulila-Elgaied A., Chardenoux S., Hachicha S., Petit C. and
Ayadi H. Mutations of GJB2 in three geographic isolates from northern Tunisia: evidence for genetic
heterogeneity within isolates. Clinical Genetics 57, 439-443, 2000.
Brobby G.W., Muller-Myhsok B. and Horstmann R.D. Connexin 26 R143W mutation associated with
recessive nonsyndromic sensorineural deafness in Africa. New England Journal of Medicine 338, 548-
550, 1998.
Brown K.A., Janjua A.H., Karbani G., Parry G., Noble A., Crockford G., Bishop D.T., Newton V.E.,
Markham A.F. and Mueller R.F. Linkage studies of non-syndromic recessive deafness (NRSD) in a
family originating from the Mirpur region of Pakistan maps DFNB 1 centromeric to D 13S175. Human
Molecular Genetics 5,169-173,1996.
Brown T.A. Genomes. BIOS Scientific Publishers Ltd, Oxford, UK, pp. 137 - 139, 1999.
Carrasquillo M.M., Zlotogora 1., Barges S. and Chakravarti A. Two different connexin 26 mutations in
an inbred kindred segregating non-syndromic recessive deafness: implications for genetic studies in
isolated populations. Human Molecular Genetics 6, 2163-2172, 1997.
Connexin Homepage (2003) [Online] Available: http://www.crg.es/deafness.
Dahl E., Manthey D., Chen Y., Schwarz H.l., Chang Y.S., Lalley P.A., Nicholson B.J. and Willecke K.
Molecular cloning and functional expression of mouse connexin 30, a gap junction gene highly
expressed in adult brain and skin. Journal of Biological Chemistry 271, 17903-17910, 1996.
Del Castillo I., Villamar M., Moreno-Pelayo M.A., Del Castillo F., Álvares A., Telleria D., Menédez I.
and Moreno F. A deletion involving the connexin 30 gene in nonsyndromic hearing impairment. New
England Journal of Medicine 346, 243-249, 2002.
120
REFERENCES
Del Castillo 1., Moreno-Pelayo M.A., Del Castillo F.J., Brownstein Z., Marlin S., Adina Q., Cockburn
DJ., Pandya A., Siemering K.R., Chamberlin G.P., Ballana E., Wuyts W., Maciel-Guerra A.T.,
Álvarez A., Villamar M., Shohat M., Abeliovich D., Dahl H.H.M., Estivill X., Gasparini P., Hutchin
T., Nance W.E., Sartorato E.L., Smith RJ.H., Van Camp G., Avraham K.B., Petit C., and Moreno F.
Prevalence and evolutionary origins of the del(GJB6-DI3S1830) mutation in the DFNB1 locus in
hearing-impaired subjects: a multicenter study. Unpublished article, American Journal of Human
Genetics 73,1-7,2003.
Denoyelle F., Lina-Granade G., Plauchu H., Brozzone R., Chaïb H., Lévi-Acobas F., Weil D. and Petit
C. Connexin 26 gene linked to a dominant deafness. Nature 393, 319-320, 1998.
Denoyelle F., Marlin S., Weil D., Moatti L., Chauvin P., Garabédian É.N. and Petit C. Clinical features
of the prevalent form of childhood deafness, DFNB 1, due to a connexin 26 gene defect: implications
for genetic counseling. The Lancet 353, 1298-1303, 1999.
Engel- Yeger B., Zaaroura S., Zlotogora 1., Shalev S., Hujeirat Y., Carrasquillo M., Barges S. and Pratt
H. The effects of a connexin 26 mutation - 35deiG - on oto-acoustic emissions and brainstem evoked
potentials: homozygotes and carriers. Hearing Research 163, 93-100, 2002.
Estivill X., Fortina P., Surrey S., Rabionet R., Melchionda S., D'Agruma L., Mansfield E., Rappaport
E., Govea N., Milá N., Zelante L. and Gasparini P. Connexin 26 mutations in sporadic and inherited
sensorineural deafness. The Lancet 351, 394-398, 1998.
Ferraris A., Rappaport E., Santacroce R., Pollak E., Krantz I., Toth S., Lysholm F., Margaglione M.,
Restagno G., Dallapiccola B., Surrey S. and Fortina P. Pyrosequencing for detection of mutations in
the connexin 26 (GJB2) and mitochondrial 12S RNA (MTRNRl) genes associated with hereditary
hearing loss. Human Mutation 20, 312-320, 2002.
Fukushima K., Sugata K., Kasai N., Fukuda S., Nagayasu R., Toida N., Kimura N., Takishita T.,
Gunduz M. and Nishizaki K. Better speech performance in cochlear implant patients with GJB2-related
deafness. International Journal of Pediatric Otorhinolaryngology 62, 151-157, 2002.
Gabriel H., Kupsch P., Sudendey 1., Winterhager E., Jahnke K. and Lauterman J. Mutations in the
connexin 26/GJB2 gene are the most common event in non-syndromic hearing loss among the German
population. Human Mutation (Online) 421,1-7,2001.
Ganguly A., Rock M.J. and Proekop D.J. Conformation sensitive gel electrophoresis for rapid detection
of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-
induced bends in DNA hetroduplexes. Proceedings of the National Academy of Science 90, 10325-
10329, 1993
Garrett H.R. and Grisham e.M. Biochemistry, 2nd edition. Saunders College Publishing, U.S.A., pp.
319, 1999.
Green G.E., Scott D.A., McDonald J.M., Woodworth G.G., Sheffield V.C. and Smith RJ.H. Carrier
rates in the Midwestern United States for GJB2 mutations causing inherited deafness. Journal of the
American Medical Association 281, 2211-2216, 1999.
121
REFERENCES
Greinwald J.H. and Hartnick CJ. The evaluation of children with sensorineural hearing loss. Archives
of Otolaryngology Head and Neck Surgery 128, 84-87, 2002.
Grifa A., Wagner C.A., D'Ambrosio L., Melchionda S., Bernardi F., Lopez-Bigas N., Rabionet R.,
Arbones M., Monica M.D., Estivill X., Zelante L., Lang F. and Gasparini P. Mutations in GJB6 cause
nonsyndromic autosomal dominant deafness at DFNA3 locus. Nature Genetics 23, 16-17, 1999.
Griffith A.J., Chowdhry A.A., Kurima K., Hood LJ., Keats B., Berlin C.l., Morell RJ. and Friedman
T.B. Autosomal recessive nonsyndromic neurosensory deafness at DFNBI not associated with the
compound-heterozygous GJB2 (connexin 26) genotype M34T1167de1T. American Journal of Human
Genetics 67, 745-749, 2000.
Guilford P., Arab S.B., Blanchard S., Levilliers J., Weissenbach J., Belkahia A. and Petit C. A
nonsyndromic form of neurosensory, recessive deafness maps to the pericentromeric region of
chromosome 13q. Nature Genetics 6, 24-28, 1994.
Guilford P., Dodé C., Crozet F., Blanchard S., Chaïb H., Levilliers J., Levi-Acobas F., Weil D.,
Weissenbach J., Cohen D., Le Paslier D., Kaplan J.C. and Petit C. A YAC contig and an EST map in
the pericentromeric region of chromosome 13 surrounding the loci for neurosensory non-syndromic
deafness (DFNBI and DFNA3) and limb-girdle muscular dystrophy Type 2C (LGMD2C). Genomies
29, 163-169, 1995.
Hall T.A. BioEdit: a user-friendly biological sequence alignment editor and analysis program for
Windows 95/98/NT. Nucleic Acids Symposium 41, 95-98, 1999.
Hamelmann C., Amedofu G.K., Albrecht K., Muntau B., Gelhaus A., Brobby G.W. and Horstmann
RD. Pattern of connexin 26 (GJB2) mutations causing sensorineural hearing impairment in Ghana.
Human Mutation (online) 428, 1-6,2001.
Hayashi K. and Yandell D.W. How sensitive is PCR-SSCP? Human Mutation 2,338-346,1993.
Houseman M.J., Ellis L.A., Pagnamenta A., Di W.L., Rickard S., Osborn A.H., Dahl H.H.M., Taylor
G.R, Bitner-Glindzicz M., Reardon W., Mueller RF. and Kelsell D.P. Genetic analysis of the
connexin-26 M34T variant: identification of genotype M34T/M34T segregating with mild-moderate
non-syndromic sensorineural hearing loss. Journal of Medical Genetics 38, 20-25, 2001.
Jun A.I., McGuirt W.T., Hinojosa R, Green G.E., Fischel-Ghodsian N. and Smith RJ.H. Temporal
bone histopathology in connexin 26-related hearing loss. Laryngoscope 110,269-275,2000.
Kabahuma RI., Mueller RF., Hutchin T.P., Lui X.Z., Ramsay M. and Penn C. Non-syndromic genetic
deafness in a South African population. Unpublished paper presented at the io" biennial congress of
the Southern African society of human genetics, Durban, 2003.
Kammen-Jolly K., Ichiki H., Scholtz A.W., Gsenger M., Kreczy A. and Schrott-Fischer A. Connexin
26 in human fetal development of the inner ear. Hearing Research 160, 15-21, 2001.
Kartz L.C. Coordination of vertebrate cellular assemblies by gap junctions. Seminars in Cell and
Developmental Biology 6, 117-125, 1995.
REFERENCES
Kelley P.M., Harris D.J., Comer B.C., Askew J.W., Fowler T., Smith S.D. and Kimberling W.J. Novel
mutations in the connexin 26 gene (GJB2) that cause autosomal recessive (DFNBl) hearing loss.
American Journal of Human Genetics 62, 792-799, 1998.
Kelley P.M., Abe S., Askew J.W, Smith S.D., Usami S. and Kimberling W.J. Human connexin 30
(GJB6), a candidate gene for nonsyndromic hearing loss: molecular cloning, tissue-specific expression,
and assignment to chromosome 13qI2. Genomies 62, 172-176, 1999.
Kelley P.M., Cohn E. and Kimberling W.J. Connexin 26: required for normal auditory function. Brain
Research Reviews 32, 184-188,2000.
KelseIl D.P., Dunlop J., Stevens H.P., Lench N.J., Liang J.N., Parry G., Mueller R.F. and Leigh I.M.
Connexin 26 mutations in hereditary non-syndromic sensorineural deafness. Nature 387,80-83, 1997.
Kemperman M.H., Hoefsloot L.H. and Cremers C.W.R.J. Hearing loss and connexin 26. Journal of the
Royal Society of Medicine 95, 171-177,2002.
Kenna M.A., Wu B.L., Cotanche D.A., Korf B.R. and Rehm H.L. Connexin 26 studies in patients with
sensorineural hearing loss. Archives of Otolaryngology Head and Neck Surgery 127, 1037-1042, 2001.
Kiang D.T., Jin N., Tu Z.J. and Lin H.H. Upstream genomic sequence of the human connexin26 gene.
Gene 199, 165- 171, 1997.
Kikuchi T., Kimura R.S., Paul D.L. and Adams J.C. Gap junctions in the rat cochlea:
immunohistochemical and ultra-structural analysis. Anatomy and Embryology 191, 101-118,1995.
Kristensen V.N., Kelefiotis D., Kristensen A. and Barresen-Dale A.L. High-throughput methods for
detection of genetic variation. Bio Techniques 30, 318-332, 2001.
Krutovskikh V. and Yamasaki H. Connexin gene mutations in human genetic diseases. Mutation
Research 462, 197-207,2000.
Kudo T., Ikeda K., Kure S., Matsubara Y., Oshima T., Watanabe K., Kawase T., Narisawa K. and
Takasaka T. Novel mutations in the connexin 26 gene (GJB2) responsible for childhood deafness in the
Japanese population. American Journal of Medical Genetics 90, 141-145,2000.
Lalwani A.K. Evaluation of childhood sensorineural hearing loss in the post-genome world. Archive of
Otolaryngology Head and Neck Surgery 128, 88-89, 2002.
Lamartine J., Essenfelder G.M., Kibar Z., Lanneluc I., Callouet E., Laoudj D., Lemaitre G., Hand c.,
Hayflick S.J., Zonana J., Antonarakis S., Radhakrishna U., KelseIl D.P., Christianson A.L., Pitaval A.,
Der Kaloustian V., Fraser C., Blanchet-Bardon C., Rouleau G.A. and Waksman G. Mutations in GJB6
cause hidrotic ectodermal dysplasia. Nature Genetics 26, 142-144,2000.
Lauterman J., Wouter-Jan F., Tenm C., Altenhoff P., Grummer R., Traub 0., Frank H.G., Jahnke K.
and Winterhager E. Expression of the gap junction connexin 26 and 30 in the rat cochlea. Cell Tissue
Research 294, 415-420, 1998.
122
1~3
REFERENCES
Lefebvre P.P. and Van De Water T.R. Connexins, hearing and deafness: clinical aspects of mutations
in the connexin 26 gene. Brain Research Review 32,159-162,2000.
Lench N., Houseman M., Newton V., Van Camp G. and Mueller R. Connexin-26 mutations in sporadic
non-syndromal sensorineural deafness. The Lancet 351, 415, 1998.
Lerer 1., Sagi M., Ben-Neriah Z., Wang T., Levi H. and Abeliovich D. A deletion mutation in GJB6
cooperating with a GJB2 mutation in trans in non-syndromic deafness: a novel founder mutation in
Ashkenazi Jews. Human Mutation (online) 458,1-10, 2001.
Lin D., Goldstein J.A, Mhatre AN., Lustig L.R., Pfister M. and Lalwani A.K. Assessment of
denaturing high-performance liquid chromatography (DHPLC) in screening for mutations in connexin
26 (GJB2). Human Mutation 18,42-51,2001.
Liu X.Z., Xia X.J., Xu L.R., Pandya A, Liang C.Y., Blanton S.H., Brown S.D.M., Steel K.P. and
Nance W.E. Mutations in connexin31 underlie recessive as well as dominant non-syndromic hearing
loss. Human Molecular Genetics 9,63-67,2000.
Liu X.Z., Xia x.r., Adams 1., Chen Z.Y., Welch K.O., Tekin M., Ouyang X.M., Kristiansen A, Pandya
A, Balkany T., Amos K.S. and Nance W.E. Mutations in GJAI (connexin 43) are associated with non-
syndromic autosomal recessive deafness. Human Molecular Genetics 10, 2945-2951, 2001.
López-Bigas N., Rabionet R., Martinez E., Branchs 1., Volpini v., Vance 1.M., Arbonés M.L. and
Estivill X. Identification of seven novel SNPs (five nucleotide and two amino acid substitutions) in the
connexin31 (GJB3) gene. Human Mutation 15, 481-482, 2000.
López-Bigas N., Olivé M., Rabionet R., Ben-David 0., Martinez-Mates J.A., Bravo 0., Branchs I.,
Volpini V., Gasparini P., Avraham K.B., Ferrer 1., Arbonés M.L and Estivill X. Connexin 31 (GJB3) is
expressed in the peripheral and auditory nerves and causes neuropathy and hearing impairment. Human
Molecular Genetics 10, 947-952, 2001.
López-Bigas N., Melchionda S., Gasparini P., Borragán A, Arbonés M.L. and Estivill X. A common
frameshift mutation and other variants in GJB4 (connexin 30.3): analysis of hearing impairment
families. Human Mutation (Online) 494, 1-4, 2002.
Louw D.A. and Edwards DJ.A. Psychology: an introduction for students in Southern Africa. Lexicon
Publishers, Johannesburg, RSA, pp. 133 -137, 1995.
Mader S.S. Biology, 5th edition. Wm. C. Brown Publishers, USA, pp. 742 - 745, 1996.
Marlin S., Garabédian É.N., Roger G., Moatti L., Matha N., Lewin P., Petit C. and Denoyelle F.
Connexin 26 gene mutations in congenitally deaf children: pitfalls for genetic counseling. Archives of
Otolaryngology Head and Neck Surgery 127, 927-933,2001.
Maestrini E., Korge B.P., Ocafia-Sierra 1., Calzolari E., Cambiaghi S., Scudder P.M., Hovnanian A.,
Monaco A.P. and Munro C.S. A missense mutation in connexin26, D66H, causes mutilating
124
REFERENCES
keratoderma with sensorineural deafness (Vohwinkel's syndrome) in three unrelated families. Human
Molecular Genetics 8, 1237-1243, 1999.
Miller S.A., Dykes D.D. and Polesky H.F. A simple salting out procedure for extracting DNA from
human nucleated cells. Nucleic Acids Research 16, 1215, 1998.
Morell R.l., Kim HJ., Hood LJ., Goforth L., Friderici K., Fisher R., Van Camp G., Berlin C.I.,
Oddoux C., Ostrer H., Keats B. and Friedman T.B. Mutations in the connexin 26 gene (GJB2) among
Ashkenazi Jews with nonsyndromic recessive deafness. New England Journal of Medicine 339, 1500-
1505, 1998.
Morton C.C. Genetics, genomies and gene discovery in the auditory system. Human Molecular
Genetics 11, 1229-1240,2002.
Muller D.l., Hand G.M., Engel A and Sosinsky G.E. Conformational changes in surface structures of
isolated connexin 26 gap junctions. The European Molecular Biology Organization Journal21, 3598-
3607,2002.
Najmabadi H., Cucci R.A, Sahebjam S., Kouehakian N., Farhadi M., Kahrizi K., Arzhangi S.,
Daneshmandan N., Javan K. and Smith RJ.H. GJB2 mutations in Iranians with autosomal recessive
non-syndromic sensorineural hearing loss. Human Mutation (online) 504, 1-4, 2002.
Nance W.E., Liu X.Z. and Pandya A Relation between choice of partner and high frequency of
connexin 26 deafness. The Lancet 356,500-501,2000.
NCB!: http://www.ncbi.nlm.nih.gov
Orita M., Suzuki Y., Sekiya T. and Hayashi K. Rapid and sensitive detection of point mutations and
DNA polymorphisms using the polymerase chain reaction. Genomies 5, 874-879, 1989.
Oxford Concise Medical Dictionary, 5th edition. Oxford University Press, Oxford, UK, 2000, s.v
'familial' and 'sporadic'.
Pallares-Ruiz N., Blanchet P., Mondain M., Claustres M. and Roux AF. A large deletion including
most of GJB6 in recessive non syndromic deafness: a digenic effect. European Journal of Human
Genetics 10, 72-76, 2002.
Pampanos A., Economides 1., Iliadou V., Neou P., Leotsakos P., Voyiatzis V., Eleftheriades N.,
Tsakanikos M., Antoniadi T., Hatzaki A, Konstantopoulou I., Yannoukakos D., Gronskov K.,
Brondum-Nielsen K., Grigoriadou M., Gyftodimou 1., Iliades T., Skevas A and Petersen M.B.
Prevalence of GJB2 mutations in prelingual deafness in the Greek population. International Journal of
Pediatric Otorhinolaryngology 65, 101-108, 2002.
Park H.l., Hahn S.H., Chun Y.M., Park K. and Kim H.N. Connexin26 mutations associated with
nonsyndromic hearing loss. Laryngoscope 110,1535-1538,2000.
125
REFERENCES
Prasad S., Cucci RA, Green G.E. and Smith R.J.H. Genetic testing for hereditary hearing loss:
connexin 26 (GJB2) allele variants and two novel deafness-causing mutations (R32C and 645-
648delTAGA). Human Mutation 16, 502-508, 2000.
Rabionet R., Zelante L., López-Bigas N., D'Agruma L., Melchionda S., Restagno G., Arbonés M.L.,
Gasparini P. and Estivill X. Molecular basis of childhood deafness resulting from mutations in the
GJB2 (connexin 26) gene. Human Genetics 106, 40-44, 2000.
Rabionet R, López-Bigas N., Arbonês M.L. and Estivill X. Connexin mutations in hearing loss,
dermatological and neurological disorders. Trends in Molecular Medicine 8, 205-212, 2002.
Rickard S., Kelsell D.P., Sirimana T., Rajput K., MacArdle B. and Bitner-Glindzicz M. Recurrent
mutations in the deafness gene GJB2 (connexin 26) in British Asian families. Journal of Medical
Genetics 38,530-533,2001.
Sambrook J and Russell D.W. Molecular cloning: a laboratory manual, 3rd edition. Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, New York, USA, pp. 12.74-12.80 and 13.49-13.56,2001.
Scott D.A., Carmi R., Elbedour K., Duyk G.M., Stone E.M. and Sheffield V.c. Nonsyndromic
autosomal recessive deafness is linked to the DFNB 1 locus in a large inbred Bedouin family from
Israel. American Journal of Human Genetics 57, 965-968, 1995.
Scott D.A., Kraft M.L., Carmi R, Ramesh A, Elbedour K., Yairi Y, Srikumari Srisailapathy C.R.,
Rosengren S.S., Markham AF., Mueller RF., Lench N.J., Van Camp G., Smith R.J.H. and Sheffield
V.C. Identification of mutations in the connexin 26 gene that cause autosomal recessive nonsyndromic
hearing loss. Human Mutation 11, 387-394, 1998A
Scott D.A., Kraft M. L., Stone E. M., Sheffield V.C. and Smith R.J.L. Connexin mutations and hearing
loss. Nature 391, 32, 1998B.
Shahin H., Walsh T., Sobe T., Lynch E., King M.C., Avraham K.B. and Kanaan M. Genetics of
congenital deafness in Palestinian population: multiple connexin 26 alleles with shared origins in the
Middle East. Human Genetics 110, 284-289, 2002.
Sirnsek M., AI-Wardy N., AI-Khayat A., Shanmugakonar M., Al-Bulushi T., Al-Khabory M., AI-
Mujeni S. and Al-Harthi S. Absence of deafness-associated connexin-26 (GJB2) gene mutations in the
Omani population. Human Mutation (Online) 460,1-4,2001.
Smith R.J.H. and Van Camp G. Non-syndromic hearing impairment: gene linkage and cloning.
International Journal of Pediatric Otorhinolaryngology 49, S159-S 163, 1999.
Sobe T., Erlich P., Berry A, Korostichevsky M., Vreugde S., Avraham K.B., Bonné-Tamir B. and
Shohat M. High frequency of the deafness-associated 167deiT mutation in the connexin 26 (GJB2)
gene in Israeli Ashkenazim. American Journal of Medical Genetics 86, 499-500, 1999.
REFERENCES
Storm K., Wilcox S., Flothrnann K. and Van Camp G. Determination of the carrier frequency of the
common GJB2 (connexin-26) 35delG mutation in the Belgian population using an easy and reliable
screening method. Human Mutation 14,263-266, 1999.
Strachan T. and Read A.P. Human molecular genetics, 2nd edition. Bios Scientific Publishers Limited,
Oxford, UK, 1999.
Tekin M., Akar N., Cin S., Blanton S.H., Xia x.r, Liu X.Z., Nance W.E. and Pandya A. Connexin 26
(GJB2) mutations in the Turkish population: implications for the origin and high frequency of the
35delG mutations in Caucasians. Human Genetics 108, 385-389,2001.
Thein S.L. and Wallace R.B. The use of synthetic oligonucleotides as specific hybridization probes in
the diagnosis of genetic disorders. Human genetic diseases: a practical approach. Davies K.E., editor.
Oxford, IRL Press, pp. 33-50, 1986.
Van Laer L., Coucke P., Mueller RF., Caethoven G., Flothrnann K., Prasad S.D., Chamberlin G.P.,
Houseman M., Taylor G.R, Van de Heyning e.M., Fransen E., Rowland L, Cucci RA., Smith R.J.H.
and Van Camp G. A common founder for the 35delG GJB2 gene mutation in connexin 26 hearing
impairment. Journal of Medical Genetics 38,515-518,2001.
White T. W., Deans M. R., Kelsell D. P. and Paul D. L. Connexin mutations in deafness. Nature 394,
630, 1998.
Wilcox S.A., Osborn A.H., Allen-Powell D.R., Maw M.A., Dahl H.H.M. and McKinlay Gardner R.J.
Connexin26 deafness in several interconnected families. Journal of Medical Genetics 36, 383-385,
1999.
Wilcox S.A., Saunders K., Osborn A.H., Arnold A., Wunderlich J., Kelly T., Collins V., Wilcox L.J.,
McKinlay Gardner R.J., Kamarinos M., Cone-Wesson B., Williamson R. and Dahl H.H.M. High
frequency hearing loss correlated with mutations in the GJB2 gene. Human Genetics 106, 399-405,
2000.
Zelante L., Gasparini P., Estivill x., Melchionda S., D'Agruma L., Govea N., Milá M., Monica M.D.,
Lutfi J., Shohat M., Mansfield E., Delgrosso K., Rappaport E., Surrey S. and Fortina P. Connexin26
mutations associated with the most common form of non-syndromic neurosensory autosomal recessive
deafness (DFNB1) in Mediterraneans. Human Molecular Genetics 9, 1605-1609, 1997.
126
APPENDIX A: INFORMED CONSENT
APPENDIX A: INFORMED CONSENT
A.I ENGLISH INFORMED CONSENT FORM
PROJECT HUMAN GENETICS AND AUDIOLOGY (DEPT. ENT) TYGERBERG HOSPIT AL:
MOLECULAR ANALYSIS OF CONNEXIN 26 AND CONNEXIN 30 MUTATIONS IN NON-
SYNDROMIC HEREDITARY DEAFNESS IN SOUTH AFRICA.
Congenital deafness affects 1/1 000 live births and 50% of this is hereditary. 70 - 80% of hereditary
deafness in non-syndromic (i.e. only the inner ear affected). Forty-five chromosomal loci have been
identified in familial non-syndromic deafness. Hearing loss has been studied through linkage
studies in families. GJB2 gene mutations are amongst those genes associated with non-syndromic
deafness. The GJB2 encodes a gap-junction protein, connexin 26, which is expressed in the inner
ear and is important in maintaining cochlea potential. DFNB 1 is localised on chromosome 13q11-
12. In the Mediterranean European population a single mutant allele of GJB2 accounts for most of
the autosomal recessive deafness defects. The mutation is referred to as 35deiG (or 30de1G) since it
is the deletion of a single nucleotide in a string of 6 guanine residues, beginning at nucleotide
position 30 and ending at position 35. In the Ashkenazi Jewish population a 167delT frameshift
mutation was commonly found.
Material and methods:
Patients: Families and affected sporadic cases referred from - Carl du Toit Centre, schools for the
deaf/ hearing disorders, other referrals. All families entered - 2 unaffected parents and at
least 2 affected siblings.
Prerequisite: Consent and audiology of parents and children
Divided in groups for analysis (if enough patients): Group 1 - European extraction
Group 2 - Other
Reason - estimate frequencies of specific mutations and identify possible differences in
order to optimise mutation testing.
Test:
Audiology, Blood test - 5-10 ml of EDTA blood for molecular analysis (1-2 teaspoon/s), DNA
testing, Pedigree
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Outcome:
Patients will be informed of the outcome of the study. Eventually one hopes to find a high
frequency of a specific mutation, in order to be of use to parents who have had one child with non-
syndromic neurosensory deafness to test whether this is a sporadic condition or has an increased
recurrence risk.
Cost:
No cost for entering, pedigree, blood tests or parental audiograms. We cannot, however, pay you for
inclusion either.
Ethics:
No results will be published that would identify any person, but accumulated results may be
published in a medical journal.
DECLARATION:
1, the undersigned, [ID ]
the patient or in my capacity as of patient , .
[ID ] of (address).
I declare that:
1. lithe patient was invited to participate in the above mentioned research project which is being
undertaken by the Division of Human Genetics of the University of Stellenbosch.
2. It has been explained to me that
2.1 The project is being undertaken to investigate the role of connexin 26 and connexm 30
mutations as a cause of deafness in the South African population.
2.2 If lithe patient participate(s) in the project, only 20-50 ml of blood will be collected from the
arm. The plasma and DNA/RNA extracted from the blood will be used in laboratory tests. Index
patients and family members will be included in follow-up studies (e.g. blood sampling,
laboratory testing, magnetic resonance imaging and completion of questionnaires).
2.3 A blood sample will be required from both affected and unaffected family members. The project
should not take more than 2 years.
2.4 If the genes are found associated with non-syndromic deafness in the South African population,
prenatal testing may be necessary in future.
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3. lithe patient have/has been warned that the drawing of blood may result in slight discomfort,
which can be coupled with bleeding where the needle pierces the skin.
4. It has been explained to me/the patient that participation in this project will result in the
broadening of medical knowledge. The possible development of an accurate diagnostic DNA
test for the condition(s) might lead to early detection and preventative treatment of affected
individuals and improved counselling and risk assessment of families.
5. lithe patient have/has been informed that all information collected will be treated confidentially.
The results will be used for publication in scientific journals/theses, without revealing the
identity of any individual.
6. IIthe patient may, during or on completion of the project, request the results of the tests without
any conditions attached thereto, since the results could be advantageous to me/the patient and
my/his family. Genetic counselling will be provided with this information.
7. IIthe patient have/has been told that participation is voluntary and that lithe patient may refuse
to participate in this project and that lithe patient may also at any time withdraw my/his or her
participation from the project. Refusal or withdrawal from the project will in no way affect
mylhis or her present or future treatment at this institution. lithe patient also understands that the
researcher may withdraw me/him or her from the project if he/she considers it in my/the
patient's best interest.
8. I/the patient was not pressurised to participate in this project and lithe patient know that I/the
patient may at any time withdraw from this project without penalisation.
9. Participation in this project will not result in unnecessary expenses for me/the patient.
10. I/the patient voluntarily agree(s) to participate in the above mentioned project
SIGNED/AFFIRMED AT ON 20 .
Signature of patient! representative of patient Witness
Forward blood sample collected in EDTA or A CD-containing tubes (5-20 ml) to the following
address to reach the laboratory within one week:
Dr G de Jong
Division of Human Genetics
Faculty of Health Sciences
Francie van Zijl Drive
Room 2126 / PO Box 19063
Tygerberg 7505
Tel (021) 9389218
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DECLARATION BY OR ON BEHALF OF THE RESEARCHER
1, declare that I
1. have explained the information in this document to the patient, and/or
hislher representative.
2. Requested hirnlher/them to ask questions where anything was unclear.
DrlMrlMs .
SIGNED AT ON 20 .
IMPORTANT INFORMATION
Dear Patient/Representative of the patient
Thank you for participating in this project. If at any time during the course of the project
1. An emergency situation arises resulting from the research, or
2. You require further information regarding the project, or
3. If any of the following occurs, please contact Dr. G de Jong at telephone number:
(021) 9389218
(a) The condition of the participant suddenly deteriorates
(b) An apparent unaffected family member suddenly becomes ill or dies
(c) A participant changes address and/or telephone number.
A.2 AFRIKAANS INFORMED CONSENT FORM
PROJEK VAN MENSGENETIKA AFDELING EN OUDIOLOGIE (DEPT. ONK) TYGERBERG
HOSPITAL: CONNEXIN 26 EN CONNEXIN 30 MUTASIES IN NIE SINDROMIESE
DOOFHEID IN DIE SUID AFRIKAANSE POPULASIE.
Aangebore doofheid affekteer ongeveer 1/1 000 lewendgeborenes en 50% hiervan is oorerflik. 70-
80% van oorerflike doofheid is nie sindromies d.w.s. slegs die binne-oor is geaffekteer. 45
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verskillende chromosomale loci is al geïdentifiseer in families met nie sindromiese doofheid.
Gehoorgestremdheid is tot nou toe bestudeer deur genetiese koppeling studies in families. Die GJB2
geen kodeer vir 'n proteien, connexin 26 wat uitgedruk word in die binne-oor en is belangrik in die
behoud van kogliêre potensiaal. Hierdie DFNB 1 geen is gelokaliseer op chromosoom 13q11-12.
Mutasies in hierdie GJB2 geen word geassosieer met nie sindromiese doofheid. In die
Mediterieense populasie vind ons dat 40% van die outosomaal resessieve doofheid geassosieer is
met 'n enkele mutasie in die GJB2 geen. Hierdie mutasie is bekend as die 35deiG (of 30de1G)
aangesien dit 'n enkele mukleotied in 'n reeks van 6 guanien residus, wat begin by die nukleotied in
posisie 30 en eindig by posisie 35. In die Ashkenazi Joodse populasie is daar 'n ander delesie wat
algemeen is nl., 167delT.
Metodes wat gebruik sal word:
Pasiënte: Families en geaffekteerde sporadiese gevalle wat verwys word van o.a. Carl du Toit
Sentrum, skole vir dowes of gehoorgestremdes en ander verwysings.
Families betrek: die wat twee ongeaffekteerde ouers het en minstens twee aangetaste kinders.
Voorvereistes: toestemming van ouers
oudiologiese evaluasie van ouers en kinders
Die groepe sal in twee verdeel word (as daar genoeg pasiënte): Groep 1 - Europese afkoms
Groep 2 - Ander
Rede hiervoor: die mutasies in die verskillende groepe mag verskil en dit is nodig om die
verskille te identifiseer om optimale toetsing te vewerkstellig.
Toetse:
Oudiologie, bloodtoets - 5-10 ml EDTA bloed vir molekulêre analise (1-2 teelepels), DNA toetsing,
stamboom.
Uitkoms:
Die pasiënte sal ingelig word oor die resultate van die studie. Die uiteindelike doel van die studie is
om hopenlik 'n spesifieke mutasie te kry wat algemeen is in ons populasie wat gebruik kan word in
families waar slegs een kind nog aangetas is om uit te sorteer of dit 'n toevallige afwyking is en of
daar 'n herhalingsrisiko gaan wees.
Koste:
Geen koste is verbonde aan toetrede tot die studie, stambome opstel, bloedtoetse of ouerlike
oudiograrnme. Ons kan egter nie vir u betaal vir insluiting by die studie nie.
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Etiese oorweginge:
Geen resultate sal gepubliseer word wat emge persoon kan identifiseer me. Die uiteindelike
resultate mag egter moontlik gepubliseer word in 'n mediese joernaalom tot nut te wees van ander
mense.
VERKLARING DEUR OF NAMENS PASIëNT
Ek, die ondergetekende, [ID ]
die pasiënt of in my hodanigheid as van die pasiënt. .
[ID ] van (adres)
Ek bevestig dat:
1. Ek/die pasiënt uitgenooi is om deel te neem aan bogemelde navorsingsprojek wat deur die
Afdeling Mensgenetika van die Universiteit van Stellenbosch onderneem word.
2. Daar aan my verduidelik is dat
2.1 Die projek onderneem word om die rol van die connexin 26 en connexin 30 mutasies to
ondersoek as 'n oorsaak van doofheid in die Suid-Afrikaanse populasie.
2.2 Indien ek deelneem aan die projek, slegs 20-50 ml bloed uit die voorarm versamel sal word.
Die plasma en DNAIRNA sal uit die bloed geïsoleer word vir gebruik in laboratorium toetse.
Indekspasiënte en hul familielede sal ingesluit word in opvolgstudies (bv. bloedmonsterneming,
magnetiese resonans beelding en gevra word om 'n vraelys in te vul).
2.3 Bloedmonsters benodig word van beide geaffekteerde pasiënte en ongeafekteerde familielede.
Die projek behoort nie langer as 2 jaar te duur nie.
2.4 lndien die gene wel betrokke is by nie sindromiese doofheid, voorgeboorte analise in die
toekoms moontlik kan word.
3. Ek gewaarsku is dat die proses van bloedtrek effense ongemak mag meebring, wat gepaard gaan
met bloeding waar die naald die vel binnedring.
4. Daar verder aan my verduidelik is dat deelname aan die projek sal bydra tot die uitbouing van
mediese kennis. Die moontlike ontwikkeling van 'n akkurate DNA diagnose van die kondisie(s)
wat mag lei to vroeë opsporing en verveterde behandeling van aangetaste persone en verbeterde
raadgewing en risiko bepaling in families.
5. Ek meegedeel is dat die inligting wat ingewin word as vertroulik beskou sal word, maar wel
aangewend sal word vir publikasies in vaktydskrifte en tesisse.
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6. Ek/die pasiënte tydens/na afhandeling van die projek die uitslag van die toetse kan aanvra
sonder dat daar enige voorwaardes aan verbonde is, aangesien die kennis tot my en my familie
se voordeel sal wees. Genetiese raadgewing gegee sal word saam met die inligting.
7. Ek meegedeel is dat ek mag weier om deel te neem/die pasiënt te laat deelneem aan hierdie
projek Iasook dat ek/die pasiënt te enige tyd deelname daaraan mag staak) en dat sodanige
weiering of staking nie op enige manier my/die pasiënt se huidige/toekomstige behandeling by
hierdie inrigting sal genadeel nie. Ek verstaan ook dat die navorser my/die pasiënt van die
projek mag onttek indien dit in my/die pasiënt se belang geag word deur hom/haar.
8. Daar geen dwang op my geplaas is om toe to stem to my/die pasiënt se deelname aan hierdie
projek nie en dat ek besef dat ek/die pasiënt deelname te enige tyd mag staak sonder enige
penalisasie.
9. Deelname aan die projek geen addisionele koste vir my/die pasiënt inhou nie.
10. Ek stem hiermee vrywillig in om deel te neem aan die bogemelde projek/dat die pasiënt
deelneem aan die bogemelde projek.
GETEKEN/BEVESTIG TE OP 20 .
Pasiënt/verteenwoordiger van pasiënt Getuie
Stuur bloemonster gekollekteer in EDTA buise (5-20 ml) na die onderstaande adres on die
laboratorium te bereik binne die bestek van een week:
Dr G de Jong
Afdeling Mensgenetika
Fakulteit Gesonheidwetenskappe
Francie van Ziyl Rylaan
Kamer 2128/ Posbus 19063
Tygerberg 7505
Tel (021) 9389218
VERKLARING DEUR OF NAMENS NAVORSER
Ek, verklaar dat ek:
1. Die inligting vervat in hierdie dokument aan die pasiënt. en/of
sy/haar verteenwoordiger verduidelik het;
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2. Homlhaarlhulle versoek het om vrae aan my te stel indien daar enigiets onduidelik was;
DrlMnrlMe .
GETEKEN TE OP 20 .
Navorser/navorser se verteenwoordiger Getuie
BELANGRIKE INLIGTING
Geagte pasiënt! verteenwoordiger van die pasiënt. Baie dankie vir u/die pasiënt se deelname aan
hierdie studie. Indien daar te enige tyd tydens die duur van die projek:
1. 'n noodsituasie onstaan wat spruit uit die navorsing, of
2. u enige verdere inligting aangaande die projek verlang, of
3. die volgende plaasvind moet u asseblief vir Dr. G de Jong, was as kontakpersoon saloptree
vir nodige verwysing van die pasiënt, kontak by telefoonnommer: (021) 9389218
(a) die siktetoestand van 'n deelnemer aan die projek skielik versleg
(b) 'n oënskynlik onaangetaste familielid skieik siek word of sterf
(c) 'n deelnemer aan die projek van adres/telefoon nommer verander
134
APPENDIX B: RESEARCH PRESENTATIONS
APPENDIX B: RESEARCH PRESENTATIONS
Results presented in this thesis were presented at the following international and national
conferences. The presenting author's name is underlined in each case.
B.I RESEARCH PRESENTED AT INTERNATIONAL CONFERENCES
52nd ANNUAL MEETING OF THE AMERICAN SOCIETY OF HUMAN GENETICS: Baltimore,
Maryland, USA, October 2002.
de Jong G., Whitehead C., Muller L., du Plessis L., Kotze M. and Warnich L. (GJB2) Connexin 26
and 30 (GJB6) mutations in a South African population with non-syndrornic deafness of probable
autosomal recessive origin.
B.2 RESEARCH PRESENTED AT NATIONAL CONFERENCES
10TH BIENNIAL CONGRESS OF THE SOUTHERN AFRICAN SOCIETY OF HUMAN
GENETICS: Durban, South Africa, May 2003.
Whitehead C., de Jong G., Muller L., Kotze MJ. and Warnich L. Non-syndromic autosomal
recessive deafness and the role that connexin 30 mutations play in the South African population.
10TH BIENNIAL CONGRESS OF THE SOUTHERN AFRICAN SOCIETY OF HUMAN
GENETICS: Durban, South Africa, May 2003.
de Jong G., Whitehead C., Muller L.M., Kotze M.l and Warnich L. Autosomal recessive deafness
and connexin 26 and 30 (GJB2 and 6 gene mutations) in a South African population.
CAPE BIOTECH: Somerset West, Cape Town, South Africa, November 2002.
Whitehead C., de Jong G., Muller L., Kotze M.J. and Warnich L. Molecular diagnostics on non-
syndromic hereditary deafnes in South Africa: Study of connexin 26 and connexin 30 mutations.
B.3 RESEARCH PRESENTED IN THE DEPARTMENT OF GENETICS,
UNIVERSITY OF STELLENBOSCH
SEMINAR DAY 2003: University of Stell enbosch, Stellenbosch, South Africa, June 2003.
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Whitehead C., de Jong G., Muller L., Kotze M.l. and Wamich L. Connexin mutations and the role
they play in the deaf population of South Africa.
SEMINAR DAY 2002: University of Stell enbosch, Stellenbosch, South Africa, June 2002.
Whitehead C., de Jong G., Muller L., Kotze M.J. and Warnich L. Childhood hereditary deafness in
the South African population.
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APPENDIX C: MUTATION ANALYSIS RESULTS
This appendix contains the results obtained during the mutation screening of GJB2 of both the
familial and sporadic study groups.
C.I FAMILIAL CASES
Wild Type/Wild Type
Mother Normal Wild Type/Wild Type
Daughter Deaf Wild Type/Wild Type
Son Deaf Wild
Caucasian 6078/99 Father Normal 35delG/Wild Type
6079/99 Mother Normal N62I/Wild Type
6865/99 Son Deaf 35delGIN62I
6080/99 Deaf 35delGIN621
Caucasian 83/00 Mother Normal Wild Type/Wild Type
82/00 Father Normal Wild Type/Wild Type
85/00 Son Deaf Wild Type/Wild Type
84/00 Deaf Wild
Caucasian 87/00 Mother Normal Wild Type/Wild Type
89/00 Son Normal Wild Type/Wild Type
88/00 Son Deaf Wild Type/Wild Type
91/00 Daughter Normal Wild Type/Wild Type
90/00 Deaf Wild
Caucasian 623/00 Mother Normal 312de1l4/Wild Type
624/00 Son Deaf 35de1G/312de1l4
625/00 Son Deaf 35de1G/312de114
Caucasian 616/00 Mother Normal 35delG/Wild Type
617/00 Son Deaf 35de1G/312de114
618/00 Deaf 35de1G/312de114
7 Caucasian 619/00 Father Normal Contaminated Sample
620/00 Mother Normal Wild Type/Wild Type
621/00 Daughter Deaf Wild Type/Wild Type
622/00 Wild
35delG/Wild Type
Mother Normal 35delG/Wild Type
Daughter Deaf 35de1G/35de1G
Daughter Deaf 35de1G/35de1G
Normal Wild
10 Caucasian 29/01 Normal
30/01 Deaf
31/01 Deaf
11 Caucasian 53/01 Mother Normal 35delG/Wild Type
54/01 Father Normal 312de1l4/Wild Type
55/01 Daughter Deaf 35de1G/312de1l4
56/01 Son Deaf 35de1G/312de1l4
12 Mixed Ancestry 230/01 Daughter Deaf
231/01 Deaf
13 Mixed Ancestry 229/01 Son Deaf Wild
228/01 Son Deaf Wild
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14 Caucasian 541/01 Father Normal 312de114/Wild Type
542/01 Mother Normal 312delI4/Wild Type
543/01 Son Deaf 312de114/312de114
544/01 Son Deaf 312de114/312de1l4
15 Caucasian SOS/Ol Father Normal Wild Type/Wild Type
506/01 Mother Normal Wild Type/Wild Type
507/01 Son Deaf Wild Type/Wild Type
508/01 Son Deaf Wild Type/Wild Type
16 Caucasian F16.1 Son Deaf Wild Type/Wild Type
F16.2 Son Deaf Wild Type/Wild Type
C.2 SPORADIC CASES
502/00
501/00
Caucasian 43/01 Deaf 35de1G/3 12del14
44/01 Normal 35delG/Wild Type
46/01 Father Normal 312de1l4/Wild
Caucasian 67/01 Mother Normal 312de114/Wild Type
68/01 Son Deaf 35de1G/312de1l4
Caucasian 225/01 Mother Normal Wild Type/Wild Type
224/01 Father Normal Wild Type/Wild Type
226/01 Son Deaf Wild
Caucasian 5.3 Father Normal Wild Type/Wild Type
247/01 Mother Normal Wild Type/Wild Type
246/01 Son Deaf Wild
Caucasian 312/0 I Father Normal Wild Type/Wild Type
313/01 Mother Normal Wild Type/Wild Type
314/01 Son Deaf Wild
Caucasian 434/0 I Father Normal 312de1l4/Wild Type
435/01 Mother Normal Wild Type/Wild Type
436/01 Deaf 312de1l4/Wild
Mixed Ancestry s9.1 Father Normal W24X1Wild Type
s9.2 Mother Normal 35delG/Wild Type
s9.3 Daughter Deaf 35deiG/W24X
s9.4 Deaf Identical twin of9.3
10 Indian s10.1 Normal Wild Type/Wild Type
slO.2 Son Deaf Wild Type/Wild Type
F also has the VI53!
Il Indian s11.1 Father Normal Wild Type/Wild Type
sI1.2 Mother Normal Wild Type/Wild Type
s 11.3 Son Deaf Wild
12 Caucasian s12.1 Father Normal Wild Type/Wild Type
s12.2 Mother Normal 312de1l4/Wild Type
F also has the VI 53!
13 Caucasian Father Normal Wild Type/Wild Type
Mother Wild Type/Wild Type
Wild
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17 Caucasian s17.1 Father Normal 35delG/Wild Type
s17.2 Mother Normal 35delG/Wild Type
s17.3 Daughter Deaf 35de1G/35de1G
18 Mixed Ancestry s18.1 Father Normal Wild Type/Wild Type
s18.2 Mother Normal Wild Type/Wild Type
s18.3 Daughter Deaf Wild Type/Wild Type
19 Caucasian s19.1 Mother Normal Wild Type/Wild Type
s19.2 Son Deaf Wild Type/Wild Type
20 Caucasian s20.1 Father Normal 312de114/Wild Type
s20.2 Mother Normal 312dell4/Wild Type
s20.3 Son Deaf 312de114/312de114
21 Indian s2l.l Father Normal V37I/Wild Type
s21.2 Mother Normal Wild Type/Wild Type
s21.3 Son Deaf V37I1Wild Type
22 Mixed Ancestry s22.1 Mother Normal Wild Type/Wild Type
s22.2 Daughter Deaf Wild Type/Wild Type
23 Caucasian s23.1 Father Normal Wild Type/Wild Type
s23.2 Mother Normal Contaminated DNA
s23.3 Daughter Normal Wild Type/Wild Type
s23.4 Son Deaf Wild Type/Wild Type
24 Caucasian s24.1 Mother Normal Wild Type/Wild Type
s24.2 Daughter Deaf Wild Type/Wild Type
25 Caucasian s25.1 Father Normal Wild Type/Wild Type
s25.2 Mother Normal Wild Type/Wild Type
s25.3 Daughter Deaf Wild Type/Wild Type
26 Caucasian s26.1 Daughter Deaf 312delI4/Wild Type
27 Caucasian s27.1 Mother Normal Wild Type/Wild Type
s27.2 Father Normal Wild Type/Wild Type
s27.3 Daughter Deaf Wild Type/Wild Type
28 Mixed Ancestry s28.1 Father Normal Wild Type/Wild Type
s28.2 Mother Normal Wild Type/Wild Type
s28.3 Daughter Deaf Wild Type/Wild Type
29 Caucasian s29.1 Father Normal Wild Type/Wild Type
s29.2 Mother Normal Wild Type/Wild Type
s29.3 Son Deaf Wild Type/Wild Type
